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Summary 
The last decades have been galvanized by efforts to reduce the ever widening 
gap that exist between functional genomics and proteomics. Assigning molecular 
functions to, and breaking through the complex networks in which each and every 
individual protein of the cellular proteome is involved is the breathtaking task that needs 
to be overcome in order to understand the molecular and physiological basis underlying 
health and disease. System-wide analysis is an approach that can permit a better 
understanding of the proteome, and there is need for robust and reliable platforms for 
such analysis to be developed. To contribute to current efforts, I have developed and 
optimized methods for the production of functional protein microarrays in a 
miniaturized form from cDNA products and genomic DNA as template source. I have 
further shown that such arrays are very useful and reliable in various applications such 
as protein-protein interactions, protein-RNA interactions, Kinase substrate identification 
and antibody selection. I have validated some data obtained from these arrays in vivo in 
a model organism, Trypanosoma brucei. This confirms that the platform can well 
contribute to the already existing proteomic tools in generating reliable biological data. 
Moreover, using cDNA products allow for the analysis of disease-related and rare 
transcripts as well as other spliced variants.   
Current diagnostic tools for human African trypanosomiases are very invasive 
and in some cases are not sensitive enough. This is compounded by a highly 
heterogeneous seropositive patient population that is difficult to classify. To address 
this, I have equally analyzed the miRNA and mRNA expression pattern in the 
peripheral blood of patients in search for new markers. Thirteen differentially expressed 
miRNAs were identified, three of which (miRNA-199a-3p, miRNA-27b and miRNA-
126*) were highly selective (>95%). These miRNAs have also been reported to be 
differentially regulated in other diseases and miRNA-199a-3p for example is used as a 
diagnostic biomarker. They are therefore not suitable as specific biomarkers in sleeping 
sickness. I have however shown that there is deregulation of miRNA expression 
following T. brucei infection, and most of the differentially regulated miRNAs are 
related to host immune responses to infectious agents and other inflammatory responses 
that may be influencing disease outcome.  
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Zusammenfassung 
In den vergangenen Jahrzenten wurden erhebliche Anstrengungen 
unternommen, die wachsende Kluft zwischen funktioneller Genomik und Proteomik zu 
schließen. Jedem einzelnen Protein molekulare Funktionen zuzuordnen und die 
komplexen Netzwerke, in die jedes Protein des zellulären Proteoms eingegliedert ist, zu 
entschlüsseln, ist die wesentliche Aufgabe, die erfüllt werden muss, um die molekulare 
und physiologische Basis von Gesundheit oder Krankheit zu verstehen. Die systemweite 
Analyse ist ein Ansatz, der es erlaubt, das Proteom besser zu verstehen, daher ist es 
nötig robuste und verlässliche Plattformen für solche Analysen zu entwickeln. Um zu 
aktuellen Bestrebungen beizutragen,  entwickelte  und optimierte ich Methoden zur 
Produktion funktioneller Protein-Microarrays mit cDNA-Produkten oder genomischer 
DNA als Matrize. Desweiteren zeigte ich, dass solche Arrays zuverlässig für 
verschiedenste Anwendungen wie Protein-Protein-Interaktionen, Protein-RNA-
Interaktionen, Kinase-Substrat-Identifikationen und Antikörperselektion benutzt werden 
können. Ein Teil der generierten Daten wurde im Modellorganismus Trypanosoma 
brucei validiert, was bestätigt, dass die entwickelte Plattform sich nahtlos in die 
etablierten Werkzeuge der Proteomik zur Erzeugung verlässlicher biologischer Daten 
einfügt. Darüberhinaus erlaubt die Verwendung von cDNA-Produkten die Analyse 
krankheitsassoziierter und seltener Transkripte, sowie von Splicevarianten. 
Aktuell verfügbare diagnostische Methoden für die afrikanische Schlafkrankheit 
beim Menschen sind nicht hinreichend sensitiv und die äußerst heterogene und daher 
schwierig zu klassifizierende serumpositive Patientenpopulation erschwert dies noch. 
Die Bestimmung des Krankheitsfortschritts erfolgt invasiv und belastet den Patienten, 
zudem werden hochtoxische Arsenverbindungen zur Therapie verwendet. Um die 
Situation zu verbessern, werden zuverlässigere und weniger invasiv bestimmbare 
Biomarker benötigt. Zu diesem Zweck habe ich gleichermaßen  miRNA- und mRNA-
Expressionsmuster im peripheren Blut von Patienten untersucht. Dreizehn differentiell 
exprimierte miRNAs konnten identifiziert werden, wovon drei (miRNA-199a-3p, 
miRNA-27b and miRNA-126*) hochselektiv (>95%) differentiell exprimiert waren. Es 
ist bekannt, dass diese miRNAs auch bei anderen Krankheiten dereguliert sind und 
miRNA-199a-3p wird beispielsweise bereits als diagnostischer Biomarker genutzt. 
Daher sind sie nicht als spezifischer Biomarker für die Schlafkrankheit geeignet. Ich 
konnte jedoch zeigen, dass infolge einer Infektion mit T. brucei Deregulierung der 
miRNA-Expression auftritt und dass der Großteil der deregulierten miRNAs mit der 
Immunantwort gegen infektiöse Erreger und andere Entzündungsreaktionen, die den 
Krankheitsverlauf beeinflussen, zusammenhängen. 
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for Functional Proteomic Analysis 
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Trypanosoma brucei
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1 Introduction 
As genomic databases are being filled with the complete genome sequences of 
several prokaryotic and eukaryotic organisms, the breathtaking challenge of assigning 
functional and molecular annotation to the thousands of predicted gene products is 
becoming unprecedentedly evident[1]. Although genes are involved in the modulation 
of cellular function, they only do so indirectly via the proteins for which they code for. 
Hence, proteins are the chief players controlling the highly complex, dynamic but well-
structured and integrated metabolic, signaling and cellular networks that sum up to form 
organisms. System-wide analysis of the molecular interactions of proteins can allow for 
a comprehensive understanding of the intricate signal transduction networks in which 
proteins are involved. This will improve our view of the complex processes that support 
living systems and make sense out of health and disease states. Unlike previously 
thought, the one gene-one protein concept is long outdated, and the genome of some 
organisms such as humans code for as much as about one hundred thousand individual 
proteins[2]. Added to this already highly complex genomes, is the phenomenon of post-
translational modifications that leads to even a higher level of complexity with more 
proteoforms and therefore added molecular functions for a single protein[3]. While 
proteins are responsible for the control and maintenance of normal cellular homeostasis, 
deregulations in protein expression and function can lead to several diseases such as 
diabetes, cancer, prions diseases and other neurological disorders[1].  
Taken together, it is evident, that complete analyses of the cellular proteome is 
an inevitable task, and conventional proteomic tools such as Enzyme-Linked 
Immunosorbent Assays (ELISA) and western blots are less adapted for system-wide 
analysis of the proteome.  This highlights the need for the development of robust but 
reliable tools for the global analysis of protein expression and function. Such tools will 
allow for parallel analysis of protein function, thereby bridging the gap that has long 
existed between genomics and proteomics, and help improve our understanding of the 
mechanistic basis of several biological processes. Although it may sound conceptually 
trivial, considering that such tools already exist for genomics, it is however important to 
note, that proteomic is far from being the protein equivalent of genomics. The highly 
heterogeneous nature of the building blocks of proteins and the physico-chemical 
properties of individual proteins add several strata of complexity to proteomics[4]. In 
fact, unlike nucleic acids, there is yet no protein-based analogue of the polymerase 
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chain reaction for the amplification of individual proteins or the post-translational 
modifications they undergo. More so, there can be a great disparity in the physico-
chemical properties of functional elements within the same protein molecules. 
Furthermore, proteins do not have well defined high affinity and high selectivity 
binding partners that can easily be used for their immobilization on array platforms as is 
the case with nucleic acids[5]. The development of high-throughput tools for 
proteomics will therefore need to take all of these into consideration and address them 
individually for every protein of interest. This has been one of the major drawbacks that 
have retarded progress in the development of thigh throughput tools for proteomics. 
Nonetheless, during the last two decades, some significant efforts have been made to 
such ends with encouraging results[1]. 
Since their first conception about two decades ago in the multianalyte microspot 
assays[6], protein microarrays have constantly evolved and have been at the center 
proteomics both in basic and biomedical research where they have helped fuel growth in 
these fields. These miniaturized protein chips offer far-reaching potentials and 
advantages, such as multiplexing and parallel analysis of several analytes, high 
sensitivity, cost and time efficiency, and the need for relatively small sample volumes[5, 
7]. The latter is very valuable in biomedical research where sample material is often 
very limited. Besides, protein microarrays allow for the analysis of direct contact 
between molecules, therefore providing the opportunity to study weak and transient 
interactions that would otherwise be difficult to predict or analyze with other 
methods[8]. Owing to its assets, protein microarrays have extensively been exploited in 
diverse domains in basic and clinical research. As such, they have been used for 
interactome mapping[9], analysis of protease-associated networks in malaria[10], 
patient screening[11], analysis of post-translational modifications[12, 13], identification 
of RNA/DNA-binding proteins[14], study of host-pathogen interactions[15], biomarker 
and drug discovery as well as antibody selection[16-18]. Despite the aforementioned, 
and even more potentials this platform may hold, its development and exploitation is 
relatively still at a very premature level. This is in part due to basic technical problems 
such as the maintenance of a well folded 3-dimensional structured protein, large scale 
production of pure but functional proteins, the lack of major post-translational 
modification and well-adapted surface chemistry that provide for high affinity and 
oriented protein immobilization. 
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An ideal situation would be one in which protein are immobilized on high 
affinity surfaces; that allow for proper immobilization of the proteins in their native 3-
dimensional structure, is inert to non-specific immobilization, permit proper orientation 
of proteins, thus exposing all active sites, and do not necessitate pre-purification[19]. 
This is however only a hypothetical ideal situation which is not met in real life 
situations, and there is therefore no universal platform for protein microarrays yet. 
Nonetheless, several strategies have been adopted for the development of protein 
microarrays. Protein prints and in situ synthesis are the most popular, with the former 
being a method of choice for analytical as well as functional protein microarrays. 
Regarding functional protein microarrays, protein printing has been used to 
generate high-density functional arrays[20-22]. The advantage of this approach is that 
the exact amount of protein on each spot can be evaluated, and the proteins are 
relatively of high purity. Moreover, the expression of eukaryotic proteins in eukaryotic 
host such as yeast, may allow for some post-translational modifications. However, it 
suffers from the challenges that are related with expression and purification of proteins 
in large amounts, and also the fact, that some proteins are toxic to host cells and tend 
not to be expressed. Besides, it requires that all genes of interest be cloned into plasmids 
and fused to affinity tags for purification, which is neither cost, time nor labor efficient. 
The size of some tags may actually be problematic to the proper functioning of the 
entire protein[19]. Exploring other avenues to circumvent these problems, cell-free 
expression has been seen to be one of the most attractive options, and has extensively 
been used to produce protein microarrays using several strategies. In principle, cell-free 
transcription/translation systems, allow for the direct synthesis of proteins from cDNA 
templates, which can either be cloned into expression plasmids or generated as PCR 
products[23, 24]. Proteins can therefore be synthesized more easily, without the need 
for cloning and spotted onto microarray support platforms or directly on solid surfaces. 
This has the advantage of being cheap, time and labor efficient, but also allow for the 
synthesis of otherwise toxic proteins and has been exploited for the production of high 
density protein microarrays[25, 26]. To add to the relatively already simplified 
approach, in situ cell-free expression has the added advantage, that proteins are 
synthesized in situ, and therefore help resolve the problem of protein availability. 
Although this approach is very promising, it however falls short in terms of protein 
purity, therefore limiting their applications only to some applications, More so, the fact 
that only approximations can be made with regards to protein concentration could linit 
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its applications. Besides, since protein expression is not uniform across the entire array, 
there is a great need for normalization to avoid bias.  
Protein in situ Arrays (PISA), one of the most recent and popular strategies 
employed for the development of protein microarrays was introduced about a decade 
ago[27]. It has been emulated with more technical development and miniaturization 
(Fig.1). The Nucleic Acid Programmable Arrays (NAPPA)[28], the DNA Array to 
Protein Array (DAPA)[29], puromycine capture[30], the HaloTag[31], and the Multiple 
Spotting Technique (MIST)[32] are different versions of PISA developed to date. With 
the exception of the NAPPA which recently produced arrays of thousands proteins for 
functional screens[33], most of the others have remain very less exploited or at least 
only at a low throughput level since they were first reported. It is plausible to speculate, 
that issues related to less optimal performances of these arrays as well as other technical 
problems could, in part explain their limited applications. In effect, if PISA chips must 
be integrated into system-wide analysis of protein function, they should not only be 
robust, but should be able to generate large but biologically meaningful data that is 
synchronizable with those obtained from other platforms. Nonetheless, given the 
numerous challenges facing protein microarray production and exploitation, reliability 
and reproducibility is not always guaranteed in every situation. The aforesaid therefore 
suggest that if much is expected from protein microarrays, much should be invested, not 
only into its development and evaluation, but also enhance its availability.  
The present study was therefore designed, to optimize, and evaluate the multiple 
spotting technique, for the production of PISA, and to investigate its functional 
performance and scope of application, based on a model organism: Trypanosoma 
brucei.  
 
 
 
Figure 1: Schematic representation of the multiple spotting technique (MIST). 
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Aim 
This work was aimed at optimizing and producing functional protein microarrays by the 
multiple spotting technique and evaluating the scope of applicability and reliability of 
such arrays for proteomic analyses. 
 
Objectives 
To arrive at the above-mentioned aim, the following objectives were set forth: 
 Evaluation of cDNA products as template source for the production of PISA 
by MIST. 
 Optimization of technical parameters for optimal array quality and 
performance. 
 Establishment of reliable protein detection method. 
 Evaluation of the scope of applicability of MIST-based protein microarrays. 
 Data validation by complementary approaches. 
1.1 Proteomics tools: State of the Art 
Following the completion of the human genome project in 2003, the 
development of DNA microarrays accelerated and they fast became very robust and 
reliable tools with unprecedented analytical performance. This has earned this platform 
wide-spread applications ranging from pharmacogenomics[34], single nucleotide 
polymorphisms[35], gene expression analysis[36], biomarker discovery[37] and 
identification of transcription factor binding sites[38] among others that marked the 
genomic revolution. Despite these major breakthroughs, the contribution of DNA 
microarrays to the understanding of the mechanisms that underlie the fundamental basis 
of life and making the difference between health and disease is very limited. This is 
mainly as a result of the fact, that DNA in most cases, is only an indirect actor in the 
control of several cellular processes via the protein for which they code, and the great 
disparity between mRNA and protein abundance within a given cell[39]. To 
complement functional genomic data and bridge the gap between genomics and 
proteomics, the post-genomic era would have to develop tools with better or comparable 
performance as the DNA microarray. The proteomic era came into play, with the rapid 
development/optimization of high throughput proteomic tools such as phage/ribosome 
display, yeast two-hybrids, mass spectrometry, and protein microarrays. 
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Although microarrays in general, and protein microarray in particular can be 
potential source of many false positives[40], they also can generate high accuracy 
data[41], are very sensitive, allowing for parallel analysis of multiple analytes and 
require highly reduce sample volumes[42]. They also can provide direct evidence for a 
physical contact between two or more analytes, and allow for the analysis of transient or 
weak interaction, which would otherwise be left out[8]. Meanwhile techniques such as 
pull-down, co-Immunoprecipitation (co-IP), and display may allow for in vivo analysis, 
they however suffer from inherent limits that circumscribe their scope of applications.  
For example, pull-down and co-IP are not only labor intensive and biased in favor of 
high affinity interactions, but do not provide any information about any physical 
interactions[43]. Display on the other hand, is also labor intensive, requiring effort to be 
invested into cloning, and fusing proteins to the relatively large surface protein for 
display. This can greatly alter the folding, and hence three-dimensional structures of the 
protein and its functionality[44]. Moreover, all these methods do not allow for 
simultaneous multiple analyte analysis, and therefore not well suited for present day 
proteomics. Although yeast two-hybrid has been developed for high-throughput 
applications, it equally cannot be applied in all settings. For example, transcriptional 
repressors are not suitable for this method; auto-activating baits could potentially lead to 
very high false positive rates, while proteins that do not localize to the nucleus may lead 
to false negatives. More so, if an intermediary protein brings the prey and bait to very 
close proximity, this could also lead to false positive interactions[45]. Though at its very 
early stage, protein microarrays appear to be the most suited for current day proteomics. 
This becomes even more evident, when one compare the numerous applications for 
which proteins microarrays have been used in recent years while considering its 
relatively developing stage with respect to other well established methods. 
1.1.1  Protein Microarrays 
Based on their applications, two major types of protein microarrays can be 
distinguished: analytical protein microarrays and functional protein microarrays. The 
former are generally composed of well-characterized molecules with specific binding 
activities such as antibodies. These arrays are often used to characterize the content of 
highly complex biological samples such as serum and cell lysates and therefore can be 
used for profiling. As such, they have been widely exploited both in basic and applied 
research for the identification of posttranslational modification[46], biomarker 
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discovery[47, 48], proteomic profiling[49], network analysis[50] and disease 
proteomics[51]. Since there is yet no available technology for in situ synthesis and 
assembly of entire antibodies, production of analytical arrays still rely on protein prints. 
Functional protein microarrays, consist of a collection of individual protein 
molecules that are immobilized on solid planar surfaces in a well-organized fashion, 
such that positional information allow for the identification of individual proteins. In 
general, these arrays are used to query the biochemical properties and activities of the 
arrayed proteins. With the advent of in-situ cell-free expression, it is now possible to 
synthesize virtually all proteins of a given organism, not considering proteoforms that 
result from post-translational modification. Protein printing has also been widely used 
for the production of functional protein arrays, although some toxic and membrane 
proteins cannot be produced in this manner. 
1.1.2  Production of Protein Microarrays  
Protein printing and in situ synthesis are the currently available methods used for 
the production of functional protein microarrays. In fact, high throughput protocols for 
the expression and purification of proteins have been developed in yeast and bacteria. In 
yeast for example, using homologous recombination, a total of about 6000 proteins have 
been cloned into GST-fusion vectors, expressed and purified in 96-well plate model as 
GST-tagged N-terminal fusion proteins. Following this strategy, it is possible to purify 
as much as 1152 proteins per day[20]. In bacteria, an automated procedure for 
expression and purification of proteins as 6×His-tagged recombinant proteins has been 
developed and has permitted the production of about 4000 individual proteins in a 
single day[21]. These proteins are then printed onto solid surfaces using contact or non-
contact printers to generate corresponding arrays. 
Meanwhile these protocols have greatly enhanced the throughput of protein 
expression and purification, cell-free expression has done even better. Using the wheat 
germ extract, more than 13,000 human proteins have been produced simultaneously for 
array purposes. This clearly out performs the results obtained from all high-throughput 
in vivo expression procedures developed to date and highlight the potentials held by this 
approach[25, 26]. Despite efforts geared toward the exploitation of this strategy for the 
production of protein microarrays, most, if not all of the protein in situ arrays developed 
to date still remain with a limited scope of application. In fact, since its first description 
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more than a decade ago[52], diverse successions of strategies based on this method have 
been developed including: 
1.1.2.1 The Nucleic Acid Programmable Arrays (NAPPA)  
Developed about a decade ago[28], this method uses biotinylated plasmids 
containing ORFs coding for the target protein as a GST-fusion protein for template 
source. The plasmids are immobilized side-by-side with capture antibodies (anti GST 
antibodies), and incubated with a cell-free expression system (Mammalian reticulocyte 
lysate) for the expression of the target protein. After successful transcription and 
translation, the nascent peptide is then captured by the by-waiting antibody. This 
method was later developed and used for the production of protein microarrays of about 
a thousand proteins[33]. As one of the most exploited PISA, NAPPA has extensively 
been used in domains such as immune response tracking[53], antibody profiling in 
cancer[54, 55], assessment of bacterial immunogenicity[56] and biomarker 
discovery[57]. 
Based on a similar approach, the HaloTag NAPPA array was developed, and 
used for the analysis of protein-protein interactions for 12,000 Arabidopsis (Promega). 
This is one of the most interesting large-scale exploitation of this array type arrays since 
it was conceived. 
1.1.2.2 The DNA Array to Protein Array (DAPA) 
The DAPA uses a sandwich model for repeated synthesis of “near pure” protein 
microarrays from DNA microarrays[29]. A permeable membrane is saturated with cell-
free expression mixture, which is then laid between a template-containing array, and 
another slide containing an affinity capture agent that immobilizes the nascent peptide. 
The advantage of this technology is the fact, that the resulting arrays contain individual 
proteins at a “near pure” state, and that the original DNA microarrays can be repeatedly 
used to produce protein arrays on-demand. More so, it uses PCR-derived fragments as 
templates, therefore circumventing labor intensive and time-consuming cloning 
procedures[58]. Though recently optimized for performance[59], DAPA arrays have 
remained with limited, if at all any functional application despite the advantages it 
brings to high-throughput proteomics. 
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1.1.2.3 Puromycine Capture from RNA Arrays 
This technique is also based on the PISA strategy, but with a different capture 
agent. Here, a ribosome is installed at the end of an RNA template, which permits the 
immobilization of nascent polypeptides by a puromycin moiety that is grafted to an 
oligonucleotide immobilized on a solid surface[30]. This certainly allows for a well-
oriented immobilization of the nascent peptide, and purification. Just like the DAPA, 
since its description nearly a decade ago, this strategy has not recorded any significant 
functional application. 
1.1.2.4 The Multiple spotting technique (MIST) 
The MIST combines cell-free expression and in situ protein synthesis for the 
generation of high density protein microarrays. The major difference between DAPA 
and MIST is the fact that instead of saturating a membrane with cell-free protein 
expression system, it is spotted in a subsequent spotting on the top of the template DNA 
using non-contact printers[32]. This procedure does not only reduce reaction volumes 
and therefore is cheap, it also uses unpurified PCR-generated templates. It is therefore 
considered a miniaturized version of the PISA technique. If affinity tags are 
incorporated into the expression template via PCR, this eliminates the need for cloning, 
and allows for the use of affinity capture for the immobilization of the nascent peptide. 
This enhances the purity of the captured proteins, and makes them more suitable for 
functional applications. Although this technique is cost, time, and labor efficient, just 
like the DAPA and puromycine capture arrays, it has recorded very little, if any 
application since it was first developed. 
1.1.2.5 Other Techniques 
As each of the above-mentioned technological developments contributed to the 
alleviation of some of the drawbacks associated with protein in-situ array, some stones 
were left unturned. For example, the need to generate tag-free native proteins, recovery 
of protein-coding DNA or RNA and the need to enhance purity while maintaining 
functionality at high-throughput among others, have motivated the development of other 
systems for the fabrication of protein microarrays. As such, the Intein-based approach, 
photo cleavage and the human protein factories have been developed[60-63]. 
Meanwhile these approaches offer the possibility to produce protein microarrays for 
customized applications; they also retain some bottle-necks including the need for 
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cloning, the use of modified amino acids, and the involvement of multiple processing 
steps with potential risk of material loss. 
The above-mentioned strengthen the fact, that the route to an ideal protein 
microarray is not a nearby destination. However, the state of the art, though not the best, 
is already good enough to take proteomics to the next level. Ideally, considering protein 
microarrays as a routine tool for proteomics, one would expect that its production 
should be relatively simple and cheap. It should also have reasonable complexity and 
long shelf half-life with simple and straightforward methods for the detection and 
analysis of the immobilized proteins. In this light, it is possible that protein in situ arrays 
may hold the key into “next-generation” proteomics. 
1.1.3  Applications and Impact of Protein Microarrays 
In the course of the past decade, microarray technology has evolved rapidly both 
in terms of technological development, and scope of applications. Thus, it has moved 
from the tool of basic analytical research, as it was first seen to be, to a more 
sophisticated platform.  It has been exploited in diverse applications in fields such as 
protein expression profiling, molecular interaction mapping, drug discovery, disease 
diagnosis, toxin detection and vaccine development[1].  
1.1.3.1 Applications in Basic Research 
Functional protein microarrays have marked its presences in due course, and 
have found applications in both basic and biomedical research. Most successful have 
been the expression-based protein arrays, but protein in-situ arrays have also recorded 
some basic applications. In basic research, both array formats have been used for the 
analysis of protein-protein interactions, wherein, HaloTag NAPPA has been used to 
map protein-protein interactions of transcription factors in Arabidopsis 
(http://www.promega.de/). Meanwhile, expression-based arrays have been used for 
several such applications including interactome mapping[9]. In immunoprofiling, PISA 
just like expression-based arrays have recorded diverse applications ranging from 
biomarker discovery[64], autoimmune disease profiling[55], analysis of immune 
responses[65] and immunogenicity studies[56].  
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A Protein-Protein Interactions 
PISAs have successfully been used for the study of protein-protein 
interactions[66]. It is estimated that almost every protein performs its biological 
function by interaction with other proteins or biomolecules. The physiological and 
pathological events that underlie health and disease are all equally protein interaction-
driven processes[4]. It is therefore crucial to understand the interactions that exist 
between proteins and other biomolecules, as this gives more insights into signal 
transduction pathway mapping, protein function determination, identification of enzyme 
substrates, understanding of metabolomics and systems Biology[67, 68]. Besides, 
protein interaction studies are key to drug discovery and personalized medicines. 
Protein microarrays has been applied for early drug target identification, target 
validation, mechanisms of drug action, specificity profiling and lead optimization 
studies[69]. Contributing in this area, PISA have been used to analyze the interaction of 
proteins that are involved in DNA replication[28], and mapping of protein interaction in 
cancer-related proteins such as c-Jun, TP53, and c-Fos[70]. 
B Toxin Detection 
One of the most fascinating applications of PISA has been its usages in toxin 
detection. Considering that some substances have the potentials to inhibit protein 
synthesis, protein in situ arrays have been used to evaluate the inhibitory effects of some 
antibiotics on protein synthesis[71]. Such an approach could be useful in the elucidation 
of the mechanism of drug action, profiling of off-targets effects and toxin identification. 
This application has the great benefits of rescaling the current efforts and resources that 
are being invested into drug discovery. 
It is worth noting that with the advent of protein in situ arrays, some otherwise 
unattainable goals in high throughput proteomics can be envisaged. For example, 
despite the potentials held by membrane receptors in drug targeting and signal 
transduction, their exploitation is barely reported in literature. Nonetheless, a reasonable 
percentage of the few that have so far been studied are currently being used as drug 
targets[72]. The toxicity and insolubility of most membrane proteins is the major 
bottleneck explaining the difficulties encountered during their characterization. Cell-
free protein expression has offered an attractive alternative to such problems, and has 
been used to successfully synthesize functional membrane proteins[73]. 
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C Protein-DNA/RNA Interactions 
Beyond the above enumerated applications, protein microarrays have also been 
exploited in other field of biology and biochemistry. As such studies aiming at 
understanding the regulation of gene expression have successfully been undertaken 
using protein microarrays. Gene expression control can be mediated by cis-acting 
and/or trans-acting elements that are capable of modulating the fate of every gene and 
its product. Steroid hormones are general modulators of gene expression, and protein-
lipid interactions have been made possible in high throughput formats thanks to protein 
microarrays. In yeast, several lipid-protein interactions have been identified using an 
array of about 5800 proteins[22]. Such discoveries are not only essential for the 
understanding of gene expression control, but also for the understanding of the 
mechanism of active or facilitated transport aided by lipid-bound membrane protein. 
DNA-binding proteins such as transcription factors, nucleases and polymerases 
and histones as well as RNA-binding proteins are key modulators that control diverse 
cellular and molecular functions, by virtue of their capacity to bind to nucleic acids, and 
influence transcription and translation[74]. Aided by protein microarrays, several novel, 
but also other well-characterized protein-DNA/RNA interactions have been identified 
and characterized[75-78]. The role of RNA/DNA-binding proteins in the development 
and progression of genetic disorders such as cancers is now well-established[78, 79]. 
The characterization of RNA and DNA-protein interactions could foster the 
understanding of the mechanisms underlying tumorigenesis, DNA damage and repair, 
RNA stability and decay metastasis and even the complex mechanisms at the basis of 
cancer development and cancer cell survival. 
D Analyses of Post Translational Modifications 
Proteins are most often the targets of a plethora of post-translational 
modifications, whose entire scope is not well established. It is estimated, that the scope 
of this dynamic process could increase the complexity of the cellular proteome to as 
high as 10
6
 fold[80]. As a result of their dynamic nature, post-translational 
modifications can greatly alter the basic properties, and hence the molecular functions 
of a protein. This can result for example in swapping its function from either from 
activator to inhibitor or from active to inactive state. This has as consequence, the 
triggering of cellular pathways, controlling cell fate and making vital decisions of life 
and death for a given cell[1]. Functional arrays have also been used in this domain for 
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the identification and characterization of diverse post-translational modifications such 
as glycosylation[81], ubiquitination[82], acetylation[83], nitrosylation[84] and protein 
phosphorylation[12] 
E Analysis of Host-Pathogen Interactions 
 Most obligate parasites and other infectious agent rely on the hijack of host 
metabolic pathways for their survival. Viruses are well known for this as well as some 
bacteria [85]. It has been shown that the Epstein–Barr virus kinase is capable of 
activating an upstream mediator of DNA damage response, the histone acetyltransferase 
TIP60. It is also capable of using the chromatin remodeling function of the same protein 
during a positive feedback loop to enhance the expression of own genes necessary for 
viral replication[19]. Functional protein microarrays have been used for the analysis of 
host-pathogen interaction in viral infections[15]. Exploring such avenues could help 
identify host genes that are vital for viral replication, and provide a framework for the 
development of antiviral agents.  
1.1.3.2 Applications in Biomedical Research 
A Biomarker Discovery 
The need for reliable biomarker has been on a constant increase, as they have 
been shown to be very informative in biomedical research. Biomarkers allow for early 
identification of disease states, treatment monitoring, and following disease 
prognosis[86]. To this end, PISA arrays have been valuable tools, and thus have been 
used extensively. NAPPA-based arrays have been used for the detection of tumor-
specific autoantibodies, and multiplexed detection of serum antibodies that are crucial 
for diagnosis and monitoring of immune responses[54, 87].In the field of vaccine 
development, PISA, and precisely NAPPA have been used for the identification of 
vaccine candidates in Plasmodium falciparum, with more than seventy highly immune-
reactive proteins being identified[88]. Furthermore, NAPPA have been used for 
successful identification of diagnostic biomarkers for Q-fever, and for the analysis of 
immunogenicity of the outer membrane of Pseudomonas aeruginosa[56, 89]. 
B Drug Discovery 
A reasonable proportion of all validated drug targets are proteins and most 
reported side-effects of most drugs are due to undesired interaction of the active 
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substance or other compounding components of a drug formulation with biomolecules, 
especially proteins[90].  Proteins have now become one of the major focuses for the 
design and development of drugs that can modulate the biological function of cellular 
pathways. However, without sophisticated screening tools, identification of biologically 
active molecules from huge libraries, on complex systems such as the cellular proteome 
can be a very daunting task[1]. Functional protein microarrays have started to be seen as 
one of the tools that could alleviate such challenges, and reduce the present 
disproportionate consumption of resources and efforts. As such, methods have been 
developed[91], and used for screening protein microarrays with small molecules[91]. 
Besides, biotinylated Small Molecule Inhibitors of Ripamycin (SMIR) have been used 
to screen a yeast proteome in microarray format. This has led to the identification of 
novel candidate targets of SMIR, and help established the binding profile of such 
molecules on the yeast proteome[92]. This, if performed on other proteomes such as the 
human proteome, could identify novel drug targets, but also help identify the ground 
causes of some observed side effects. 
Despite these significant applications, the exploitation of PISA still lags behind 
that of expression-based arrays, which for example have been used for the analysis of 
posttranslational modification[13], study of enzyme kinetics[12], drug discovery[93], 
host-pathogen interactions[15] and the  identification of RNA-binding proteins[14].  
1.1.4  Current Challenges facing protein microarrays development and 
exploitation 
Despite recent developments, several drawbacks have impeded effective 
application of protein in situ microarrays in several fields. Most crucial of these, 
include, protein immobilization (appropriate surface chemistry). In fact, the success or 
failure of every microarray experiment, depends on the suitability of the properties of 
the surface chemistry used[94]. Protein purity, functionality, large scale expression of 
functional proteins and cheap methods for template generation are some major issues to 
be dealt with. Besides, although the current detection strategies available might be of 
relatively good resolution with up to single molecule detection[95], they might simply 
be just too expensive for routine usage, or may require analyte manipulations that can 
put the functionality of the proteins in jeopardy. 
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1.1.4.1 Immobilization and Surface Chemistry 
There is still no universal platform applicable to all array types and screen, and 
the right surface chemistry for every application needs to be determined empirically[5]. 
Some surfaces perform well for one application, resulting in an improved signal to noise 
ratio, and for another application, they are not suited. For example, FAST slides have 
been shown to perform well for the analysis of protein-DNA interactions and 
acetylation assays but not for phosphorylation[96, 97]. Nickel chelated slides are well 
adapted for acetylation, but not phosphorylation[97]. Ideally, a surface coating should 
provide, not only for specific and oriented capture with high affinity, but should be able 
to yield a good signal to noise ratio and descent spot morphology with long shelf 
life[98]. All such properties are however difficult to have on one surface type. For 
example, three-dimensional matrices such as agarose and polyacrylamide have been 
developed and used to coat glass slides for microarray fabrication. These surfaces have 
the advantages of retaining protein functionality, with high binding capacities. They 
also exhibit limited lateral diffusion as compared to PVDF, nitrocellulose and 
polystyrene, They however require highly sophisticated equipment for high density 
loading of the nanowells[19]. Non-covalent adsorption allows for high capacity binding, 
with little impact on the protein structure, but the amount of protein and its orientation 
is not controlled. As such, reaction efficiency, reproducibility and accuracy are variable 
and it has been found, that protein activity is reduced up to 10-fold when proteins are 
immobilized randomly[99]. Oriented capture, especially affinity capture seems to be an 
option of choice. However, the introduction of large affinity tags may affect protein 
folding and hence functionality, meanwhile some of the available surfaces for affinity 
capture yield very poor signal to noise ratios. 
1.1.4.2 Data Readout 
A Label-Dependent Detection 
Several methods exist for microarray readout, and are grouped under two main 
principles: label-dependent and label-free detection[5]. In label-dependent detection 
methods, radioisotopes and fluorescent dyes are often used to detect molecules bound to 
the microarray. The use of radioisotopes is one of the most ancient detection strategies 
that have been used in several biological applications. It has the advantage over 
fluorescent dyes that it is more sensitive and reliable, but need the manipulation of 
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radioactive substances. Most protein microarray-based enzyme assays to date have 
relied on radiolabelling [18, 83, 97]. Fluorescent dyes, such as Cy3/5 and other 
homologues are now becoming very popular for probe detection. They circumvent the 
need to manipulate radioactive substances, but are less sensitive than radioisotopes. 
Their relatively large size could influence the outcome of an experiment, or even make 
it unsuitable for probes with low molecular weight. Fluorescent dyes, also have the 
advantage of reducing cost, as they can be used for simultaneous detection and direct 
comparison of different samples, thereby avoiding chip-to-chip variations[5]. To 
overcome the problem of sensitivity, other label-dependent, nonradioactive detection 
methods have been developed. Semiconductor quantum dot labeling[100] and enhanced 
chemiluminescence[101] have also been applied for sensitive and stable detection on 
protein microarrays. Signal amplification strategies have also been developed for the 
detection of samples with low abundance even down to the femtomole level. Rolling 
cycle amplification[102], and tyramide amplification are now available for more 
sensitive detection of labeled probes[103]. Moreover, fluorescence-linked 
immunosorbent assay has been applied for the detection of exposure to tuberculosis 
toxin at the single molecule level. This increases the sensitivity that can be achieved 
with label-dependent techniques, but there is need for sophisticated equipment that is 
not always available. 
Other indirect detection methods have also been established, especially for the 
detection of protein-protein interactions using specific antibodies to recombinant bait 
proteins[104]. Meanwhile this does not require the manipulation of the protein 
structure; it however demands that the bait protein be fused to an epitope tag, which 
could affect the protein folding and function. Besides, it is also possible, that during 
protein folding, the antibody-binding epitope is localized close to the binding domain of 
the bait protein. After interaction of both proteins, stearic hindrance could affect 
antibody detection either by reducing the signal, or excluding it entirely leading to false 
negative results. 
B Labe-Free Detection 
Since label-dependent methods always require a modification of the native 
structure of the probe molecule, label-free strategies have been introduced. These 
methods allow for real-time monitoring of a binding event using a probe in its native 
state. Label-free detections generally rely on the measurement of a change in some 
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optical parameters during the course of a reaction. Imaging Surface Plasmon Resonance 
Spectroscopy (SPR)[105], Imaging Optical Elipsometry (OE)[106] and Reflectometric 
Interference Spectrometry[107] are label-free detection methods, that rely on the 
measurement of the optical dielectric response on a thin film such as changes in the 
physico-chemical properties of the film with time. 
A more sensitive variant of elipsometry; the Oblique-Icidence Reflectivity 
Difference (OIRD), has also been developed and used for real time analysis of DNA 
hybridization and protein-protein interactions. This detection method demonstrated its 
potentials for high throughput application, with a detection limit of 14 fg and a 
resolution time of about 20 µs[108]. Mass spectrometry has also been applied for 
microarray readout with the advantage that it is simple, fast, and requires relatively 
small amounts of samples and is applicable to complex samples such as urine, plasma 
and cell lysates[109]. Another label-free detection method, the Atomic Force 
Microscopy, measures topological changes on the microarray surface such as increase 
in the height of a protein/antibody spot[110]. 
Label-free detection methods have largely enhanced the sensitivity of microarray 
readout, and circumvent the need for sample manipulation that can jeopardize the native 
structure of some proteins. However, the simple fact that most of these methods require 
very sophisticated equipment and specialized training for their exploitation make them 
inaccessible to the global scientific community.  It is therefore evident that the need for 
more simple, reliable and cost efficient detection methods for microarray readout is still 
of prime importance and remains a bottle neck to be overcome. 
1.1.4.3 The Issue of False-Positives and False-Negatives 
In most high throughput experiments, several samples are analyzed 
simultaneously and multiple hypothesis are tested. Faced with multiple hypotheses 
testing, it is possible to make type 2 statistical errors resulting in false-positives, or type 
1 error, resulting in false-negatives. There is therefore a need for methods to control the 
probability of making erroneous conclusions[111]. Moreover, in microarray 
experiments, molecules that would otherwise not come into contact due to cellular 
compartmentalization are brought together, and it is possible that such molecules have 
affinities to one another or simply just stick to each other. Adequate positive and 
negative controls and the analysis of interaction events as a function of 
compartmentalization are needed. This is a difficult task, as some molecules can transit 
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from one compartment to another and some unknown proteoforms of a given protein 
might specifically localized in unexpected cellular compartments. Large-scale 
complementary in vivo experiments may be helpful in such cases. However, the design 
and execution of such experiments could be extremely challenging. 
1.2 Gene Expression and Control in Trypanosomes 
Trypanosomes are unicellular protozoa parasites that are responsible for human 
and animal diseases in tropical areas especially Africa and South America. Unlike other 
eukaryotes where transcriptional and post transcriptional regulation of gene expression 
is well developed and ensures a balance in the steady state of RNA levels, most of their 
gene expression control is at the posttranscriptional level[112]. Just like other 
kinetoplast such as Leishmanias, their genetic organization is unusual in that each 
polymerase II promoter controls the transcription of multiple open reading frames down 
stream of it. Individual transcripts are then processed and regulated individually by 
trans-splicing and polyadenylation[113]. It is therefore almost impossible to exert 
transcriptional regulation for the expression of individual genes with such genomic 
organization. Besides, some protein-coding genes such as the GPEET procyclic surface 
coat protein are under the control of polymerase I[112]. Without any transcriptional 
regulation of gene expression, one would expect, as it is the case, that the combined 
effects of cis- and trans-acting elements such as RNA-binding proteins that are involved 
in RNA processing, translation and degradation fine tune gene expression and 
determine the fate of individual RNA or subset of RNA molecules. Most of the trans-
acting elements bind to cis-elements in the 3 UTR and 5 UTR, but some are known to 
bind coding regions even if the later seem awkward regarding translation[114].  It is 
estimated, that between 100–200 different proteins encoded in the trypanosome genome 
have RNA-binding properties[115], and about 70 proteins are known to possess RNA 
recognition motifs (RRM)[116]. These proteins are sub classified according to their 
functions or RNA recognition domains and play distinct roles. 
 The ALBA domain proteins, for example, are known to interact with 
polyribosomes, proteins of the translation machinery such as the cap-binding protein 
eIF4E4 and polyA-binding proteins [117]. These observations fuel the speculation that 
even if they may have some other function, they are most probably involved in RNA 
stability. Another example, the Pumilio domain proteins, a class of ten proteins known 
in most organisms to be involved RNA decay, RNA transport, rRNA processing and 
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translational repression by sequence-specific binding to target RNA molecules[118]. In 
trypanosomes however, the only characterized member of this protein family, the PUF9, 
has been shown to stabilize a subset of mRNAs [119]. It is well possible, that added to 
the already known functions of these proteins, they exert other functions that are either 
cell cycle-specific or that depend on other pressures exerted on the cell. Zinc finger 
proteins, another class of RNA-binding proteins are known to play diverse roles. Some, 
such as ZFP1 and ZFP 2 are involved in stage differentiation, meanwhile others such as 
ZFP3 and ZC3H11 are known to stabilize some RNA transcripts under stress 
conditions[112]. The polyA-binding proteins, PABP1 and PABP2 binds to the polyA 
tail of mRNA and stabilizes the mRNA by interaction with the initiation factor eIF4 
located at the 5 cap of mRNA transcripts forming a loop structure that is necessary for 
efficient translation. Other proteins with RRMs such as the U-binding proteins do not 
seem to have sequence specific functions, even if they have been shown to be 
essential[112]. The polypyrimidine trac binding proteins (PTB), yet another class of 
RNA-binding proteins, are involved in cis- and trans-splicing, as well as stabilization of 
some mRNA transcripts and like other mammals, they regulate RNA metabolism from 
synthesis to degradation[120]. 
 Besides proteins that are involved in RNA processing, translation and stability, 
others, by their RNA-decay properties, conjugate their efforts to ensure the balance 
between synthesis and abundance. They are proteins involved in RNA degradation and 
generally tend to destabilize transcripts and in most cases, this starts with transcript 
deadenylation. In trypanosomes just as with other eukaryotes, the CAF/NOT complex is 
responsible for deadenylation. This leads to the dissociation of the PABP and hence 
release of the loop structure exposing the polyA tail to degradation by exosomes. 
Meanwhile, removal of the 5-cap structure following the release of the loop-structure 
exposes the 5 end which can then be degraded by 5 exoribonuclease XRNA[121]. It 
seems therefore that the action of the CAF/NOT complex in many cases is likely to be a 
key step into RNA degradation and may also be the limiting step. In trypanosomes, the 
CAF-NOT complex unlike in other eukaryotes does not have the NOT4 protein, which 
is known to be an ubiquitin ligase [122, 123]. The complex is made up of the following 
subunits CAF1, NOT1, NOT2, NOT5 NOT9, NOT10, and NOT11 all of which are 
most likely, but not exclusively involved in RNA degradation. In addition to its role in 
RNA decay and ubiquitination, it has recently been shown to have more functions than 
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previously expected. The CCR4-Not complex has been shown the play an indispensable 
role in miRNA-mediated silencing by facilitaiting miRNA-dependent decapping and 
deadenylation[123]. A novel role has also been described for the complex, involving its 
participation in the regulation of cellular proteostasis and protein quality control by 
translational arrest[124, 125]. 
Considering the central role played by proteins and their involvement in the 
regulation of cellular homeostasis and the subsequent implications in health and disease, 
understanding the intricate networks underlying such functions is very important. This 
could allow not only for system-wide analysis of the extent and mechanisms of protein 
involvement in diverse cellular and physiological conditions, but also improve the 
outcome of clinical interventions. With the very complex nature of the cellular 
proteome, reliable and cost efficient methods for simultaneous analysis of protein 
structure and function need to be developed and validated. 
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2 Materials and Methods 
2.1 Materials  
Antibodies    
Product Catalogue  N
o
 Manufacturer 
AntiPhosphoserine/Threonine/ 
Tyrosine Antibody  
MA1-38450 Thermo Scientific 
Monoclonal Anti-V5, Cy3 conjugate V 4014 Sigma-Aldrich 
Penta·His Alexa Fluor647 Conjugate 35370 Qiagen 
Kits 
Product Catalogue  N
o
 Manufacturer 
BCA protein assay Kit 23225 Thermo Scientific 
EasyXpress Insect Kit II 32561 Qiagen 
Magnetic RNA-Protein Pull-Down Kit 20164 Thermo Scientific 
miScript II RT Kit 218160 Qiagen 
miScript SYBR® Green PCR Kit 218073 Qiagen 
PCR Extract Mini Kit 2300600 5 Prime 
pET101/102 Directional Topo cloning kit K101/102-01  Invitrogen 
PureLink PCR Purification Kit K3100-01 Invitrogen 
PURExpress™ In Vitro Protein Synthesis Kit E6800S NewEngland Biolabs 
PureYield Plasmid Miniprep System A1222 Promega 
QIAprep Miniprep Kit 27106 Qiagen 
RNA 3 End Biotinylation Kit 20160 Thermo Scientific 
RNA 3 End Desthiobiotinylation Kit 20163 Thermo Scientific 
S30 T7 High-Yield Protein Expression Kit  L1110 Promega 
TNT T7 Quick for PCR DNA 
Expression Kit 
L5540 Promega 
TranscriptAid T7 High Yield Transcription Kit  K0441 Thermo Scientific 
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Chemicals 
Product Catalogue  N
o
 Manufacturer 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
HN77.4 Carl Roth 
Acetic acid 27221 Sigma-Aldrich 
Acrylylamide/Bisacrylamide 3029.1 Carl Roth 
Agar-Agar,Kobe I 5210.3 Carl Roth 
AirPore Tape Sheets 19571 Qiagen 
Ammonium per sulfate A3678  Sigma-Aldrich 
Amplicillin (Sodium salt) M3110 Genaxxon 
Bacteria Cell Spreader 89042-018 VWR International 
Betaine Monohydrate B2754 Sigma-Aldrich 
Biozyme LE Agarose 840004 Biozyme 
Bovine serum Albumine 05470 Sigma-Aldrich 
Butane 106-97-8 Camping Gaz 
Chloroform 288306 Sigma-Aldrich 
Cy3-UTP PA53026 GE Healthcare  
Cy5-UTP PA55026 GE Healthcare  
DL-Dithiothreitol (DTT) R0861 Thermo Scientific 
dNTP set, Sodium salt M3015.4100 Genaxxon 
Ethanol, absolute 24102 Sigma-Aldrich 
Ethidium bromide M3178.0010 Genaxxon 
Ethylenediaminetetraacetic acid E9884 Sigma-Aldrich 
GeneRuler DNA marker SM  0311 Thermo Scientific 
Glutathione agarose 16100 Thermo Scientific 
Glycerol G5516 Sigma-Aldrich 
Guanidine Hydrochloride 6009.2 Carl Roth 
Halt™ Protease and Phosphatase 
Inhibitor 
78443 Thermo Scientific 
Hellmanex II 320.001 Hellma GmbH 
Heparin sodium salt from Porcine 
Intestinal Mucosa 
H4784 Sigma-Aldrich 
HisPur™ Ni-NTA Resin 88221 Thermo Scientific 
Hydrochloric acid (HCl),  (37%) 85848.290 VWR International 
Materials and Methods 
 
24 
 
Imidazole 3899.2 Carl Roth 
Isopropanol W292907 Sigma-Aldrich 
Isopropyl-β-D thiogalactopyranoside M3198.1001 Genaxxon 
Kanamycine K4378 Sigma-Aldrich 
L-Glutamic acid potassium saltmonohydrate G1501 Sigma-Aldrich 
LightCycler
®
 480 Multiwell Plate 384, white 04729749001 Roche 
Magnesium acetate tetrahydrate M0631 Sigma-Aldrich 
Methanol 322415-2L Sigma-Aldrich 
Millex-GP, 0.22 µm  filter SLGP033RS EMD Millipore 
MultiScreen PCRµ96 Plate LSKM PCR 50 EMD-Millipore 
N,N,N′,N′-
Tetramethylethylenediamine 
(TEMED) 
T9281 Sigma-Aldrich 
NEXTERION® Slide E 1066643 SCHOTT 
Nickel Chelate slides VNC 000 10 Xenopore 
Nitrocellulose slides SMN Arrayit corporation 
Nuclease-Free Water AM9939 Life Technologies 
PCR tubes,8 strip 0,2ml AM12230 Life Technologies 
Peptone from Casein 70171 Sigma-Aldrich 
Phenylmethylsulfonyl fluoride 36978 Thermo Scientific 
Polystyrene cell culture tubes 187261 Greiner bio-one 
Ponceau S solution 33427.01 Serva 
Potassium chloride (KCl) P5405 Sigma-Aldrich 
Q5 High-Fidelity DNA polymerase M0491L New England Biolabs 
RNaseOUT™ RibonucleaseInhibitor 10777-019 Invitrogen 
Sodium Chloride (NaCl) S9888 Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) 71725 Sigma-Aldrich 
Sodium phosphate dibasic(Na2HPO4) S9763 Sigma-Aldrich 
Sodium phosphate monobasic(NaH2PO4) S9638 Sigma-Aldrich 
SpectraMulticolor Broad range 
protein ladder 
26623 Thermo Scientific 
Streptavidin-coated slides MPC 000 10 Xenopore 
SYPRO
®
 Ruby Protein Gel Stain S4942 Sigma-Aldrich 
Syringes50 ml SS03L2138 Terumo 
Tergitol
®
 solution NP40S Sigma-Aldrich 
Triton X-100 T8787 Sigma-Aldrich 
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Trizma
®
 Base T1503 Sigma-Aldrich 
Trizma
®
 HCl T3253 Sigma-Aldrich 
TRIzol Reagent 15596-018 Invitrogen 
tRNA from E.coli 10109541001 Roche Diagnostics 
Tween
® 
20 P2287 Sigma-Aldrich 
Yeast Extract Biotechnology Grade 1830,1000 Gerbu 
Zinc chloride (ZnCl2) 208086 Sigma-Aldrich 
β-mercaptoethanol M6250 Sigma-Aldrich 
Labware 
Product Catalogue  N
o
 Manufacturer 
Adhesive PCR Seal 600208 Biozyme 
Amicon Ultra-15 Centrifugal Filter Units UFC900308 EMD Millipore 
Cell culture 96 well microplate,U-bottom 650160 Greiner Bio-One 
Centrifugal Ultrafiltration device VC1002 Sartorius 
Conical bottom falcon tubes(15 ml/ 50ml) 
227261/210261 
Greiner Bio-One 
Eppendorf Safe-Lock tubes 
(0.5 ml, 1.5 ml and 2 ml) 
0030121694/  
0030121597/  
0030121570 
Eppendorf 
Gloves, Latex Medical Examination  BM 11228-PF-AV Blossom 
Gloves, Nitril Freeform SE FFS-700 Microflex 
Hydrogel slides SLDF Arrayit corporation 
Nunc 96 well plates M9410 Sigma-Aldrich 
Nunc-Lab-Tek petri dishes 4021 Thermo Scientific 
Parafilm
®
 M P8505 Labomoderne 
Thin wall standard 96-well PCR plate 82-0600-A Peqlab 
Whatman
®
  UNIPLATEmicroplates 
384 well, V-bottom  
7701-5101 GE Healthcare Life 
Science 
Equipment 
Name Manufacturer 
Arrayscan 4000XL Pekin Elmer 
Biofuge, Pico Hereaus  Instruments 
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Electronic Balances, Kern 434,440–45 Kern & Sohn GmbH 
Heating Block Grant Instrument 
Hoefer TE 70 Semidry Transfer Unit GE Healthcare 
Ice maker Scotsman 
Laminar Hood Hereaus instruments 
Microcomputer electrophoresis power supply Renner GmbH 
Microwave oven Bosch 
Mixmate Microplate Mixer Eppendorf 
Nanodrop Spectrophotometer N1000 Peqlab 
Nanoplotter 2 GeSIM 
Orbital Shaker Edmund Bühler 
Power Scanner Tecan 
Refrigerated centrifuge 2k15 Sigma 
Rocky shaker  Fröbel Instruments 
RS-TR05 Phoenix Instruments 
Centrifuge R5810 Eppendorf 
Thermocycler MJ Research, LifeEco 
TKA MilliQ watter supply Millipore 
Ultraspec 2000 Spectrophotometer  Pharmacia Biotech 
Ventillated Oven Kendro Instruments 
Vortex Mixer Neolab 
Water bath Grant Instruments 
 
Buffers and media       
Name Composition 
Binding buffer 5×  25 mM Hepes pH 7.9, 50 mM Glutamte potassium 
salt, 1 mM DTT, 8 mM Magnessium acetate,  10% v/v 
glycerol 
Ethidium bromide solution 0.5 μg/ml Final concentration 
Laemmlibuffer 30.1 g Tris Base, 144.2 g Glycine, 50 ml SDS (20%), 
add 1 l dH2O  
LB-Agar  LB-Medium + 1.5% (w/v) Agar  
LB-Medium (1 liter)  10 g Tryptone/Pepton, 5 g yeast extract, 
5 g NaCl, pH 7.2  
PBS 10× (1 liter)  80 g NaCl, 2 g KCl, 26.8 g Na2HPO4, 2.4 g KH2PO4, 
pH 7.4  
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TBE 10× (1 liter)  108 gTris, 55 g Boric acid, 40 ml 0.5 M Na2EDTA, 
pH 8  
TBS 10× (1 liter)  50 mM Tris, 150 mM NaCl with HCl, pH 7.5  
TBST  1× TBS/0.05% Tween-20  
Transfer buffer 150 mM Glycine, 25 mM Tris-base, 20% Ethanol  
PBST 1× (1 liter) 1× PBS/0.05% Tween-20 
1M HEPES-KOH pH 7.5 Dissolve 238.30 g HEPES in 1 l H2O. Use KOH Stock 
solution to adjust pH to 7.5 
0.5 M EDTA pH 8.0 Dissolve 186.1 g Na2EDTA.2H2O in 800 ml diH2O. 
Adjust pH to 8.0 with NaOH (~20 g of NaOH pellets). 
EDTA will dissolve at pH 8.0. Adjust volume to 1 liter 
with diH2O. Sterilize by autoclaving and store at room 
temperature. 
1 M Tris-HCl pH 6-8 12.1 g tris base in 100 ml H2O, adjust pH with 
concentrated HCl 
10 M NaOH 40 g NaOH in 100 ml H2O 
1 M NaH2PO4 (monobasic) 138 g NaH2PO4.H2O in sufficient H2O to make a final 
volume of 1 liter 
1M Na2HPO4 (dibasic) 142 g of Na2HPO4 in sufficient H2O to make final 
volume 1 liter 
6× Gel loading buffer 25 mg bromophenol blue and 4 g sucrose, make up 
volume to 10 ml with diH2O, store at 4°C 
6× Gel loading buffer with 
Ficoll 
25 mg bromophenol blue, 25 mg xylene cyanol FF and 
1.5 g Ficoll (Type 400;Pharmacia) in 10 ml diH2O, 
store at 4°C 
Gluthathione free acid reduced  Sigma-Aldrich Chemie GmbH, Germany 
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2.2 Methods 
2.2.1  Template Generation for Protein Microarray Production 
Template DNA for PCR-based generation of protein expression constructs was 
obtained from a cDNA library cloned in lambda zap CMV. The library was constructed 
from procyclic mRNA of Trypanosoma brucei and directionally cloned into the 
phagemid with a complexity of 150,000 pfu/ml. Individual clones were obtained by 
plaque lifting as described in the manufacturers. Briefly, XL1bleu E.coli cells were 
grown to an optical density of 0.6, and then inoculated with about 1.5×10
2 
pfu from the 
phage library. The bacteria-phage mixture was then incubated at 37°C for 30 minutes 
for phage attachment. After attachment, 1.8ml of top agar containing 10mM MgSO4 and 
0.2% Maltose maintained at 48°C was immediately added to the phage-bacteria mixture 
and then poured onto NZY agar plates in 150×25mm polystyrene culture dishes (Becton 
Dicson). The plates were allowed at room temperature for 30 minutes, then inverted and 
incubated overnight at 37°C. Plaques were chilled at 4°C for 1 hour and lifted using 
sterile toothpicks. Individual plaques were lifted into sterile U-shaped 96 well plates 
(Cellstar) containing 200 µl of milliQ water. The plates were sealed and heated at 80°C 
for 15 Minutes in a ventilated oven. Clone individuality was checked by PCR and the 
heat-killed bacteriophage was then used for the generation of cell-free expression 
templates. For Open Reading Frames (ORF), primers were designed and synthesized 
(Biomers) to amplify specific genes directly from gDNA. All gene-specific primers 
carried 5 and 3 overhangs which were later used as priming sites for the generation of 
expression constructs. 
All expression primers were similar in their basic structure, but their 
complementary sequences varied depending on template source (Index 1). The basic 
primer consisted of an upstream spacer, T7 promoter internal spacer, a ribosome 
binding site/Kozak sequence and a downstream spacer. For ORFs, the downstream 
spacer was followed by a start codon, a 6×His epitope and the complementary region. 
Meanwhile, for the cDNA products, the downstream spacer was directly followed by 
the complementary sequence. PCRs were carried out in V-bottom 384 well clear PCR 
plates in a total volume of 25 µl containing 1× Q5 reaction buffer, 1× Q5 high GC 
enhancer, 0.25 µM forward and reverse primers, 0.2 mM dNTP, 5 µl of heat-killed 
Materials and Methods 
 
29 
 
bacteria plaques and 2.5 U of Q5 high fidelity DNA polymerase. Cycling was done 
following the manufacturer’s instructions and 5 µl of amplicons was randomly checked 
on 1.2% agarose gels. 
2.2.2   In Situ Cell-Free Protein Expression 
The Multiple spotting technique was used for on-chip protein expression, and 
several cell-free expression systems were tested including: the T7 TNT quick for PCR 
DNA (Promega), the EasyExpress insect kit II (Qiagen), PureXpress In vitro protein 
synthesis kit (New England Biolabs), and the S30 T7 High yield protein expression 
system (Promega). Expression constructs were mixed with 0.5 M betaine (final 
concentration) in V-bottom 384 Uniplate (whatman). The plate was briefly spun down 
and mixed on a micromate mixer for 30 seconds at 1600 rpm. Approximately 0.9 nl of 
template was spotted using a non-contact Nanoplotter 2 (GeSIM) onto the glass surface 
followed by 3.6 nl of the cell-free expression mixture with or without transcend-biotin-
lysyl tRNA (in the case of streptavidin slides). The slides were then incubated in deep 
humid hybridization chamber for protein expression. Many expression temperatures and 
incubation periods were tested on diverse surface coatings. Therefore, spotting was 
either done on epoxysilane slides (Nexterion slide E), Ni-NTA coated slides (Millipore), 
Streptavidin-coated slides (Millipore) or Nitrocellulose slides (Arrayit corporation), and 
incubated in a ventilated oven: at room temperature, at 37°C for two hours, at 37°C 
overnight, at 37°C for two hours plus 30°C overnight and at 37°C for one hour and 
30°C overnight oven. Slides were removed from the incubation chambers and stored at 
–20°C for at least 24 hours before use.  
2.2.3  Detection of Expressed Proteins 
Two strategies were adopted for the detection of expressed proteins, depending 
on whether or not the expressed proteins were fused to epitope tags. For proteins 
expressed from ORFs, Alexa Fluor 647-conjugated monoclonal anti 6xHis was used for 
detection. Therefore, slides were mounted on slide frames and blocked at room 
temperature for one hour in blocking buffer containing 2% BSA in PBST on an orbital 
shaker. The slides were washed three times 5 minutes each in PBST before incubation 
with a 1:1000 dilution of the antibody in blocking buffer. Incubation was done at room 
temperature for one hour on an orbital shaker and the slides were washed in PBST three 
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times 5 minutes each. Finally, the slides were rinsed in milliQ water, air-dried at 30°C 
for 30 minutes and scanned in a Tecan power scanner. Images were saved as tagged 
image files (TIF) and analyzed with GenePix Pro.6.0. Meanwhile, proteins expressed 
from cDNA products were stained with SyproRuby protein gel stain. For this purpose, 
proteins were fixed on slides in a solution of 50% methanol and 7% acetic acid at room 
temperature for 30 minutes. Then, the slides were incubated with SyproRuby protein gel 
stain for 90 minutes at room temperature on an orbital shaker. Afterwards, slides were 
washed in a solution of 10% methanol and 7% acetic acid for 30 minutes at room 
temperature, rinsed in milliQ water, air-dried at 30°C for 30 minutes and scanned on a 
ScanArray 5000 microarray scanner. Images were saved as TIF files and analyzed as 
above. 
2.2.4  Test of Functionality and Protein Quantification  
Since the main aim of this study was the production of functional array, we 
equally evaluated the functionality of protein expressed on the platform. Therefore, the 
Green Fluorescent Protein (GFP) was used. Purified recombinant GFP was spotted in 
serial dilution, and on the same slide, GFP was expressed by the multiple spotting 
technique. The slides were incubated together for the expression of GFP. One slide was 
scanned directly for the auto fluorescence of GFP while the other was treated with 6 M 
guanidine-hydrochloride before scanning. Moreover, the trypanosome trypanothione 
reductase was expressed in the S30 T7 high yield system and assayed for its activity 
using Trypanothione (TS2) and NADPH 
2.2.5  Expression and Purification of Recombinant Bait Proteins and 
Enzymes 
The DNA sequences of the Bait proteins and enzymes were amplified from 
gDNA and cloned into the Champion pET 101 directional Topo expression vector 
(Invitrogen) or in pDEST 15 following the manufacturer’s protocol. Briefly, PCR 
products were purified using Purelink PCR purification kit (Life technologies), and 
quantified using Nanodrop. About 75 ng of purified PCR products were mixed with 15 
ng of pET plasmid in the presence of 0.6 mM NaCl and 0.03 mM MgCl2. The reaction 
was allowed at room temperature for 15 minutes and 3 µl of the cloning reaction was 
used to transform Top10 chemically competent cells and later plated onto LB ampicillin 
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(100 µg/ml) agar plates. Single colonies were picked from the agar plates and grown in 
LB medium containing 100 µg/ml Ampicillin for 8 hours and plasmid DNA was 
isolated using the Qiaprep plasmid isolation kit (Qiagen) following the manufacturers 
protocol. The presence of the insert was confirmed by PCR using vector and insert-
specific primers. Positive clones were sequenced and used for transformation of BL21 
star E.coli cells. Cells were transformed with 50 ng of the plasmid and grown in 10ml 
LB medium containing 100 µg/ml of ampicillin. The culture was grown until an optical 
density of 0.6 and test protein expression was initiated by the addition of 250 mg/l of 
IPTG. After 6 hours of culture, the cells were harvested by centrifugation at 4000 rpm 
for 30 minutes, proteins extracted and a western Blot was performed. 
 For pilot expression, a 10ml of overnight culture was transferred into a 1liter 
culture flask containing 2YT medium. The culture was grown until an optical density of 
0.6 and pilot protein expression was initiated by the addition of 250 mg/l of IPTG. After 
induction, the cells were grown for further 4–16 hours and harvested by centrifugation 
at 5000g for 15 minutes in an RC-5C super speed centrifuge (Sorvall). The pellet was 
washed in ice-cold PBS (pH 7.5). Proteins were extracted using the B-PER reagent 
supplemented with lysozyme (1mg/ml) according to manufacturer’s protocol and 
recombinant proteins purified using Ni-NTA agarose (Invitrogen). The concentration of 
the purified protein was measured using the BCA protein assay Kit (Pierce) and stored 
in HEPES buffer (pH 7.5), containing 150 mM NaCl, and 25% glycerol.  
2.2.5  RNA preparation 
The genes coding for candidate RNA were amplified by PCR and cloned 
downstream of the T7 promoter. The resulting linear construct was used as template for 
the synthesis of RNA using the Transcript Aid T7 high yield in vitro transcription kit 
(Fermentas) according to the manufactures protocol. For the synthesis of fluorescently-
labeled RNA probes, this protocol was modified by using a ratio of 1:3 of UTP and 
Cy3-UTP (GE Healthcare) respectively. The reaction was incubated at 37°C for 6–8 
hours, and RNA was purified by sodium acetate precipitation, re-suspended in 
Nuclease-free water containing 20mM EDTA and stored at −80°C. Biotinylated probes 
were synthesized in a similar manner, but without Cy-Dye UTP and labelled using the 
Pierce™ RNA biotinylation/destiobiotinylation kit following manufacturer’s 
instructions. Therefore, 25% DMSO was added to the synthesized RNA and heated at 
90°C for 5 minutes on a heating block and immediately placed on ice. The ligation 
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reaction, containing 1× RNA ligation reaction buffer, 40U of RNase inhibitor, and 40U 
of T4 ligase, 1 nmol biotinylated cytidine (bis) phosphate and 15% polyethylene glycol 
in a total volume of 30 µl was prepared. The denatured RNA was added to the reaction 
mixture and incubated at 16°C for 8 hours. After ligation, the reaction volume was 
completed to 100 µl, and labelled RNA was purified by isoamyl acohol:chlorofoam 
extraction. RNA oligos that could not be synthesized due to size constraints were 
commercially synthesized and labelled as desired. 
2.2.6  Protein-Protein Interactions (PPI) 
Protein microarrays were thawed directly in blocking buffer (20 mM Tris-HCl, 
pH 7.9, 0.1% Triton X-100, 0.2 mM PMSF,5 mM CaCl2, 5 mM MgCl2, 100   mM NaCl 
1mM DTT, 1× Halt protease and phosphatase inhibitor cocktail, 20% glycerol and 1% 
BSA) and blocked for one hour at room temperature on an orbital shaker. The arrays 
were washed three times 5 minutes each in wash buffer (20 mM Tris-HCl, pH 7.9, 0.1% 
Triton X-100, 0.2 mM PMSF, 5 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, 1 mM DTT, 
1× Halt protease and phosphatase inhibitors). Bait proteins were fluorescently labeled 
with Dylight 532/647 and purified on Zeba spin columns. Bait proteins were diluted as 
appropriate (25 µg/ml) in blocking buffer and incubated on the arrays overnight at 4°C. 
Afterwards, arrays were washed again three times 10 minutes each, and then rinsed in 
milliQ water. All arrays were air-dried and scanned on a Tecan scanner. Data was 
extracted using GenePix 6.0 Pro and analyzed with the Limma package in R. 
2.2.7  Protein-RNA Interactions (PRI) 
For PRIs, protein microarrays were screened with either 0.1 µM concentrations 
of short oligomers, or 2 µg for longer RNA species such as 3 UTRs, polyA RNA and 
total RNA. The arrays were thawed in Blocking buffer (25 mM Hepes-KOH, 50 mM 
Glutamic acid potassium salt, 8 mM magnesium acetate, 100 µM zinc chloride, 20 
µg/ml heparin, 50 µg/ml E. coli tRNA, 0.1% Triton X-100, 40U RNaseOUT RNase 
inhibitor, 1× Halt protease and Phosphatase inhibitor cocktail and 1% BSA) and 
blocked for 1 hour at room temperature with gentle shaking (50 rpm). The arrays were 
washed in wash buffer (25 mM Hepes-KOH, 50 mM Glutamic acid potassium salt, 
8mM Magnesium acetate, 100 µM Zinc chloride, 20 µg/ml heparin, 50 µg/ml E. coli 
tRNA, 0.1% Triton X-100, 40U RNaseOUT RNase inhibitor, 1× Halt protease and 
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Phosphatase inhibitor cocktail) three times 5 minutes each, and then probed with 
labelled RNA probed in Binding buffer (blocking buffer containing 0.4 mg/ml E. coli 
tRNA and 40 µg/ml heparin) overnight at 4°C without shaking. Arrays were again 
washed three times 15 minutes with gentle shaking at room temperature, air-dried and 
scanned as above.   
2.2.8  Minimal Sequence Mapping 
Selected fragments of the 3-UTR of 6 genes were analyzed on protein 
microarrays. To investigate if the observed binding was sequence-specific, minimal 
sequence mapping was performed. Therefore, the trypanosome hexose transporter gene 
3-UTR was used. Fragments were generated via PCR to have 100nt difference in 
length, and subsequently fused to a T7 transcription construct. The fragments were 
transcribed as above and used to screen the arrays in triplicates as before. In silico 
folding of the fragments was performed using RNAfold web server[126]. A stem loop 
conserved across all fragments was commercially synthesized and biotin-labeled. This 
stem loop was then used to rescreen the arrays as described previously 
2.2.9  Kinase Substrate Identification 
Substrates of the T. brucei Aurora Kinase B (Centrin II and Histone H3) were 
expressed using the MIST technique and arrays were used for protein kinase assay.  To 
this end, slides were blocked in superblock supplemented with 0.1% Triton X-100 for 
one hour at room temperature on an orbital shaker. The arrays were then washed twice 
in Kinase buffer (25mM Hepes-KOH pH 7.9, 150mM NaCl, 10mM MgCl2, 0.1% Triton 
X-100,1× Halt protease and phosphatase inhibitor cocktail and 25% glycerol) for 5 
minutes at room temperature. The kinase reaction containing 50 µg of Aurora kinase B 
from Trypanosoma brucei, and 33 mM ATP in kinase buffer was incubated at 30°C for 
2 hours, then washed in kinase buffer 3 times 5 minutes. A 1:100 dilution of mouse anti 
phosphoaminosereine/threonine/tyrosine antibody (SPM 101) was made in kinase 
buffer containing 1% BSA and incubated on the slides for 90 minutes. The arrays were 
again washed as previously, and a 1:5000 dilution of Cy5-conjugated anti mouse 
secondary antibody was incubated on the slides for one hour. Finally, the slides were 
washed three times 10 minutes and then rinsed briefly in milliQ water, air-dried and 
scanned.  
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2.2.10 Antibody Selection 
To check if specific proteins could be expressed from cDNA products, arrays 
made from cDNA products were screened with a pool of T. brucei protein-specific 
antibodies. In this instance, arrays were blocked in 1% BSA in PBST at room 
temperature for 1 hour, then washed in PBST three times and incubated with 1:1000 
dilution of the antibody pool. The slides were washed again, and then incubated with a 
1:5000 dilution of fluorescently labelled secondary antibody for one hour at room 
temperature. The arrays were washed as above; air-dried and read out using a Tecan 
power scanner. Images were stored as Tiff files and analyzed using GenePix pro 6.0. 
2.2.11 Microscale Thermophoresis 
To evaluate the binding affinity between some protein-RNA and protein-protein 
pairs, microscale thermophoretic measurements were made. To this end, RNA 
oligonucleotide probes were fluorescently labeled at the 3-end with Cy5. Proteins of 
interest were purified and quantified by using the BCA protein assay kit (Pierce). 
Dilutions of the RNA probe were made to cover a range between the concentrations 
used on the microarrays ± 2 fold. These dilutions were used for a capillary scan to 
determine the appropriate dilution for thermophoresis. Sixteen serial dilutions of the 
protein were made, starting with undiluted sample. An equal volume of the RNA probe 
was added into each serial dilution and filled into standard capillaries. A capillary scan 
was performed to evaluate the fluorescence distribution and the binding reaction was 
monitored for all capillaries using 20% and 40% MST and 90% LED power. Date was 
analyzed using the NTAnalysis software and exported into excel sheet 
2.2.12 Cell Culture 
Blood stream form cells were used for all experiments, and cells were grown and 
maintained in HMI medium supplemented with 10% fetal bovine serum, 0.2µg/ml of 
phoemycine, 1.3 mM of L-cystein in ß-mercaptoethanol at 37°C under 5% CO2 
conditions. Bloodstream1312514 cell were used for the RNAi and in situ tagging 
experiments and grown in hygromycine or Blasticidin-containing medium, for the 
RNAi plasmid and for epitope tagging plasmid respectively. Meanwhile bloodstream 
form 13132277 and 13131991 cells were used for the CAT assay and were grown in 
hygromycine-containing medium (5µg/ml). 
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2.2.12.1  Candidate Gene Knock Down 
Double stranded RNA interference was used to knock down some genes that 
showed significant binding to RNA. For this, 400 bp fragments of each gene starting 
from the start codon were amplified by PCR using Taq DNA polymerase. The resulting 
amplicon was purified using the PureLink PCR purification kit and quantified by 
Nanodrop. These fragments were clones into the p2T7 plasmid after digestion with 
Eam1105I restriction enzyme to generate TA cloning sites. The plasmid carries two T7 
polymerase promoters each of which is under the control of a bacterial tet repressor and 
a hygromycine resistance gene as a selection marker. After successful cloning, plasmids 
were digested with Not1, and precipitated with sodium acetate. Afterwards, 
5 µg of digested plasmid was transfected into the parasites. Parasites were allowed to 
grow overnight, and the selection marker was added and cells plated into 24 well plates 
in serial dilutions and incubated for five day. Three positive clones from the most 
diluted wells were transferred into hygromycine-containing medium and allowed to 
grow.  Cells were then diluted and reseeded in 10 ml cultures in duplicates, one of 
which was induced with 0.75 µl of tetracycline (5mg/ml) and the other served as a 
control. Cells were counted for six successive days during which they were counted 
before and after dilution. 
2.2.12.2 Epitope Tagging and RNA Pull-Down 
Genes were endogenously tagged using a one-step PCR-based strategy as 
previously described[127] with some modifications. To this end, pair of 90-nt fragments 
of each ORF starting with the start codon downstream and the 5’ UTR upstream was 
commercially synthesized. These fragments were made to carry overhangs that permit 
them to anneal to the blasticidine-V5 cassette of Bla-V5 vector. The resulting construct 
generated therefore contains 90-nt immediately upstream of the start codon of the gene, 
followed by the bla-resistance marker, an intergenic region, a V5 epitope and the first 
90-nt of the ORF. The entire construct was used to transfect parasites which were later 
selected in blasticidine-containing medium. Positive clones were isolated and allowed to 
grow in 50 ml cultures. 7.5×10
6
 cells were lysed in lamini buffer and used for western 
blot to check for correct epitope tagging. To pull-down the tagged proteins and 
associated RNA, 50µl (per sample) of agarose immobilized anti-V5 antibody was 
washed five times in in 1× PBS, followed by equilibration in immunoprecipitation 
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP40 and 1× Halt™ Protease 
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and phosphatase cocktail) .Approxiamtely 1×10
9
celles were centrifuged at 2000 rpm for 
10 minutes, and the cell pellet was washed in PBS. The pellet was the transferred into 
1.5 ml Eppendorf tubes and kept on ice where 100 µl of lysis buffer (20 mM Tris-HCl, 
10 mM NaCl, 0.1% NP40 and 1× Halt™ Protease and phosphatase inhibitors) was 
added and cells passed through a 21-gauge needle 10 times. Cell debris was removed by 
centrifugation for 15 minutes at 15k at 4°C and the supernatant was transferred into a 
new tube. As control, wild type cells, and cells expressing c-terminal c-myc were used. 
The resulting protein extract was divided into two fractions. One was used for input 
RNA extraction and the other for immunoprecipitation.  
For immune precipitation, cell lysate was incubated at 4°C with the immobilized 
antibody for 5 hours with gentle rotation. The beads were washed five times in IP buffer 
and RNA was extacted from the beads using Trizol and precipitated in sodium acetate. 
One fraction of the beads was boiled in lamini buffer and analysed on a 4–12% gradient 
SDS gel. One microgram of the input and immunoprecipitated RNA were used for 
cDNA synthesis using Protoscript cDNA synthesis kit. The resulting cDNA was used as 
template to amplify fragments of the 3 UTR of genes that were previously analyzed on 
protein microarrays. Amplicons were resolved on 2% agarose gels and stained with 
ethidium bromide. 
2.2.12.3 Immunofluorescence 
Following successful in situ tagging of candidate protein, their cellular 
localization was verified by immunofluorescence microscopy. For this, cells were 
grown to mid-log phase and 2.5×10
9 
cells were harvested by centrifugation as above and 
washed in 0.5 ml PBS. A 0.01% solution of polylysine was prepared in water and used 
to coat 4-chamber cell/tissue culture slides. The slides were incubated at room 
temperature for 15 minutes without shaking and washed 4 times with 1ml of water. The 
cell pellet was resuspended in 25 µl of PBS and 0.5 ml of freshly prepared 4% 
paraformaldehyde in PBS was added to the cells and incubated at room temperature for 
18 minutes. Cells were collected by centrifugation at 6000 rpm for 2 minutes, and 
washed twice in 0.5ml PBS. Fixed cells were resuspended in PBS and dispensed onto 
the polylysine modified slides and incubated at 4°C overnight. Unattached cells were 
removed by suction, and the slides were incubated at room temperature with 0.2% 
Triton X-100 gentle shaking for 20 minutes for permeabilization. Excess Triton was 
removed by washing with PBS three times five minutes. Slides were blocked with 0.5% 
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gelatin in PBS for 20 minutes, and then incubated with a 1:200 dilution of mouse Anti-
V5 antibody for 60 minutes at room temperature. The slides were washed twice with 
PBS, and a Cy3/5-conjugated anti-mouse antibody in a 1:500 dilution was added 
including 100 ng/ml of DAPI nuclear staining dye and incubated at room temperature 
for 60 minutes with gentle shaking. Slides were washed with excess PBS, air-dried, 
mounting medium added and sealed with cover slips using nail polish. Cells were 
observed under 100× oil objective on a CellR Olympus camera and images taken. 
2.2.12.4 Pair-Wise Yeast Two Hybrids 
Preliminary validation of protein interaction by yeast two-Hybrid screening was 
performed (by the Genomic and proteomic core facility at the DKFZ). Therefore, genes 
coding for selected candidate were amplified from gDNA by PCR and cloned into bait 
(pGKBT7) and prey (pGADT7) vectors between EcoRI and BamHI.  A Single colony 
of each was allowed grown over night in 2 ml selective medium at 30 °C and 200 rpm. 
Thereafter, a volume of 500 µl of bait and prey were mixed, spun down at 2800 rpm for 
5 min at room temperature. Two milliliters ofmYPDA/PEG mating medium was then 
added. Cells were thoroughly mixed in mating medium and mating was achieved by 
incubating them at 30 °C and 100 rpm for 3 h. Cells were harvested at 2800 rpm for 3 
min, then washed with 5 ml of ∆LW medium and resuspended in 1.5 ml ∆LW. Diploids 
were grown for 2 days in liquid ∆LW at 30 °C without shaking and then plated on 
selective agar plates (∆LWH). In the case where the bait and prey protein interacted, 
visible colonies could be seen 2 days later. Stringency was adjusted by adding an 
appropriate amount of 3-AT to the selective agar plates. 
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3 Results and Discussion 
3.1 Protein Expression Microarrays 
3.1.1  Template Construction 
Genomic DNA and cDNA products were used for the construction of protein 
expression templates. The use of gDNA was possible since trypanosomes, unlike other 
eukaryotes lack intron and open reading frames can directly be amplified. Primers were 
designed for the amplification of 384 individual genes. About 97% of the target genes 
were amplified successfully with the right size, most of which gave single amplicons 
(Fig. 2a). Expression constructs were generated in a second PCR step using a primer 
pair carrying sequences complementary to the overhangs of the gene-specific primers. 
In most cases, such a construct allowed for protein expression. However, constructs 
containing a start codon 6 nucleotides after the Ribosome Binding Site (RBS) followed 
by an N-terminal 6×His tag led to enhanced expression. A start codon alone 
downstream of the RBS preceding the primer annealing site was less performant, but 
did better than constructs without supplementary start codons (Fig. 2c) The basic 
expression construct consisted of a 6 nucleotide upstream spacer, a T7 RNA polymerase 
promoter followed by a spacer, a ribosome binding site and another spacer. Omission or 
replacement of the upstream spacer significantly decreased expression by more than 
50%. The reverse primer in some cases contained a V5 or c-myc epitope for detection 
of the full-length protein. The c-myc epitope constructs were seen to yield less protein 
expression than the C-terminal V5 epitopes constructs. 
A phage cDNA library (provided by Prof. Isabel Roditi University of Bern) was 
used to transform bacteria with an efficiency of about 150 pfu/µl. Individual plaques 
were lifted, and clone uniqueness could be confirmed by PCR. A total of about 14,000 
plaques were lifted, of which more than 75% were PCR positive containing single 
inserts.  Expression constructs generated from cDNA products were closed at both ends, 
and protein expression relied exclusively on gene-specific translation start from full-
length cDNA. Two primer pairs were designed to generate expression constructs from 
cDNA products. One primer pair annealed directly next to the cloning sites while the 
second annealed about 50-nt further. Both primers allowed for the amplification of the 
inserts. The first pair had an extremely high melting temperature (68°C), requiring the 
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use of PCR additives and yielded highly specific products (Fig. 2b). The second pair 
annealed at a relatively low temperature, but was less specific then the first. Besides, it 
was impossible to achieve significant protein expression using this primer (Fig. 2d). In 
both cases, the size distribution of the amplified constructs was analyzed on 1.2% 
agarose gel. A very significant number of the constructs were about 1 kb in length.  
Templates generated from gDNA were expressed and full-length proteins could 
be detected using C-terminal epitope tags. Constructs generated from cDNA products 
using primer pair I equally allowed for protein expression. It was impossible to say if 
the correct or even full-length proteins were expressed. Protein-specific antibodies 
however reacted with some of the expressed proteins (Fig. 2e). The corresponding 
constructs were sequenced and verified. 
 
Figure 2: DNA template construction for full-length expressed protein on the array. 
(a) PCR products from gDNA (b) PCR products from cDNA library (c) Full length protein 
stained with antibody to c-terminal V5 tag. DNA template constructions with no 
supplementary ATG (i), with supplementary ATG alone (ii), with supplementary ATG 
followed by 6xHis (iii). (d) Slide stained with SyproRuby following expression. Primer 
used for expression has a 56-nt distance from RBS (e) Protein-specific antibody detection 
of proteins with antibodies to tubulin, treparedoxin, trypanothione reductase and XRND. 
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The distance between the RBS and the start codon is crucial for successful 
protein expression[128]. The less expression observed for the second primer par could 
actually be attributed to the distance between the putative start codon and the RBS. This 
is compounded by the fact, that trans-splicing in trypanosomes add a 39 nucleotide 
splice leader sequence to the 5end of mRNA transcripts which is meant to play the role 
of the cap[129]. The enhanced expression observed for constructs carrying N-terminal 
6xHis is indeed interesting. This epitope is often used for affinity purification and 
immobilization and can help insure protein availability which is in most cases 
problematic. It is possible, that a 6× repeat of histidine offers an easy translation start, 
thereby favoring the expression of the host template. This is however a simple 
speculation, and the exact cause-effect relationship still needs to be established. 
Expression construct generation from gDNA may seem to be an attractive option that 
circumvents gene synthesis. It offers template flexibility, allowing the user to decide 
which portion of the open reading frame is to be expressed.  
Furthermore, when there are undesired sequences such as signal peptide, it is 
possible to eliminate such sequences.  This is however only valid for organisms lacking 
introns and only possible for well annotated genes. Besides, generating large primer sets 
with similar melting temperature could prove to be challenging. cDNA products on the 
other hand have the major disadvantage of being less flexible as a result of upstream 
sequences and a stop codon. More so, one can expect only about a third of the construct 
to xpress the correct protein. There is always the need for protein-specific antibodies or 
complementary methods for detection of the expressed protein. They are however cheap 
template source, and most importantly, can allow for the study of rare or unknown 
splice variants especially in disease states. They have for long been used as template 
source for protein expression[130].It is therefore possible to generate protein arrays 
from both cDNA products and open reading frames derived from diverse sources. A 
minimal distance must be kept between the RBS and the initiation codon to ensure 
proper and optimal expression. A sequence upstream of the T7 RNA polymerase 
promoter is very essential to avoid stalling of the transcription complex. 
3.1.2  On-Chip Cell-Free Protein Expression 
The multiple spotting technique was used to produce protein microarrays from 
PCR-generated templates. The performance of several cell-free expression systems, 
including the TNT T7 for PCR (Promega), the Easy express insect Kit II (Qiagen), the 
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PurExpress (New Englan Biolabs) and the S30 T7 High yield protein expression system 
(Promega) was evaluated. PurExpress, TNT T7 for PCR and the EasyXpress insect kit 
II were unsuitable for the application. The all yielded relatively low protein expression 
levels, sometimes beyond detection limit and reacted with detection antibodies. 
Additionally, the TNT T7 was very viscous and could not easily be spotted easily. The 
insect kit was uncoupled and required an additional spotting step. All these led to the 
discontinuation of these expression systems, and the S30 T7 high yield from Promega 
was continued.  
As previously reported[131], there was no need for expression template cleanup, 
and purified PCR products yielded less protein than their corresponding unpurified 
counterparts (Fig. 3). There was an moderate relationship between gene size and 
expression level and different proteins were expressed at different levels with larger 
proteins showing better expression than smaller ones (R
2
<0,6).  
 
Figure 3: DNA template preparation for protein microarrays. Seven T brucei proteins 
(from top row, U70k, U24k, U1C, U1A, TFIIA, TRF4 and SNAPc) expressed on single 
slide using unpurified PCR and purified PCR products. Each protein was spotted across 
the row. Array stained with SyproRuby for expression (left) and quantification boxplot 
(right). 
Nikel coated (Xenopore), Epoxysilane (SCHOTT Nexterion), Streptavidin-
coated (Xenopore) and Nitrocelluloseslides and hydrogel (Arrayit Corporation) were 
tested.  Protein expression was detectable on all except the nitrocellulose and hydrogel 
slides. Nickel chelate slides were not used for the immobilization of proteins expressed 
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from cDNA construct. When used, they produced well-rounded spot morphologies and 
in some cases tail-like features could be seen attached to the spots (Fig. 4a).  
 
 
Figure 4: Optimal condition for protein expression microarrays. (a) Expression of seven 
different T brucei proteins  (from top U70k, U24k, U1C, U1A, TFIIA, TRF4 and SNAPc)  on 
nickel chelate (i), streptavidin-coated slides (ii), and the epoxy slides (iii). Expressed proteins 
were detected with antibody against c-terminal V5 epitope. (b) Comparison of incubation 
temperature for optimal protein expression. Slides incubation was performed at: t1) room 
temperature; t2) 37°C overnight; t3) 37°C 2Hour and 30°C overnight; t4) 37°C 2 hours room 
temperature overnight; t5) 37°C 2 hours; and t6) 37°C 1 hour and 30°C overnight. 
Streptavidin coated slides equally gave similar spot morphology as the Nickel 
chelate slides (Fig. 4a), but with more background than the nickel slides but without 
tail-like features. Epoxysilane substrate gave a large spot, which at times diffuses, 
towards adjacent spots. However, it later could be controlled by adjusting the humidity 
in the incubation chambers (Fig. 4a). More so, there were no tails seen for this surface 
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coating, but some proteins whose expression could be detected on other surfaces could 
not be detected on epoxy substrate. Of all the surfaces, the epoxysilane was the only that 
gave very high signal to noise ratio, but the spot morphology was not as good as the 
other slide surfaces.  
The incubation temperature and duration was equally a crucial factor affecting 
protein expression. By fine-tuning these parameters, the level of expressed protein for 
different proteins could be controlled.  Incubation at room temperature after spotting the 
expression system yielded the least expression level of all proteins with a great variation 
in the level of expression for different proteins (Fig 4b). Incubating at 37°C overnight 
favored the expression of certain proteins, meanwhile others were not expressed under 
the same conditions. Furthermore, incubation for two hours at 37°C followed by 
incubation at 30°C overnight led to low and variable expression, and this was 
ameliorated when 37°C incubation was followed by incubation at room temperature. 
Finally, incubating at 37°C for 1 hour followed by incubation at 30°C overnight gave 
the best, though not highest expression. The expression level for all proteins was within 
a well-defined range. 
Regarding template and expression system spotting volumes, a maximum of 
0.9nl of template, but not less than 0.6nl gave the highest achievable expression 
(Fig. 5a). About 3.6nl of the S30 T7 High-Yield Protein Expression mixture was the 
optimal volume when 0.9nl were spotted, and 3nl was optima for 0.6 nl template (Fig. 
5b). More so, higher volumes could not be supported while keeping good spot 
morphology and a high array spot density. Following optimal parameters, it was 
possible to express more than 85% of all amplified constructs, this, both for cDNA 
generated constructs (about 14000 constructs) and gDNA-derived constructs (384 
constructs) (Fig. 6). 
The MIST is a well-miniaturized version of the PISA and requires extremely low 
amounts of starting material for protein expression. This mean, that all conditions must 
be optimal to insure optimal protein expression. The failure to detect expressed proteins 
from the PurExpress, EasyXpress and TNT T7 for PCR could result from suboptimal 
expression. In fact, the PurExpress is said to produce between 10 and 200 µg/ml of 
protein per ml of lysate, while the EasyXpress produces just up to 50 µg/ml of lysate.  
The TNT T7 for PCR on the other hand does not provide any information about 
performance. Its viscosity greatly limits its use in such a system, coupled with 
difficulties associated with detection of expressed protein, as it stains with most of the 
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commonly used antibodies. If only 3.6 nl of expression system is used, one would 
logically expect a yield of up to 50 and 200 picograms of proteins for more than 3 hours 
of incubation for the EasyXpress and pure express respectively. 
 
Figure 5: The optimal ratio of PCR products and expression mix volume. (a) 
Increasing DNA template (U1A as template) volume with constant expression mix 
quantity. (b) Increasing cell-free expression volume with constant PCR products quantity.  
microarray scanned image (left) and signal quantification (Right) 
 
Figure 6: Protein expression microarray from T. brucei cDNAs as template. (a) The 
false color image of one out of nine slides of protein microarrays. (b) Signal intensity 
from more than 14,000 protein of T. brucei, in nine different protein microararys chips, 
each contains about 1600 spots representing individual proteins. 
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These are however only estimations for expression from plasmid DNA, which 
produces about 10 fold more protein than linear templates. It is therefore possible that 
the numbers are much lesser. Besides, the uncoupled nature of the EasyExpress makes it 
even less suitable for PISA technology. The S30 T7 expression system produces 
relatively high amount (500 µg/ml) in just one hour and this increases with incubation 
time. This might explain why overnight expression can allow for synthesis of detectable 
amount of proteins following the MIST.  
There is currently no universal surface chemistry for the production of protein 
array and this must be determined empirically depending on array type and intended 
application[5, 97]. Protein expression on epoxysilane substrate was most consistent, but 
antibody-based detection was not suitable for the detection of all proteins. Spot 
morphology was also not uniform, and tends to smear at higher humidity. Poor 
detection on this surface could have resulted from random covalent immobilization, 
making some epitopes inaccessible to the antibodies. Smearing and morphology are 
certainly intrinsic problems related to the contact angle of the epoxy surface, which is 
about 105°. Nonetheless, epoxy slides were seen to give the best signal to noise ratios 
both for functional and analytical arrays[98]. Random immobilization on this platform 
might actually interfere with downstream applications as a result of modifications on 
some amino acid residues that are involved in protein activity. However, some 
functional applications performed so far, suggest that even if a considerable amount of 
the active sites might not be accessible, there is still enough for screening purposes. 
Nickel chelate and streptavidin coated surfaces produce uniform spots, with little or no 
smearing. They also provide for oriented immobilization and this could be interesting in 
cases where full protein functionality is required. However, since these surfaces are less 
inert than the epoxy substrate, a low signal to noise ratio is characteristic of them, and 
Nickel chelate surface bind with weaker strength and easily saturated leading to tail-like 
features. Such surfaces are known to be suitable for acetylation studies, but not 
phosphorylation[97]. It still unclear, why nitrocellulose and hydrogen surfaces failed on 
this platform since they are routinely used in most proteomic applications.  
Protein abundance can very much influence the outcome of an assay. Without 
any handy and straightforward method to control the level of expression of the several 
thousands of proteins on a PISA and hence avoid abundance biases, fine-tuning 
expression parameters might be a useful but indirect method. Discrepancies observed in 
expression with different incubation parameters might be related to the relative stability 
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of individual transcripts, and ease of expression. Meanwhile, an incubation period of 
1 hour at 37°C and 30°C overnight could be helpful in normalizing expression levels. 
Although it is not possible to prescribe a unique surface for the production of MIST-
based arrays; protein expression levels can be controlled. Depending on the desired 
application, a suitable surface can be selected between epoxy, Nickel and streptavidin 
substrates. More than 80% expression can be achieved from cDNA-derived templates. 
However, whether or not these are full-length proteins, or if they are in the correct 
frame cannot be guaranteed for all expressed proteins. Nonetheless, one would expect a 
third of the expressed proteins to be in the right reading frame. This is of prime 
importance when investigations into disease-related proteomes are intended. Finally, the 
combined use of cDNA products and miniaturized sample volumes required make the 
MIST a cost efficient and available high throughput proteomic tool.  
3.1.3  Protein Detection  
Generation of protein microarrays from open reading frames has the advantage 
of flexibility over cDNA products. This actually allow for the addition of epitope tags 
for protein detection. Without information of all proteins expressed from cDNA 
products, and the lack of protein-specific antibodies for all expressed proteins, 
complementary detection strategies must be adopted. Two strategies were used to detect 
proteins expressed on the microarrays. For protein expressed from ORFs, antibody 
staining was used to detect the N-terminal 6×His epitope tag. Detection of full-length 
proteins using C-terminal V5 epitopes was also used in when this was possible. Arrays 
Generated from cDNA products on the other hand could not be detected in a similar 
manner. As such, total protein staining was optimized for protein detection.  
The SyproRuby protein gel stain was used to stain expressed protein, with 
comparable outcomes (Fig. 7). SyproRuby staining gave a more uniform result across 
several proteins, while antibody detection was highly variable. However, there was a 
near background signal for negative controls with antibody detection, while SyproRuby 
gave a relatively strong signal, which was clearly less than the signals from expressed 
proteins. Much caution is however needed when interpreting such resuts in order to 
avoid erroneous conclusions and care must be taken to avoid over staining.  
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Figure 7: Comparing terminal tag-antibody detection and SyproRuby staining of 
seven  expressed proteins (U70k, U24k, U1C, U1A, TFIIA, TRF4 and SNAPc). 
 SyproRuby is one of the most recommended protein staining dyes due to its high 
sensitivity[132]. Being a total protein stain, it was expected to raise signals against the 
negative control, which contains proteins from the PCR reaction and the cell-free 
expression system. The fact therefore, that cDNA products cannot be fused to epitope 
tags for detection cannot rule out the utilization as template source for protein 
expression. They are however not the best for whole proteome screening, but most 
intendend when the need to screen the cellular proteome under a given condition is 
desired. 
3.1.4  Protein Quantification and Functionality 
Since functionality was an aspect not to be left behind, we evaluated the 
possibilities, that functional proteins could be made by cell-free expression systems, and 
that in situ expression will maintain functionality if any. Trypanothione reductase was 
amplified from gDNA and used to generate an expression construct. The construct was 
expressed in a tube format and its activity was measured by measuring the absorption of 
NADPH at 340nM as a function of time (Fig. 8a). A linear decrease in the absorbance 
of NADPH could be observed confirming its depletion as it is used to for the reduction 
of trypanothione in the crude mixture. On chip protein functionality was tested using 
green fluorescent protein.  
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For this purpose, purified recombinant green fluorescent protein (GFP) was 
spotted in serial dilutions, and on the same array, GFP was also expressed using the 
MIST. One array was scanned at 488 nM for the auto-fluorescence of GFP, and another 
slide was first treated with 6 M guanidine hydrochloride at 80°C before scanning. 
Signals were obtained for both the expressed and spotted standard GFP (Fig. 8b). 
Meanwhile the guanidine hydrochloride-treated slide gave a blank image. A standard 
plot was made from the spotted GFP, from which the approximate amount of the 
expressed GFP could be extrapolated. About 4 fmole of GFP was synthsized, 
corresponding to about 800 pgram of protein. 
 
Figure 8: Function test of cell-free expressed protein. (a) In vitro protein functionality 
test of cell-free expressed (unpurified mixture) Trypanothione reductase and Scheme of TR 
reaction (purple line) and control (green line) Absorbance of NADPH is measured at 
340nm as it depletes. (b) Auto-fluorescence of standard GFP () and cell-free expressed 
GFP (). TR reaction adapted from Patricia Paglini-Oliva and Hector Rivarola (September 
2002) 
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3.2 Functional Applications 
3.2.1  Protein-Protein Interactions 
We performed protein-protein interaction screen on the cDNA and gDNA-
derivedy arrays. For this purpose, the Trypanosoma brucei CAF40 (Tb927.4.410), a 
member of the CCR-NOT complex was expressed as a 6×His fusion protein and 
purified by affinity chromatography (Fig. 9a, b). The protein was fluorescently labelled 
and screened against proteins expressed on the arrays. Two proteins, the T brucei 
Aurora kinase B and T brucei polo-like kinase were used as background control to fish 
out sticky proteins. Previously reported, as well as novel interactions were found 
pending in vivo validation (Fig. 9c). For example, it has been reported[133], that 
CAF40 can interact with the Nascent polypeptide-associated complex as well as the 60s 
ribosomal protein S3[134]. These interactions as well as other novel interactions could 
be found. The same protein was screened against another targeted protein microarray, 
leading to identification of other binders. Novel interactions including hypothetical 
SWAP domain proteins and the DHH1 helicase were identified. The ATP-dependent 
RNA helicase DHH1 is also known to interact with CAF 40 in Saccharomyces 
cerevisiae[135, 136]. In trypanosomes, it is known, that CAF 40 interacts with the 
NOT1 scaffold protein of the CCR4-NOT complex[137]. This interaction could not be 
confirmed in the screen with the targeted arrays containing two fragments of the NOT1 
protein.  
Interactions of T. brucei CAF 40 with NOT1, which was shown to exist by 
pairwise yeast two-hybrid, could not be confirmed[137]. Using the N-terminal fragment 
of NOT1 as a positive control, for a pair-wise screen, this interaction was not found. 
(See yeast two-hybrid data). It is possible, that this fragment alone could not allow for a 
strong binary interaction on the array and was therefore washed away, or it might not 
have folded properly. The CCR4-NOT complex has been shown to play key roles in 
cellular proteostasis, by controlling protein quality[124, 125]. The interaction of CAF 
40 with components of the NAC complex could imply several roles including 
proteostasis control. The NAC has been shown to be involved in the control of cellular 
proteostasis[138], and it is therefore possible, that the CCR4-NOT not only play roles in 
RNA turnover as it has previously been known, but also recruit chaperon for other 
functions.  
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In yeast, the NOT4 component of the CCR4-NOT complex is responsible for the 
ubiquitination of the NAC. However, its T. brucei homologue does not exist, or at least 
is not known to date. DHH1, play a role in mRNA decapping, and is known to interact 
with dacapping and deadenylase complexes[139]. The CAF-NOT complex in 
trypanosomes is responsible for mRNA deadenylation among others. Interaction 
between the DHH1 and CAF 40 could well be indeed a functional interaction. 
Confirmations of these interactions via complementary methods are currently being 
pursued. 
 
Figure 9: Protein-protein interactions. (a) Coomassi staining for purification of CAF 40 by 
IMAC. M=Mw Marker, P= partially purified protein, L= Lysate (b). Detection of spotted 
(Each protein is spotted across the row)  purified protein with anti 6×His antibody (c) 
Protein-protein interactions for CAF 40 on large array and mini array examples of triplicate 
signals are indicated. 
3.2.2  Protein-RNA Interactions 
Protein-RNA interactions were also performed on targeted arrays initially as 
proof of concept and functional screens. Well-characterized interactions between 
specific RNA sequences or molecules and known protein could be reproduced. In this 
case, the U1 snRNA of Trypanosoma brucei, involved in the splicing of the polyA 
polymerase was screened against the U1 proteins. It was reported, that the U1-70K 
protein can specifically bind the U1 snRNA [140]. We used this as a model for our 
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protein-RNA interactions, and were able not only to reproduce this interaction, but 
could identify a binding effect between the U1 snRNA and the U1A protein which has 
equally been reported elsewhere[141] to have an affinity for the U1 snRNA (Fig. 10a). 
Other reported protein-RNA interactions were tested, and the arrays could differentiate 
a wild type from a mutant TbZC3H11 (Fig. 10b) which was recently shown to bind to 
the 3UTR AU-rich element (ARE)[142]. Single mutation in the Zinc finger domain of 
this protein was swufficient to abolish binding on a shift assay; but a triple mutation was 
needed on the microarray (Fig. 10c). 
Table 1: Proteins bound by both the classical and non-classical ARE  
 
A targeted array screen with the classical and non-classical ARE sequences 
identified other binders, including the ZC3H11 included on the array as a positive 
Control (Fig. 10d). Both sequences shared common binding proteins such as the 
ZC3H11 (Table 1), but equally had proteins that exclusively bound just one of the 
sequences. The non-classical sequence bound with low affinity to than the classical.  
As background control, a polyU, a polyC and a mutant of the ARE were 
screened as well (Fig. 11a). Other sequences were screened against the targeted array, 
including a sequence reported to bind to TbPUF9 and 3 UTR fragment for the 
trypanosome hexose transporter (THT), the amino acid transporter (AAT1) expression 
site associated gene 9 (ESAG9), Phosphoglycerate Kinase (PGK), Cytochrome Oxidase 
(COX) and the EP procyclin genes. The number of binding proteins increased with 
RNA probe sequence length which varied from 23nt (ARE) to more than 600nt (THT) 
Most of the sequences screened were found to bind UBP1 and RBP3 except the polyC 
sequence which bound to all protein at background level. However, the PUF-binding 
sequence reproducibly bound a hypothetical protein but not to other proteins on the 
array (Fig. 11b). 
Gene ID Name ZScore/FD 
Classical 
Z-Score/FD 
Non classical 
Function 
     
Tb927.11.530 RBP3 11,5 9,7 16,4 16,5 RNA binding 
Tb927.11.500 UBP1 2,5 2,5 6,1 6,9 RNA binding 
Tb927.5.810 ZC3H11 0,8 2,3 1,4 2,5  RNA binding 
Tb927.9.6870 RBSR1 1,9 3,0 1,2 2,4 RNA processing 
Tb927.7.1390 RBSR2 2,8 3,7 1,7 2,9 RNA processing 
Tb927.11.2250 hypothetical 4,1 4,6 3,5 4,5  
Tb927.7.4660 hypothetical 7,2 7,2 3,7 4,7  
Negative Control  -0,3 1 -0,4 1  
FD= Fold difference with Negative control 
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This sequence was expected to bind PUF9, which was equally expressed on the 
array, but it failed to. The PGKCR, the EP1 and to a lesser extent the COX reproducibly 
bound to a set of identical proteins including the ALBA domain protein and the DRBD 
proteins (Table 2) all of which are involved in RNA stability and translation[117, 143]. 
These sequences were seen to bind to a significant set of exosome complex proteins and 
like the other to many other hypothetical proteins. ESAG9 UTR and the PGKCR bound 
to a relatively higher number of proteins; meanwhile COX bound a rather restricted 
number, although they were all of identical lengths. The THT UTR, as a result of its 
size was fragmented and analyzed in a minimal sequence-mapping assay.  
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Figure 10: Protein-RNA interaction for AU-rich element and U1 snRNA in proof of 
concept. (a) False color image, confirmation of expressed proteins (red array) and 
detection of U1-protein interactions (green array). Plot of signal intensities of expressed 
proteins and it interaction with snRNA U1 (light and dark color bar, respectively). (b) 
Expression and the interaction of the classical and non classical ARE with TbZC3H11 WT 
and Mutants (triple mutant) together with expression control (Diablo Human mitochondrial 
Protein). (c) Comparison of single and triple mutation of CCCH domain on the array. (d) 
Interaction of ARE on mini array and plot of Z-score of protein binders of classical ARE. 
 AA= amino Acid, WT=wild Type, MT= Mutant Type 
Cy3-uuauuauuauuauuauuauuauu 
 
Cy3-uauuuauuuauuuauuuauuuau 
 
U1 snRNA probe 
=Tb927.5.810 
=Tb927.11.530/Tb927.11.500 
ARE classical 
ARE classical ARE classical 
ARE non classical 
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Figure 11: Protein-RNA interaction on mini array. (a) Plot of poly U binding proteins 
(i) and plot of UUC binding proteins (ii). (b) Mini array was screened with PUF-binding 
element (left panel). One protein was reproducibly bound to the array. Plot of PUF-binding 
protein (right panel). 
In addition to U1-70K which is known to bind the U1 SnRNA in trypanosomes, 
we also found the U1A binding the same molecule, though with weaker strength. U1A 
in humans bind to the U1 SnRNA more strongly than U1-70K[140]. The weak signal 
could either result from less active sites exposed on the epoxy surface, or that there is 
simply transient interactions between both. Interactions between ZC3H11 and the ARE 
is known to regulate heat shock protein 70 (HSP70) mRNA in bloodstream forms[142]. 
Both the classical and non-classical ARE were shown to bind wild type ZC3H11 but not 
its mutant. A single mutation of a cysteine residue was sufficient to abolish binding, but 
only a triple mutation of two cysteine residues and a histidine residue of the CCCH 
domain could abolish binding on microarrays. 
The single mutant could actually have bound the RNA, but the complex, due to 
its weak interaction simply might have dissociated as it ran through the gel. This was 
not the case on microarray platform. The PUF domain used was reported to bind PUF9 
and regulate the stability of a subset of mRNA[119]. This sequence did not yield any 
(ii) 
Cy5-uaacauuguaccaugcauaacauuguaccaucag 
 
Cy3-uuuuuuuuuuuuuuuuuuuuuuu 
Cy3-uucuucuucuucuucuucuucuu 
 
Tb927.8.7820 
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significant binding on the arrays, either as a result of low expression or folding on the 
epoxy surface. It is conceivable, that the 3 UTR of the EP1, PGKCR and COX contain 
cis-acting elements involved in mRNA stabilization, since most of these sequences 
bound significantly to the DRBD protein family. The polypyrimidine tract binding 
proteins are known to regulated RNA stability in trypanosomes[144].  
Table 2: Common proteins binding the EP1, PGK, and COX UTR fragments (Z-score≥1,5) 
 
Besides, the EP1, the COX and the PGK all share a common 26-mer element 
that is said to control RNA stability and translation[145, 146]. It is therefore not 
astonishing, that these sequences all show preference for the polypyrimidine binding 
proteins and the ALBA domain proteins, which are all involved in mRNA stabilization 
and translation. Exosomes are major machinery in RNA degradation following 
deadenylation of the 3 extremity. Finding exosomes binding to 3 UTR elements is 
Samples shown have fold difference of ≥2 for all probe considered 
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therefore not surprising. However, the fact that some sequences, but not others bound to 
a relatively high number of exosome complex proteins is unusual. 
3.2.2  Minimal Sequence Mapping of the THT1 
A 600-nt fragment of the THT UTR was fragmented to generate fragments 
differing by 100nt in length.  Fragments were fused to a T7 RNA polymerase construct 
for transcription and subsequently labelled at the 3 end with biotin. RNA-protein 
interaction was identified by incubation with fluorescently labelled extravidin. 
Fragments bound between 40 and 106 different protein with the number increasing with 
probe length. The most reproducible results were obtained for the 100, 200 and 300-nt 
long fragments. Beyond this size, there was little consistency in the binding patter. 
Analysis of the folding patterns of the different fragments was done using RNAfold web 
server, and this led to the identification of a stable stem loop across all fragment and 
with all parameters applied (Fig. 12a and b). 
 
Figure 12: Identification of potential sequences element for THT interaction. (a) 
Minimal motif mapping of the Trypanosome Hexose Transporter TH1 3 UTR. Fragment 
length increases from the 5´ end of the 3´UTR from T1 to T5. (b) RNAfold in Silico analysis 
of THT1 fragments. (i) Minimal fold energy (ii) Centroid secondary structure. Colors 
indicate the probabilities of base-pairing, increasing from green to red. (c) SDS-PAGE gel for 
enrichment of RBP using THT oligomer. Eluate from beads was stained with coomassi   
The stem loop, which was 26nt long, was synthesized and biotin-labelled as with 
the others. Screening this oligomer against the array gave about 80% of the proteins that 
reacted with the parent fragment (Table 3). The fragment was then labelled with 
desthiobiotin, and used to pull-down proteins from blood stream form and procyclic cell 
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lysate. There was an important protein enrichment in the blood stream lysate compared 
to the bead control, and procyclic (Fig. 12c).  
Longer probes tend to give more unspecific binding than their short counterparts 
due to the possibility of multiple loop structures. It is well possible, although this must 
be confirmed otherwise, that the conserved stem loop across all fragments might contain 
the element needed for binding. Bloodstream form express about 40 fold more of the 
THT1 than THT2. THT2 is expressed in a glucose-dependent manner in 
procyclics[147].  
Cell lysate enrichment is of course not an ideal procedure for the identification of 
RNA-binding proteins, but could provide an insight into RBP enrichment between 
lysates or conditions. The data generated from such enrichment must therefore be 
analyzed with much caution. Nonetheless, using such an approach as a complementary 
method is worth the pain. 
Table 3: Shared binders of THT1 oligomer and precursor fragment (Samples Z-score≥1,5) 
 
 
Samples have fold differences between 2.5 and 7.5 with respect to negative control 
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3.2.3  Kinase Substrate Identification 
As proof of concept, the identification of kinase substrates was done using the T. 
brucei Aurora kinase 1. Two of its substrates Centrin II and Histone H3 were expressed 
by MIST, and incubated with purified kinase. Two other unrelated proteins were 
equally expressed together as phosphorylation control. All proteins were well expressed 
(Fig. 13), but only the two substrates of the kinase showed significant phosphorylation 
following incubation with the enzyme. Protein phosphorylation was detected by 
incubation with anti phosphoserine/threonine and tyrosine antibody. Histone H3 gave a 
stronger signal compared with Centrin II and the other proteins gave background 
signals. Protein microarrays have been used for the identification of kinase 
substrates[12]. However, this has only been done with printed arrays and there are no 
reports of the performance of protein in situ arrays regarding such an application. 
Besides, all reported cases have been based on radioactivity. Combining PISA, protein-
protein interactions and kinase substrate identification could lead a revolution into the 
understanding of complex signaling cascades. 
 
Figure 13: Proof of concept for on-chip protein phosphorylation. Confirmation of 
expressed TbAUK B substrates by c-terminal anti-6xHis antibody (left array) and on-chip 
phosphorylation detected by antiphosphoprotein antibody (right array). All proteins are 
replicated across the row. 
3.2.4  Antibody Selection 
 Microarrays made from cDNA products were screened with protein specific 
antibodies in a pool format. This was meant first to verify if some of the expressed 
proteins were correct in their primary structure, and secondly to find out if the array 
could be useful for the selection of antibodies. Antibodies to T. brucei proteins such as 
Trypanothione reductase, Tryparedoxin alpha tubulin and XRND were tested. Antibody 
binding was detected using the corresponding anti mouse antibody conjugated to Cy5. 
Some of these antibodies could specifically bind to their antigens, and this was later 
confirmed by sequencing (Fig. 14). Tubulin was found to be highly abundant with 3 out 
of five sequences corresponding to tubulin. These findings were interesting, since this 
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will mean that such array can be used to identify antigens for antibody libraries, or 
reactivity to protein isoforms or simply to check for antibody quality. 
 
Figure 14: Pooled antibody screen on large array using a pool of 21 T brucei protein-
specific antibodies. Antibody binding was confirmed by detection with Cy5-conjugated 
antimouse antibody. Only one array shown here on the right is an enlarged portion of the 
array. 
3.3 In Vivo Studies 
There are often many discrepancies between results obtained from high 
throughput platforms when compared with data generated in vivo. However, since in 
vivo techniques are rather less adapted for high throughput application, it is important 
that high throughput platforms be validated to make them more reliable. Besides, any 
biological data will only be useful, if it reflect a real life situation. For this reason 
candidate proteins were chosen for in vivo validation. 
3. 3.1 Gene Knockdown  
Fragments of the coding region of the genes were cloned into the vector p2T7, 
digested with NOT1 and transfected into BF 1313514 cells for double stranded RNAi 
and selected in Hygromycin-containing medium.  RNAi was induced with 0.75 µl/10 ml 
of tetratcycline continuously for 6 days. Knock down of two of the four genes led to a 
lethal phenotype. One of the lethal phenotypes occurred as early as 48 hours post 
induction (Fig. 15a) and the other 6 days post induction (Fig. 15b). Of the other two 
genes, one led to mild growth defects meanwhile the other had no major difference with 
control cell (Fig. 15c and d). The lethal phenotype observed could suggest that these 
genes are essential genes in bloodstream form of the parasite. 
alpha tubulin 
alpha tubulin 
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Figure 15: Cummulative growth curves for dsRNAi knockdown of candidate genes. (a) 
Knockdown of Tb927.10.2190. (b) Knockdown of Tb927.10.14150. (c) Knockdown of 
Tb927.10.12330. (d) Tb927.5.1990 Knockdown. Tet− (blue) and Tet+ (red). 
 
3.3.2  In Situ Tagging, Immunofluorescence and Pull-Down 
In situ epitope tagging was performed for all four genes using PCR-generated 
blasticidin-V5 cassettes. The constructs were transfected into BF 1313514 cells and 
selected in blasticidin-containing medium. Three of the four genes were successfully 
tagged, while the other failed in five successive trials. Successful tagging of the genes 
could be confirmed by western blot using anti-V5 antibodies (Fig. 16a).  
Wild type BF1313514 cells and BF13132277 cells carrying an N-terminal c-myc 
tagged GFP were used as negative controls. Proteins were extracted from all cells 
including the controls, and 40 µg of protein was immunoprecipitated from each lysate. 
The precipitating protein fraction was used for RNA extraction, and part was analyzed 
on SDS PAGE. It was possible to amplify fragments of some of the UTR used in the 
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microarray experiments. All the fragments of the THT1(T1 to T6) could be amplified 
strongly; meanwhile the PCR for the other UTR was positive with weak bands at 
background level. The PCR efficiency was variable between all three genes. One of 
them (Tb927.10.2190) gave very weak bands, while the others (Tb927.10.12330 and 
Tb927.10.14150) stronger bands. There was low amplification both for the wild type 
control and the GFP control (Fig. 16b). The amount of bound RNA as revealed by PCR 
did not correlate with the binding intensity from the microarray experiment for one of 
the proteins (Tb927.10.2190). Immunofluorescence microscopy revealed, atleast two of 
the proteins localized to the cytoplasm, although the images are not the best (Fig. 17).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Epitope tagging and RNA IP for candidate genes. (a) In situ epitope tagging 
confirmed by Western Blot via N-terminal V5 epitope tag. (b) RT-PCR of UTR from RNA IP. 
Primers used to amplify the initial fragments were used for PCR. THT1 UTR fragments T1 
through T6 increases in length by about 100nt and loaded in duplicates. E1to E6 are UTRs of the 
AAT1, PGK, COX, ESAG9, EP1 and Gim5 respectively. 
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Unfortunately, the GFP and wildtype controls did bind RNA, even if the 
amplification of THT 1 RNA bound to two of the proteins (Tb927.10.12330 and 
Tb927.10.14150 was higher. This may be interesting, but must be interpreted with 
caution, since the THT1 might have been abundant. However, if this would be the case, 
one would expect to have similar amplifications on all samples, which is not the case. 
This data could therefore be preliminary interesting data that needs to be quantified. 
Moreso, if a protein destabilizes RNA, it is very unlikely to find RNA binding to it, or 
at least in significant mount. One would therefore speculate that the weak bands 
obtained for one of the proteins could imply its involvement in RNA decay or such like. 
Meanwhile, the other might be involved in translation and mRNA stabilization. 
Polysome analysis could shed more light on this. This is being investigated currently via 
CAT reporter assays.  
The current data from the immune fluorescence assay are not very conclusive. 
Although one could tell that some of the proteins localize to the cytoplasm, it will be 
necessary to repeat the assay with better resolution to be able to draw proper 
conclusions. If in effect these proteins turn out to be cytoplasmic, their potential role in 
RNA metabolism could be more evident. 
In all it is very likely, that the RNA-binding obtained on the arrays could actually 
be real pending more validation. Interpretation of the data must however be taken with 
caution especially when dealing with very long probes as there is a tendency, that they 
form secondary structures that help them bind even strongly to some proteins.  
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Figure 17: Immunofluorescence assay for epitope tagged endogenous 
proteins. Nuclear staining for Tb927.10.14150, Tb927.10.2190 and  Tb927.10.12330 respectively (a,d and g). 
Anti-V5 immunostaining for Tb927.10.14150, Tb927.10.2190 and Tb927.10.12330 (b,e and f). Overlay of Nuclear 
and epitope staining,for Tb927.10.14150 (C).  
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3.3.3  Yeast-Two Hybrid 
Initial pair-wise yeast two hybrid experiments were performed (By the genomic 
and proteomic core facility). One samples gave a positive result with the CAF40 as bait 
(Fig. 18). This is the alpha subunit of the NAC which was one of the binders from 
microarray experiments. The fragments of the NOT1, which has been shown to bind to 
CAF40 failed to bind in this assay. These results were however only obtained for one to 
one bait-prey screen where one protein was bait and the others prey. Some interactions 
could be lost if the role of the proteins (as prey and bait) are interchanged. It therefore 
will be wise to do further validations of these data to make them more conclusive.  
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Y2H protein-protein interaction for candidate genes from large array. 
TbCAF40 was used as bait in pGKBT7 and screened against candidate genes as prey in 
pGADT7. Agar plate image (left) and sample annotation (right) 
A microarray experiment generally translates binary interaction and enriches 
transient interaction [8]. Meanwhile there could be high chances of false positives as 
well; this would not be true for an entire data set. The decision of the prey and bait 
constructs can also be of key importance, since some proteins tend to be weak 
activators. Interaction between CAF 40 and the NAC has also been reported in S. 
cerevisaie[148]. Failure to identify an interaction between CAF 40 and NOT1 could 
depend on several factors including misfolding and low expression.  
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3.3.4  Affinity Measurements 
Microscale thermophoresis (MS) was used to measure the binding kinetics 
between some protein-RNA pairs. Bovine serum albumin and TbAUK1 were used as 
negative controls. The binding of ZC3H11 and another hypothetical protein 
(Tb927.7.4660) with the classical ARE were also measured. The binding reaction was 
performed using the well characterized classical ARE RNA conjugated at its 5` end 
with Cy5 as a probe. The dissociation constant (Kd) was for ZC3H11 between 10-14 
nM (Fig. 19). BSA and TbAUK1 both gave Kd values beyond 20,000 nM. The Kd 
values for ZC3H11 and the hypothetical protein correlated well with the signal strength 
on the array. Although this correlation may not be strong enough, it however indicate 
that the signal intensity observed could be indicative of the affinity between the 
interacting species. This must however be confirmed for a reasonable number of 
proteins. 
 
 
Figure 19: Kinetic results of protein-RNA interactions. (a) Plot of MST data for 
ZC3H11 binding to the classical ARE. (b) Plot of MST data for TbAUK1 interaction with 
the classical ARE. Majority of the data points are horizontal and further extrapolation is 
approximative for AUK1. 
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ZC3H11 
Protein concentration (nM) 
Protein concentration (nM) 
Conclusion 
 
66 
 
4 Conclusion 
We set out to produce functional protein microarrays from cDNA products and 
evaluate the usability of such arrays in a model organism (Trypanosoma brucei). We 
have optimized and produced a protein microarray from a cDNA library using the 
multiple spotting technique. For optimal performance, primers must be designed to 
minimize the distance between the ribosome binding site and the translation initiation 
codon as much as possible. When open reading frames are used, the addition of an 
N-terminal 6×His tag can greatly enhance protein expression. Syproruby protein 
staining dye can be reliably used to detect protein expression when it is not possible to 
fuse expression construct with epitope tags for detection. Purification of PCR generated 
expression template is not needed and protein expression across the array can be 
controlled by controlling the incubation temperatures and time. It is possible to generate 
expression constructs directly from gDNA with the advantage of generating template 
flexibility and it will be advisable to normalize cDNA libraries to avoid redundancy of 
overrepresented transcripts. Arrays generated from gDNA-and cDNA-derived templates 
can be used for functional applications with great reliability. 
We have shown for example, that such arrays could be useful for protein-protein 
interaction, protein-RNA interactions, identification of Kinase substrates and antibody 
selection. It is quite possible, that the scope of application of such arrays be wider if 
optimized. As with other protein microarray platforms, there is no universally suitable 
platform for MIST-based array. However, when signal-to-noise ratio is fundamental 
factor to consider, epoxysilane substrates perform better in this light. Streptavidin and 
Nickel chelate slides show good spot morphology compensating for high background 
signal. Some data obtained from our microarrays have been validated for protein-RNA 
interaction and protein-protein interaction to an extent. Combining cost efficiency, 
reliability, robustness and ease of use, this tool will be a plus in the arsenal of proteomic 
tools, and will bring protein microarray technology to almost everyone interested. Using 
cDNA products as template source offer the advantage of not only being cost effective, 
but important when studying disease conditions. It also offers the chance of screening 
rare and unknown transcripts. It is therefore most important for screening cellular 
proteomes in well-defined conditions. Nonetheless, some templates may therefore be 
absent if not transcribed during a given situation or lost during template preparation. 
Furthermore, it is not possible to confirm if any full-length protein is expressed. It is 
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therefore important that procedure for cDNA synthesis be well optimized. Taken 
together, the MIST is a reliable technology for the development of functional protein in 
situ arrays. Protein microarrays made by the MIST are highly versatile and of high 
quality, capable of generating biologically meaningful data. 
 
References 
 
68 
 
REFERENCES 
1. Sun, H., G.Y. Chen, and S.Q. Yao, Recent advances in microarray technologies 
for proteomics. Chem Biol, 2013. 20(5): p. 685-99. 
2. Pandey, A. and M. Mann, Proteomics to study genes and genomes. Nature, 2000. 
405(6788): p. 837-46. 
3. Pflieger, D., et al., Linking the proteins--elucidation of proteome-scale networks 
using mass spectrometry. Mass Spectrom Rev, 2011. 30(2): p. 268-97. 
4. Aebersold, R. and B.F. Cravatt, Proteomics--advances, applications and the 
challenges that remain. Trends Biotechnol, 2002. 20(12 Suppl): p. S1-2. 
5. Zhu, H. and J. Qian, Applications of functional protein microarrays in basic and 
clinical research. Adv Genet, 2012. 79: p. 123-55. 
6. Ekins, R. and F. Chu, Multianalyte microspot immunoassay. The microanalytical 
'compact disk' of the future. Ann Biol Clin (Paris), 1992. 50(5): p. 337-53. 
7. Lee, Y., et al., ProteoChip: a highly sensitive protein microarray prepared by a 
novel method of protein immobilization for application of protein-protein 
interaction studies. Proteomics, 2003. 3(12): p. 2289-304. 
8. Fuentes, M., et al., Solid phase proteomics: Dramatic reinforcement of very weak 
protein-protein interactions. J Chromatograph B, 2007. 849(1-2): p. 243-50. 
9. Huang, Y.P., et al., Global tumor protein p53/p63 interactome Making a case for 
cisplatin chemoresistance. Cell Cycle, 2012. 11(12): p. 2367-79. 
10. Lilburn, T.G., et al., Protease-associated cellular networks in malaria parasite 
Plasmodium falciparum. BMC Genomics, 2011. 12. 
11. Chen, J.X., et al., A Protein Microarray for the Rapid Screening of Patients 
Suspected of Infection with Various Food-Borne Helminthiases. PLoS Negl Trop 
D, 2012. 6(11): p. e1899. 
12. Mok, J., H. Im, and M. Snyder, Global identification of protein kinase substrates 
by protein microarray analysis. Nat Protoc, 2009. 4(12): p. 1820-7. 
13. Oh, Y.H., et al., Chip-based analysis of SUMO (small ubiquitin-like modifier) 
conjugation to a target protein. Biosens Bioelectron, 2007. 22(7): p. 1260-7. 
14. Scherrer, T., et al., A screen for RNA-binding proteins in yeast indicates dual 
functions for many enzymes. PLoS One, 2010. 5(11): p. e15499. 
15. Margarit, I., et al., Capturing host-pathogen interactions by protein microarrays: 
identification of novel streptococcal proteins binding to human fibronectin, 
fibrinogen, and C4BP. FASEB J, 2009. 23(9): p. 3100-12. 
16. Robinson, W.H., et al., Autoantigen microarrays for multiplex characterization of 
autoantibody responses. Nat Med, 2002. 8(3): p. 295-301. 
17. Hu, S., et al., A protein chip approach for high-throughput antigen identification 
and characterization. Proteomics, 2007. 7(13): p. 2151-61. 
18. Zhu, J., et al., Protein array identification of substrates of the Epstein-Barr virus 
protein kinase BGLF4. J Virol, 2009. 83(10): p. 5219-31. 
References 
 
69 
 
19. Zhu, H. and J. Qian, Applications of Functional Protein Microarrays in Basic and 
Clinical Research. Adv Genet, Vol 79, 2012. 79: p. 123-55. 
20. Gelperin, D.M., et al., Biochemical and genetic analysis of the yeast proteome 
with a movable ORF collection. Gen Dev, 2005. 19(23): p. 2816-26. 
21. Chen, C.S., et al., A proteome chip approach reveals new DNA damage 
recognition activities in Escherichia coli. Nat Methods, 2008. 5(1): p. 69-74. 
22. Zhu, H., et al., Global analysis of protein activities using proteome chips. 
Science, 2001. 293(5537): p. 2101-5. 
23. Allen, S.V. and E.S. Miller, RNA-binding properties of in vitro expressed 
histidine-tagged RB69 RegA translational repressor protein. Anal Biochem, 
1999. 269(1): p. 32-7. 
24. Murthy, T.V.S., et al., Bacterial cell-free system for high-throughput protein 
expression and a comparative analysis of Escherichia coli cell-free and whole cell 
expression systems. Protein Express Purif, 2004. 36(2): p. 217-25. 
25. Goshima, N., et al., Human protein factory for converting the transcriptome into 
an in vitro-expressed proteome. Nat Methods, 2008. 5(12): p. 1011-17. 
26. Crompton, P.D., et al., A prospective analysis of the Ab response to Plasmodium 
falciparum before and after a malaria season by protein microarray. Proc Natl 
Acad Sci USA, 2010. 107(15): p. 6958-63. 
27. He, M.Y. and M.J. Taussig, Single step generation of protein arrays from DNA by 
cell-free expression and in situ immobilisation (PISA method). Nucleic Acids Res, 
2001. 29(15): p.e73-3. 
28. Ramachandran, N., et al., Self-assembling protein microarrays. Science, 2004. 
305(5680): p. 86-90. 
29. He, M., et al., Printing protein arrays from DNA arrays. Nat Methods, 2008. 5(2): 
p. 175-7. 
30. Tao, S.C. and H. Zhu, Protein chip fabrication by capture of nascent 
polypeptides. Nat Biotechnol, 2006. 24(10): p. 1253-4. 
31. Wang, J., et al., A versatile protein microarray platform enabling antibody 
profiling against denatured proteins. Proteomics Clin Appl, 2013. 7(5-6): p. 378-
83. 
32. Angenendt, P., et al., Generation of high density protein microarrays by cell-free 
in situ expression of unpurified PCR products. Mol Cell Proteomics, 2006. 5(9): 
p. 1658-66. 
33. Ramachandran, N., et al., Next-generation high-density self-assembling functional 
protein arrays. Nat Methods, 2008. 5(6): p. 535-8. 
34. van't Veer, L.J. and R. Bernards, Enabling personalized cancer medicine through 
analysis of gene-expression patterns. Nature, 2008. 452(7187): p. 564-70. 
35. Qu, H.Q., et al., Genome-wide profiling using single-nucleotide polymorphism 
arrays identifies novel chromosomal imbalances in pediatric glioblastomas. 
Neuro Oncol, 2010. 12(2): p. 153-63. 
36. Ambra, R., et al., Transcriptome analysis of human primary endothelial cells 
(HUVEC) from umbilical cords of gestational diabetic mothers reveals candidate 
References 
 
70 
 
sites for an epigenetic modulation of specific gene expression. Genomics, 2014. 
103(5-6): p. 337-48 
37. Harris, C. and N. Ghaffari, Biomarker discovery across annotated and 
unannotated microarray datasets using semi-supervised learning. BMC 
Genomics, 2008. 9. 
38. Zhu, J.Y., Y. Sun, and Z.Y. Wang, Genome-wide identification of transcription 
factor-binding sites in plants using chromatin immunoprecipitation followed by 
microarray (ChIP-chip) or sequencing (ChIP-seq). Methods Mol Biol, 2012. 876: 
p. 173-88. 
39. Gry, M., et al., Correlations between RNA and protein expression profiles in 23 
human cell lines. BMC Genomics, 2009. 10. 
40. Stiffler, M.A., et al., Uncovering quantitative protein interaction networks for 
mouse PDZ domains using protein microarrays. J Am Chem Soc, 2006. 128(17): 
p. 5913-5922. 
41. Kwon, J.A., et al., High diagnostic accuracy of antigen microarray for sensitive 
detection of hepatitis C virus infection. Clin Chem, 2008. 54(2): p. 424-428. 
42. Lee, Y., et al., ProteoChip: A highly sensitive protein microarray prepared by a 
novel method of protein, immobilization for application of protein-protein 
interaction studies. Proteomics, 2003. 3(12): p. 2289-2304. 
43. Miernyk, J.A. and J.J. Thelen, Biochemical approaches for discovering protein-
protein interactions. Plant J, 2008. 53(4): p. 597-609. 
44. Dias-Neto, E., et al., Next-Generation Phage Display: Integrating and Comparing 
Available Molecular Tools to Enable Cost-Effective High-Throughput Analysis. 
PLoS One, 2009. 4(12): p.e8338. 
45. Bruckner, A., et al., Yeast Two-Hybrid, a Powerful Tool for Systems Biology. Int J 
Mol Sci, 2009. 10(6): p. 2763-88. 
46. Ivanov, S.S., et al., Antibodies immobilized as arrays to profile protein post-
translational modifications in mammalian cells. Mol Cell Proteomics, 2004. 3(8): 
p. 788-95. 
47. Sanchez-Carbayo, M., Antibody microarrays as tools for biomarker discovery. 
Methods Mol Biol, 2011. 785: p. 159-82. 
48. Puig-Costa, M., et al., Discovery and validation of an INflammatory PROtein-
driven GAstric cancer Signature (INPROGAS) using antibody microarray-based 
oncoproteomics. Oncotarget, 2014. 5(7): p. 1942-54. 
49. Sanchez-Carbayo, M., Antibody array-based technologies for cancer protein 
profiling and functional proteomic analyses using serum and tissue specimens. 
Tumour Biol, 2010. 31(2): p. 103-12. 
50. Voshol, H., et al., Antibody-based proteomics: analysis of signaling networks 
using reverse protein arrays. FEBS J, 2009. 276(23): p. 6871-9. 
51. Borrebaeck, C.A.K. and C. Wingren, Design of high-density antibody 
microarrays for disease proteomics: Key technological issues. J Proteomics, 
2009. 72(6): p. 928-35. 
References 
 
71 
 
52. He, M. and M.J. Taussig, Single step generation of protein arrays from DNA by 
cell-free expression and in situ immobilisation (PISA method). Nucleic Acids Res, 
2001. 29(15): p. e73-3. 
53. Ramachandran, N., et al., Tracking humoral responses using self assembling 
protein microarrays. Proteomics Clin Appl, 2008. 2(10-11): p. 1518-1527. 
54. Anderson, K.S., et al., Application of protein microarrays for multiplexed 
detection of antibodies to tumor antigens in breast cancer. J Proteome Res, 2008. 
7(4): p. 1490-1499. 
55. Miersch, S., et al., Serological autoantibody profiling of type 1 diabetes by 
protein arrays. J Proteomics, 2013. 94: p. 486-96. 
56. Montor, W.R., et al., Genome-wide study of Pseudomonas aeruginosa outer 
membrane protein immunogenicity using self-assembling protein microarrays. 
Infect Immun, 2009. 77(11): p. 4877-86. 
57. Wallstrom, G., K.S. Anderson, and J. LaBaer, Biomarker discovery for 
heterogeneous diseases. Cancer Epidemiol Biomarkers Prev, 2013. 22(5): p. 747-
55. 
58. Stoevesandt, O., M. He, and M.J. Taussig, Protein microarrays printed from DNA 
microarrays. Methods Mol Biol, 2011. 671: p. 95-106. 
59. Schmidt, R., et al., Optimised 'on demand' protein arraying from DNA by cell free 
expression with the 'DNA to Protein Array' (DAPA) technology. J Proteomics, 
2013. 88: p. 141-8. 
60. Chattopadhaya, S., L.P. Tan, and S.Q. Yao, Strategies for site-specific protein 
biotinylation using in vitro, in vivo and cell-free systems: toward functional 
protein arrays. Nat Protoc, 2006. 1(5): p. 2386-98. 
61. He, M. and M.J. Taussig, Rapid discovery of protein interactions by cell-free 
protein technologies. Biochem Soc T, 2007. 35: p. 962-65. 
62. Lim, M. and K.J. Rothschild, Photocleavage-based affinity purification and 
printing of cell-free expressed proteins: application to proteome microarrays. 
Anal Biochem, 2008. 383(1): p. 103-15. 
63. Goshima, N., et al., Human protein factory for converting the transcriptome into 
an in vitro-expressed proteome. Nat Methods, 2008. 5(12): p. 1011-7. 
64. Anderson, K.S., et al., Serum antibodies to the HPV16 proteome as biomarkers 
for head and neck cancer. Brit J Cancer, 2011. 104(12): p. 1896-905. 
65. Ceroni, A., et al., Systematic analysis of the IgG antibody immune response 
against varicella zoster virus (VZV) using a self-assembled protein microarray. 
Mol Biosyst, 2010. 6(9): p. 1604-10. 
66. Tom, I., et al., Protein microarrays for identification of novel extracellular 
protein-protein interactions. Curr Protoc Protein Sci, 2013. Chapter 27: p. Unit 
27 3. 
67. Predki, P.F., Functional protein microarrays: ripe for discovery. Curr Opin Chem 
Biol, 2004. 8(1): p. 8-13. 
68. Chandra, H. and S. Srivastava, Cell-free synthesis-based protein microarrays and 
their applications. Proteomics, 2010. 10(4): p. 717-30. 
References 
 
72 
 
69. Fang, Y., J. Lahiri, and L. Picard, G protein-coupled receptor microarrays for 
drug discovery. Drug Discov Today, 2003. 8(16): p. 755-61. 
70. Hurst, R., et al., Protein-protein interaction studies on protein arrays: effect of 
detection strategies on signal-to-background ratios. Anal Biochem, 2009. 392(1): 
p. 45-53. 
71. Mei, Q., et al., Toxin detection by a miniaturized in vitro protein expression 
array. Anal Chem, 2005. 77(17): p. 5494-500. 
72. Rathod, V., et al., Human pregnane X receptor: a novel target for anticancer drug 
development. Drug Discov Today, 2014. 19(1): p. 63-70. 
73. Schwarz, D., V. Dotsch, and F. Bernhard, Production of membrane proteins using 
cell-free expression systems. Proteomics, 2008. 8(19): p. 3933-3946. 
74. Vaquerizas, J.M., et al., A census of human transcription factors: function, 
expression and evolution. Nat Rev Genet, 2009. 10(4): p. 252-263. 
75. Hall, D.A., et al., Regulation of gene expression by a metabolic enzyme. Science, 
2004. 306(5695): p. 482-84. 
76. Ho, S.W., et al., Linking DNA-binding proteins to their recognition sequences by 
using protein microarrays. Proc Natl Acad Sci USA, 2006. 103(26): p. 9940-5. 
77. Hu, S.H., et al., Profiling the Human Protein-DNA Interactome Reveals ERK2 as 
a Transcriptional Repressor of Interferon Signaling. Cell, 2009. 139(3): p. 610-
22. 
78. Bielli, P., et al., The RNA-binding protein Sam68 is a multifunctional player in 
human cancer. Endocr Relat Cancer, 2011. 18(4): p. R91-R102. 
79. Abdelmohsen, K. and M. Gorospe, Posttranscriptional regulation of cancer traits 
by HuR. Wiley Interdiscip Rev RNA, 2010. 1(2): p. 214-29. 
80. Tyers, M. and M. Mann, From genomics to proteomics. Nature, 2003. 422(6928): 
p. 193-197. 
81. Kung, L.A., et al., Global analysis of the glycoproteome in Saccharomyces 
cerevisiae reveals new roles for protein glycosylation in eukaryotes. Mol Syst 
Biol, 2009. 5: p. 308. 
82. Habelhah, H., Emerging complexity of protein ubiquitination in the NF-kappaB 
pathway. Genes Cancer, 2010. 1(7): p. 735-47. 
83. Lin, Y.Y., et al., Protein Acetylation Microarray Reveals that NuA4 Controls Key 
Metabolic Target Regulating Gluconeogenesis. Cell, 2009. 136(6): p. 1073-84. 
84. Foster, M.W., M.T. Forrester, and J.S. Stamler, A protein microarray-based 
analysis of S-nitrosylation. Proc Natl Acad Sci USA, 2009. 106(45): p. 18948-53. 
85. Li, R., et al., Conserved herpesvirus kinases target the DNA damage response 
pathway and TIP60 histone acetyltransferase to promote virus replication. Cell 
Host Microbe, 2011. 10(4): p. 390-400. 
86. Ramachandran, N., S. Srivastava, and J. Labaer, Applications of protein 
microarrays for biomarker discovery. Proteomics Clin Appl, 2008. 2(10-11): p. 
1444-59. 
References 
 
73 
 
87. Wong, J., et al., Rapid detection of antibodies in sera using multiplexed self-
assembling bead arrays. J Immunol Methods, 2009. 350(1-2): p. 171-82. 
88. Doolan, D.L., et al., Profiling humoral immune responses to P. falciparum 
infection with protein microarrays. Proteomics, 2008. 8(22): p. 4680-94. 
89. Beare, P.A., et al., Candidate Antigens for Q Fever Serodiagnosis Revealed by 
Immunoscreening of a Coxiella burnetii Protein Microarray. Clin Vaccine 
Immunol, 2008. 15(12): p. 1771-9. 
90. Schreiber, S.L., Organic synthesis toward small-molecule probes and drugs. Proc 
Natl Acad Sci USA, 2011. 108(17): p. 6699-702. 
91. Meng, L., D. Mattoon, and P. Predki, Small molecule protein interaction profiling 
with functional protein microarrays. Methods Mol Biol, 2009. 572: p. 177-88. 
92. Huang, J., et al., Finding new components of the target of rapamycin (TOR) 
signaling network through chemical genetics and proteome chips. Proc Natl Acad 
Sci USA, 2004. 101(47): p. 16594-9. 
93. Huang, J., et al., Finding new components of the target of rapamycin (TOR) 
signaling network through chemical genetics and proteome chips. Proc Natl Acad 
Sci USA 2004. 101(47): p. 16594-9. 
94. Guilleaume, B., et al., Systematic comparison of surface coatings for protein 
microarrays. Proteomics, 2005. 5(18): p. 4705-12. 
95. Schmidt, R., et al., Single-molecule detection on a protein-array assay platform 
for the exposure of a tuberculosis antigen. J Proteome Res, 2011. 10(3): p. 1316-
22. 
96. Hu, S., et al., Profiling the human protein-DNA interactome reveals ERK2 as a 
transcriptional repressor of interferon signaling. Cell, 2009. 139(3): p. 610-22. 
97. Lu, J.Y., et al., Acetylation of yeast AMPK controls intrinsic aging independently 
of caloric restriction. Cell, 2011. 146(6): p. 969-79. 
98. Tao, S.C., et al., Lectin microarrays identify cell-specific and functionally 
significant cell surface glycan markers. Glycobiology, 2008. 18(10): p. 761-9. 
99. Peluso, P., et al., Optimizing antibody immobilization strategies for the 
construction of protein microarrays. Anal Biochem, 2003. 312(2): p. 113-24. 
100. Zajac, A., et al., Protein microarrays and quantum dot probes for early cancer 
detection. Colloids Surf B Biointerfaces, 2007. 58(2): p. 309-14. 
101. Huang, R.P., Detection of multiple proteins in an antibody-based protein 
microarray system. J Immunol Methods, 2001. 255(1-2): p. 1-13. 
102. Zhou, H., et al., Two-color, rolling-circle amplification on antibody microarrays 
for sensitive, multiplexed serum-protein measurements. Genome Biol, 2004. 5(4): 
p. R28. 
103. Varnum, S.M., R.L. Woodbury, and R.C. Zangar, A protein microarray ELISA for 
screening biological fluids. Methods Mol Biol, 2004. 264: p. 161-72. 
104. Biesiadecki, B.J. and J.P. Jin, A High-Throughput Solid-Phase Microplate 
Protein-Binding Assay to Investigate Interactions between Myofilament Proteins. 
J Biomed Biotechnol, 2011: p. 421701. 
References 
 
74 
 
105. Nelson, B.P., et al., Near-infrared surface plasmon resonance measurements of 
ultrathin films. 1. Angle shift and SPR imaging experiments. Anal Chem, 1999. 
71(18): p. 3928-34. 
106. Wang, Z.H. and G. Jin, A label-free multisensing immunosensor based on imaging 
ellipsometry. Anal Chem, 2003. 75(22): p. 6119-23. 
107. Piehler, J., et al., Label-free monitoring of DNA-ligand interactions. Anal 
Biochem, 1997. 249(1): p. 94-102. 
108. Liu, S., et al., Label-free, real-time detection of the dynamic processes of protein 
degradation using oblique-incidence reflectivity difference method. Appl Phys 
Lett, 2014. 104(16): p. 163701. 
109. Evans-Nguyen, K.M., et al., Protein arrays on patterned porous gold substrates 
interrogated with mass spectrometry: Detection of peptides in plasma. Anal 
Chem, 2008. 80(5): p. 1448-58. 
110. Yan, H., et al., DNA-templated self-assembly of protein arrays and highly 
conductive nanowires. Science, 2003. 301(5641): p. 1882-84. 
111. Pounds, S. and S.W. Morris, Estimating the occurrence of false positives and false 
negatives in microarray studies by approximating and partitioning the empirical 
distribution of p-values. Bioinformatics, 2003. 19(10): p. 1236-42. 
112. Clayton, C., The regulation of trypanosome gene expression by RNA-binding 
proteins. PLoS Pathog, 2013. 9(11): p. e1003680. 
113. Michaeli, S., Trans-splicing in trypanosomes: machinery and its impact on the 
parasite transcriptome. Future Microbiol, 2011. 6(4): p. 459-74. 
114. Clayton, C.E., Life without transcriptional control? From fly to man and back 
again (vol 21, pg 1881, 2002). EMBO J, 2002. 21(14): p. 3917-17. 
115. Berthier, D., et al., Serial analysis of gene expression (SAGE) in bovine 
trypanotolerance: preliminary results. Genet Sel Evol, 2003. 35 Suppl 1: p. S35-
47. 
116. Wurst, M., et al., An RNAi screen of the RRM-domain proteins of Trypanosoma 
brucei. Mol Biochem Parasitol, 2009. 163(1): p. 61-5. 
117. Mani, J., et al., Alba-domain proteins of Trypanosoma brucei are cytoplasmic 
RNA-binding proteins that interact with the translation machinery. PLoS One, 
2011. 6(7): p. e22463. 
118. Abbasi, N., Y.I. Park, and S.B. Choi, Pumilio Puf domain RNA-binding proteins 
in Arabidopsis. Plant Signal Behav, 2011. 6(3): p. 364-8. 
119. Archer, S.K., et al., Trypanosoma brucei PUF9 regulates mRNAs for proteins 
involved in replicative processes over the cell cycle. PLoS Pathog, 2009. 5(8): p. 
e1000565. 
120. Stern, M.Z., et al., Multiple roles for polypyrimidine tract binding (PTB) proteins 
in trypanosome RNA metabolism. RNA, 2009. 15(4): p. 648-65. 
121. Manful, T., A. Fadda, and C. Clayton, The role of the 5 '-3 ' exoribonuclease 
XRNA in transcriptome-wide mRNA degradation. RNA, 2011. 17(11): p. 2039-47. 
122. Winkler, G.S., et al., An altered-specificity ubiquitin-conjugating 
enzyme/ubiquitin-protein ligase pair. J Mol Biol, 2004. 337(1): p. 157-65. 
References 
 
75 
 
123. Inada, T. and S. Makino, Novel roles of the multi-functional CCR4-NOT complex 
in post-transcriptional regulation. Front Genet, 2014. 5: p. 135. 
124. Halter, D., M.A. Collart, and O.O. Panasenko, The Not4 E3 ligase and CCR4 
deadenylase play distinct roles in protein quality control. PLoS One, 2014. 9(1): 
p. e86218. 
125. Matsuda, R., et al., Protein quality control systems associated with no-go and 
nonstop mRNA surveillance in yeast. Genes Cells, 2014. 19(1): p. 1-12. 
126. Gruber, A.R., et al., The Vienna RNA websuite. Nucleic Acids Res, 2008. 36(Web 
Server issue): p. W70-4. 
127. Shen, S., et al., In vivo epitope tagging of Trypanosoma brucei genes using a one 
step PCR-based strategy. Mol Biochem Parasitol, 2001. 113(1): p. 171-3. 
128. Vimberg, V., et al., Translation initiation region sequence preferences in 
Escherichia coli. BMC Mol Biol, 2007. 8: p. 100. 
129. Nilsson, D., et al., Spliced Leader Trapping Reveals Widespread Alternative 
Splicing Patterns in the Highly Dynamic Transcriptome of Trypanosoma brucei. 
PLoS Pathog, 2010. 6(8): p. e 1001037. 
130. Larsson, M., et al., High-throughput protein expression of cDNA products as a 
tool in functional genomics. J Biotechnol, 2000. 80(2): p. 143-57. 
131. Angenendt, P., et al., Generation of high density protein microarrays by cell-free 
in situ expression of unpurified PCR products. Mol Cell Proteomics, 2006. 5(9): 
p. 1658-66. 
132. Chakravarti, B., et al., Comparison of SYPRO Ruby and Deep Purple using 
commonly available UV transilluminator: Wide-scale application in proteomic 
research. J Proteome Res, 2008. 7(7): p. 2797-802. 
133. Reimann, B., et al., Initial characterization of the nascent polypeptide-associated 
complex in yeast. Yeast, 1999. 15(5): p. 397-407. 
134. del Alamo, M., et al., Defining the specificity of cotranslationally acting 
chaperones by systematic analysis of mRNAs associated with ribosome-nascent 
chain complexes. PLoS Biol, 2011. 9(7): p. e1001100. 
135. Tarassov, K., et al., An in vivo map of the yeast protein interactome. Science, 
2008. 320(5882): p. 1465-70. 
136. Hata, H., et al., Dhh1p, a putative RNA helicase, associates with the general 
transcription factors Pop2p and Ccr4p from Saccharomyces cerevisiae. Genetics, 
1998. 148(2): p. 571-9. 
137. Farber, V., et al., Trypanosome CNOT10 is essential for the integrity of the NOT 
deadenylase complex and for degradation of many mRNAs. Nucleic Acids Res, 
2013. 41(2): p. 1211-22. 
138. Kirstein-Miles, J., et al., The nascent polypeptide-associated complex is a key 
regulator of proteostasis. EMBO J, 2013. 32(10): p. 1451-68. 
139. Coller, J.M., et al., The DEAD box helicase, Dhh1p, functions in mRNA 
decapping and interacts with both the decapping and deadenylase complexes. 
RNA, 2001. 7(12): p. 1717-27. 
References 
 
76 
 
140. Palfi, Z., et al., U1 small nuclear RNP from Trypanosoma brucei: a minimal U1 
snRNA with unusual protein components. Nucleic Acids Res, 2005. 33(8): p. 
2493-503. 
141. McConnell, T.S., R.P. Lokken, and J.A. Steitz, Assembly of the U1 snRNP 
involves interactions with the backbone of the terminal stem of U1 snRNA. RNA, 
2003. 9(2): p. 193-201. 
142. Droll, D., et al., Post-transcriptional regulation of the trypanosome heat shock 
response by a zinc finger protein. PLoS Pathog, 2013. 9(4): p. e1003286. 
143. Kramer, S. and M. Carrington, Trans-acting proteins regulating mRNA 
maturation, stability and translation in trypanosomatids. Trends Parasitol, 2011. 
27(1): p. 23-30. 
144. Estevez, A.M., The RNA-binding protein TbDRBD3 regulates the stability of a 
specific subset of mRNAs in trypanosomes. Nucleic Acids Res, 2008. 36(14): p. 
4573-86. 
145. Mayho, M., et al., Post-transcriptional control of nuclear-encoded cytochrome 
oxidase subunits in Trypanosoma brucei: evidence for genome-wide conservation 
of life-cycle stage-specific regulatory elements. Nucleic Acids Res, 2006. 34(18): 
p. 5312-24. 
146. Quijada, L., et al., Expression of the human RNA-binding protein HuR in 
Trypanosoma brucei increases the abundance of mRNAs containing AU-rich 
regulatory elements. Nucleic Acids Res, 2002. 30(20): p. 4414-24. 
147. Bringaud, F. and T. Baltz, Differential regulation of two distinct families of 
glucose transporter genes in Trypanosoma brucei. Mol Cell Biol, 1993. 13(2): p. 
1146-54. 
148. Panasenko, O., et al., The yeast Ccr4-Not complex controls ubiquitination of the 
nascent-associated polypeptide (NAC-EGD) complex. J Biol Chem, 2006. 
281(42): p. 31389-98. 
 
Part II 
 
 
 
 
 
 
 
 
 
 
 
Part II: 
Blood-Born 
miRNA/mRNA Signatures in 
Human African Trypanosomiasis 
 
 
 
 
 
 
 
Introduction 
 
78 
 
 
1 Introduction 
African Trypanosomiases (AT) or sleeping sickness are diseases of humans and 
animals transmitted by tse-tse flies (Fig. 1). Human African Trypanosomiases (HAT) 
and Animal African Trypanosomiases (AAT) are caused by unicellular protozoa 
parasites called trypanosomes. Trypanosoma brucei gambiense (Tbg) and Trypanosoma 
brucei rhodensiense (Tbr) are the major disease-causing agents in humans and are also 
known to infect domestic and wild animals. This leads to a possible generation of an 
animal reservoir of HAT[1]. Recently, reports indicate that domestic animals such as 
pigs could be potential reservoirs for both human and animal-infective trypanosomes[2]. 
Such findings are very frustrating, as they actually render the eradication of the disease 
inconceivable, and therefore minimize all efforts toward maintaining a low transmission 
rate.  
 
Figure 1: Transmission cycle of Human African Trypanosomiases (HAT) and Animal 
African Trypanosomiases. A possible scheme for the conservation of Animal reservoire 
According to recent estimates, some 70 million people are at risk of contracting 
HAT and about one hundred and seventy-five thousand cases were reported between 
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2000 and 2009, with an annual infection rate of 10,000[3, 4]. Clinically, the disease is 
divided into two stages. An initial hemolymphatic stage; with no specific symptoms 
which progresses to a late encephalitic stage involving the central nervous system[5]. 
The progression profile from one stage to the other greatly varies from patient to 
patient, but also depends upon the infecting Trypanosome strain. Classically, Tbg is 
known to cause a chronic disease that is geolocalized within West and Central Africa; 
meanwhile Tbr causes an acute infection in East Africa. HAT caused by Tbr is less 
prevalent than Tbg disease and some exceptions have been observed in the reported 
disease profiles[6, 7]. 
 Diagnosis of Tbg infection is done via the card agglutination test for 
trypanosomiasis (CATT). CATT positive subjects are then subjected to the trypanolysis 
test and subsequent microscopic examination for confirmation and disease staging[4]. 
Both the CATT and the trypanolysis test all depend on circulating immunoglobulin 
against variant surface antigens of the trypanosomes[8]. Presently, there is no 
homologue of the CATT for Tbr infection, and staging in both cases involves 
examination of cerebrospinal fluid (CSF). This is a very invasive procedure and 
discourages most of those living in endemic areas to participate in mass field screening. 
Although parasite DNA amplification is possible, the facilities are generally not 
available, and it is not suited for field diagnosis[4, 9]. Disease staging is of particular 
importance, as this provides the basis for the choice of therapeutic regiments, which is 
done in a case-by-case manner. Meanwhile, some molecular markers have been 
identified for staging; they all also rely on CSF. Moreover, patient classification differ 
from one country to the other and hence treatment outcomes[10-12]. 
 HAT patients constitute a very heterogenous population. This heterogeneity 
makes the disease classification more complex. In most foci, several serologically 
positive, but parasitological negative subjects are constantly encountered. The 
possibility of false positives due to non-specific agglutination in the CATT assay cannot 
account for all cases[13, 14]. One possible explanation to such observations could be a 
low parasite load at the time of examination. To circumvent this problem, the mini 
anion exchange chromatography column has been introduced for parasite 
concentration[15]. Although this enhances the sensitivity of parasitological diagnosis, it 
does not make it 100% sensitive, and some patients are left out or wrongly assigned. 
Analysis of one of such patient population has led to the identification of three patient 
groups: the first group of these serologically positive, but parasitological negative 
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subjects, were in the very early stage of the infection and later developed the disease. A 
second group, maintain high serological titers, but never develop the disease 
(asymptomatic carriers), and the third group, who become CATT negative after some 
time, might have self-cured[7].  
Many factors, may actually account for this heterogeneity, among which; the 
host and parasite genetic diversity, host immune responses, and multiple infections[16]. 
Regarding host genetic diversity, it is possible, that the phenomenon of 
trypanotolerance, which has long been reported in cattle, also occur in humans, rather 
than the self-cure hypothesis[17, 18]. The heterogeneity does not only threaten control 
strategies, but also complicate the decision of whether or not a patient should be treated, 
and even so, if stage I or stage II treatment should be administered. In the light of this, 
different recommendations have been adopted by control programs in different 
countries[19, 20]. An ideal situation however would be to develop reliable less invasive 
diagnostic standards that can guide therapeutic decision and encourage patient 
enrollment. As with most communicable and non-communicable diseases, molecular 
diagnosis is fast becoming a standard and many molecular biomarkers have been 
reported for several diseases[21, 22]. Several biomolecules have reportedly been used as 
biomarkers in some infectious and noninfectious diseases, amongst which miRNAs[23]. 
 MicroRNAs (miRNAs) are small RNAs of about 21-nt which bind to the 
3 UTR of mRNAs and play key roles in the control of mRNA stability and gene 
expression control[24, 25]. miRNAs play diverse roles in mammals and are involved in 
several cellular processes ranging from immune responses, differentiation, proliferation 
and apoptosis, development and feedback loops[26]. Dysregulation of miRNA 
expression and functions have been associated with several diseases, and there have 
been several attempts to investigate the correlation of circulating miRNA profiles with 
disease progression, prognosis and staging[23, 27-29]. Besides, the potentials of 
miRNAs as biomarkers have extensively been studied in metabolic and genetic diseases 
such as cancer and diabetes. However, less attention has been attributed to the role of 
miRNA in infectious diseases. Most of the few cases addressed, have been focused on 
experimental infections and no natural infections[30-33]. There are reports of 
modulation of host gene expression post infection in some infectious diseases. In mice 
for example, macrophage activation and cytokine responses have been observed 
following infection by Trypanosoma brucei brucei[34, 35]. It is therefore reasonable, to 
hypothesize, that infection by disease-causing trypanosomes can lead to variations in 
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the expression profiles of miRNAs. This could be as a result of the activation of 
immune responses and other biochemical processes that are controlled by genes, whose 
expression are regulated by miRNA. It is with this in mind, that this study was designed 
to analyze the expression profiles of circulating miRNA with a view of biomarker 
identification and immune response analysis. 
Objectives 
In the struggle for survival during T. brucei infection, the mammalian host has 
developed strategies to eliminate the parasite. Innate and active immune responses as 
well as immunosuppression are all processes that are activated following infection. It is 
possible, that the activation of such defense mechanisms and related pathways involve 
the expression of genes whose expression is regulated at the posttranscriptional level by 
miRNA. This can result in differences in the expression profiles of the regulating 
miRNAs 
Aim 
This work was designed to analyze the expression profiles of circulating miRNA 
and mRNA in the peripheral blood cells of patients infected by Trypanosoma brucei 
gambiense, in an attempt to identify less invasive disease biomarkers and stage-specific 
markers and to understand the mechanisms that underlie the outcome of Tbg infection. 
1.1 Human African Trypanosomiases 
1.1.1 Historical Background 
The awareness of the two variants of HAT in many endemic areas dates far back. 
However, knowledge about the precise causative agent was first reported in the late 19
th
 
century by David Bruce, while working on a wasting disease of cattle called 
nagana[36]. It was then established, that trypanosomes could infect wild game animals 
and serve as a reservoir. In 1899, the parasite was named Trypanosoma brucei, and in 
1902, the first patient with Tbg infection was identified. In 1903, the first evidence of 
trypanosomes in CSF and Blood of sleeping sickness patients was established, and in 
1910, Tbr was described for the first time. During the early 1950, HAT was almost 
brought under control owing to vast vector/parasite control campaigns. However, due to 
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political unrest, war, socio-economic factors and game reservoir, resurgence was 
observed in the late 1970[37, 38]. 
1.1.2  Epidemiology 
About 70 million people living on an estimated area of about 1.55 million km
2
 in 
200 different foci in 36 African countries are thought to be at risk[4, 10]. 
Approximately 82% of people are at risk of Tbg infection in West and central Africa, 
while less than 18% are at risk of the more acute Tbr infection in east Africa[4]. An 
annual infection rate of about 10.000 cases has been reported, with the Democratic 
Republic of Congo, Congo, Uganda, Cote d’Ivoire, Guinea, Nigeria and south Sudan 
having the highest populations at risk of Tbg infection. Meanwhile, Uganda, Tanzani 
and Kenya are by far the countries with the largest populations at risk of Tbr[3, 4]. 
1.1.3  Life Cycle of Trypanosome brucei and Infection  
Trypanosomes are spindle shaped unicellular protozoa parasites of the 
Trypanosomatidae family. They measure about 20–30 by 1.3–3.5 µM with a single 
flagellum that projects from the posterior end of the parasite and runs along the cell 
membrane. The flagellum is attached by an undulating membrane and is associated with 
the kinetoplast[10]. During its entire life cycle in both the human and vector host, the 
parasite multiplies by binary fission (Fig. 2). Human infection starts with the injection 
of metacyclic forms of the parasite into a healthy subject, by an infected tse-tse fly 
while taking a blood meal. The parasites then multiply locally for a few days before 
invading the lymphatic system, blood and other tissues and organs such as the central 
nervous system causing the sleep disorder that is characteristic of the disease.  
The parasites then continue to multiply and differentiate into two distinct forms 
(i) the long slender dividing form, (ii) and the short stumpy quiescent form. The latter is 
then taken up by a fly while feeding and can be transmitted to other subjects. While in 
humans, the parasite is covered with a dense coat of surface glycoprotein, preventing it 
from lysis by complement factors[39]. Immunoglobulin, especially the IgM class 
against the surface glycoprotein can help destroy the parasite. However, a fraction of the 
parasites is capable of escaping the host immune response, and generate a new surface 
antigen via a mechanism of antigenic variation. The Trypanosoma brucei genome 
encodes about 1,000 different genes of the Variant Surface Glycoprotein (VSG) that are 
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expressed in a mutually exclusive fashion[40-43]. Switching from one VSG to another, 
may account for the variations observed in parasite load during infection. 
1.1.4  Clinical Features 
In its clinical presentation, two distinct stages of HAT are recognized, namely: the early 
hemolymphatic stages where parasites are found in blood and the lymphatic system and 
the late encephalitic stage with CNS involvement. The distinction is more observable in 
Tbg infection, than in Tbr infection[38]. Conventionally, it is accepted, that Tbg 
infection leads to a chronic disease that can last for years before the eventual death of 
the patient if left untreated, meanwhile, Tbr causes a chronic disease that is fatal within 
weeks to months if untreated. However, there are several exceptions reported with 
chronic illness described for Tbr infection and fulminant illness for Tbg infection[10]. 
 
Figure 2: Representation of the life cycle of Trypanosoma brucei in the human and 
the tsetse fly. Alexander J. da Silva and Melanie Moser, Centers for Disease Control Public 
Health Image Library. 
1.1.4. T. brucei gambiense Disease 
After injection of the parasites, a chancre appears 5–15 days post infection. This 
will in most cases resolve without being noticed in most patients. Patients then starts 
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presenting intermittent nonspecific symptoms such as fever, fatigue, enlarge lymph 
nodes, headaches, arthralgia, and pruritus. Furthermore, in some cases a skin rash, 
splenomegaly and hepatomegaly are also some non-specific symptoms of the early 
stage of Tbg infection[44]. Following invasion of the central nervous system by 
trypanosomes and a consequential immune response, neuropschychiatric signs and 
symptoms starts appearing[45]. It may take months and in some case even years for the 
transition for first to second stage to be observed. The clinical features of the second 
stages are divided into groups including: motor, sensory, psychiatric, and sleep cycle 
disorder. Some observable mental disorders include: irritability, lassitude, headache, 
personality change, and psychosis. Kerandel’s sign can also be noted and a reversal of 
the normal sleep-wake cycle, with daytime somnolence alternating with night-time 
insomnia. Weight loss, endocrine disorders (amenorrhea), and impotence are sometimes 
observed and if left untreated, patients ultimately die[46].  
Following Tbr infection, an acute febrile illness begins 1–3 weeks post infection, 
with more pronounced, but non-specific symptoms including generalized 
lymphadenopathy keratitis and conjunctivitis. Practically, there is no clear boundary 
between first and second stage Tbr disease. Manifestations of CNS involvement may 
include drowsiness and tremor, congestive heart failure, arrhythmia, and pericardial 
effusion[47]. These conditions may kill the patients within the first six months post 
infection leaving no time for other Tbr-specific signs to be observed[48, 49]. 
1.1.5 Diagnosis of Sleeping Sickness 
Diagnosis of sleeping sickness is a multi-step task that is performed routinely by 
control program during mass field screening and usually combine serological, 
parasitological and/molecular diagnosis. It generally involves screening, diagnosis 
confirmation, disease staging and enrollment for follow-up. During this process, active 
cases are detected and recruited into a surveillance scheme. As such, it is of prime 
importance, that field diagnosis, be simplified, sensitive and patient friendly. Field 
diagnosis of Tbg infection currently rely on the card agglutination test for 
trypanosomaisis (CATT/Tbg), which has been reported to be more sensitive than the 
cervical Lymph Node (CLN) palpitation and puncture[50]. A complementary 
serological test, the trypanolysis test has recently been evaluated, and is reported to 
complement the CATT and minimize false results[8]. Confirmation of serodiagnosis 
relies on parasitological detection of parasites in blood, lymph and cerebrospinal fluid. 
Introduction 
 
85 
 
Although successful in some cases, about 20% to 30% of infected subjects are missed 
out either as a result of low parasite load, and/or low sensitivity and experience[50].  
Disease staging allow for the classification of patients in either of two major 
categories that are: first or hemolymphatic stage and the second or encephalitic stage, 
with the parasites crossing the blood-brain barrier. Without reliable tools for the 
detection of parasites in the brain, staging is often achieved by examination of CSF for 
the presence of trypanosomes, white cell count, and protein concentration. According to 
the world health organization recommendations, patients should be classified as being 
in second stage disease, if one of the following conditions are fulfilled: (i) raised white 
blood cell count (>5 cells/µl), (ii) presence of trypanosomes (iii), and increased protein 
content (>370 mg/l measured by dye-binding protein assay) [51, 52]. Despite these 
recommendations, control programs in different countries have adopted local measures 
depending on treatment outcomes[53-55].  
1.1.5.1 Serological Diagnosis of Sleeping Sickness 
Serological diagnosis is the first line diagnostic measure used during field 
screening. It generally aims at finding parasite-specific antigens or antibodies directed 
against parasite-specific antigens. In the latter case, one or more of three surface 
antigens (LiTat 1.3, 1.5, and 1.6) are used to search for circulating antibodies 3–6 weeks 
post infection[42]. As such, the CATT/Tbg, CATT/Latex and trypanolysis have been 
developed for the detection of circulating Tbg-specif antibodies. The specificity of the 
CATT/Tbg, and CATT/Latex Tbg are in the order of 87%–98% and 96%–99% 
respectively, with similar sensitivities (71%–100%)[56]. The reduced sensitivity of the 
CATT/Tbg can be explained in part, by the use of only one of the antigens (LiTat 1.3) 
as opposed to all three antigens in CATT/Latex.  
The immune trypanolysis test which uses all three antigens was recently re-
evaluated and reported to show a close to 100% specificity and sensitivity[8]. Both 
immunofluorescence assay (IFA) and enzyme-linked immunosorbent assays have 
successfully been used in some countries. However, the high cost and sophisticated 
equipment requirements coupled with the need for expertise limit their use in routine 
diagnosis[57, 58]. Antigen-specific tests have also been developed for diagnosis of 
trypanosome infection. In fact, although none of the test developed to date have actually 
been successful, this strategy is more attractive, as it will solve the dilemma of deciding 
whether or not to treat serologically positive but parasitological negative subjects. The 
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TryptectCIATT, one of such test was evaluated with promising results, but subsequent 
studies raised several doubts about its specificity[59, 60]. Other indirect methods have 
been evaluated using other body fluids such as saliva[61]. Recently, a new antibody-
based test (SD BIOLINE HAT) was launched in the Democratic Republic of Congo 
which is expected to be cheap, easy and fast to use.  
So far, there is no equivalent of the CATT/Tbg for field screening of Tbr. 
Several serological tests do exist however, but they are not used for routine field 
screening as is the case with CATT/Tbg. For example, the trypanosomiasis 
agglutination card test and other variants as well as other immunofluorescence and 
ELISA-based test are all used in reference centers[62, 63]. Confirmation of Tbr 
infection and disease staging is achieved using similar methods as with Tbg. But unlike 
in Tbg infection, Tbr-infected subjects have high parasite counts and therefore ease 
parasitological diagnosis.  
1.1.5.2 Parasitological Diagnosis of Sleeping Sickness 
Parasite detection is a major step toward confirmation of trypanosome infection, 
and in Tbg infection, this is often done on serologically positive patients (Figure 3). 
However, it is a more routine procedure in the diagnosis of Tbr, as very few serological 
tests exist. Parasitological examination is carried out on blood, chancre aspirates, CLN 
and CSF during mass population screening, or concomitantly with diagnosis of other 
infectious diseases[64]. Although trypanosome detection suffers from low sensitivity 
due to low parasite load (in Tbg especially) on the one hand and user experience on the 
other hand, it however allows for disease staging and diagnostic confirmation. It 
therefore helps in the decision of the treatment regimen. The sensitivity of parasite 
detection methods ranges between 40% to 80% and the sample must be processed as 
fast as possible, since trypanosomes are lysed by sunlight[65]. To increase sensitivity, 
several centrifugation techniques have been developed. The microhematocrite 
centrifugation technique or the Woo test, the quantitative buffy coat are all 
centrifugation techniques, that improve parasite detection by increasing parasite 
concentration[66, 67]. The quantitative buffy coat is more specific since parasite 
kinetoplast is stained with acridine orange, differentiating it from the other white cells. 
Mini-anion-exchange centrifugation technique, which is based on the separation of 
trypanosomes (that are less negatively charged than blood cells) from blood, and their 
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subsequent concentration by centrifugation increases sensitivity. The test sensitivity can 
be enhanced by using buffy coat[15]. 
1.1.5.3 Molecular Diagnosis of Sleeping Sickness 
An arsenal of molecular tools has been developed for the molecular diagnosis of 
HAT, with PCR at their basis[68]. They range from the amplification species-specific 
DNA fragment, to sub-type identification[69-71]. Studies have been performed, to 
evaluate the specificity and sensitivity of PCR-based diagnosis of HAT and the results 
are promising although there are still some variations in accuracy[72, 73]. The major 
drawbacks observed so far, is the need of sophisticated equipment, trained personnel 
and constant electricity supply, which are conditions that are not always all met in 
endemic areas. With regards to the later, isothermal amplification techniques, such as 
the Loop-Mediated Isothermal Amplification (LAMP)[74] and Nucleic Acid Sequence-
Based Amplification (NASBA)[75] have been developed as well as other combined 
techniques including the oligochromatography (OC), and the HAT-PCR-OC[76]. 
Current trends indicate that parasite detection methods might soon be replaced by PCR-
based diagnosis, in areas where the facilities permit given the reported specificity and 
sensitivity[72]. 
1.1.5.4 Treatment of Sleeping Sickness 
There are currently very few drug used for the treatment of HAT, and are 
classified into two groups. Their classification depends on whether or not they can cross 
the blood-brain barrier and to a lesser extent, their effectiveness on different parasite 
species. Meanwhile the precise mechanism of action in either case remains poorly 
understood, some are exclusively stage I drugs, and other recommended for both 
disease stages[77]. Generally, drugs used for the treatment of stage I disease are well 
tolerated and show mild side effects (though reversible). Unlike those used in stage I 
disease, stage II drugs are associated with post treatment related encephalopaties and 
death in some cases[78]. Pentamidine and Suramin are the drugs of choice for the 
treatment of stage I infection by Tbg and Tbr respectively.  
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Figure 3: Example of a conventional field algorithm for the diagnosis and staging of 
T.b. gambiense HAT. (Adapted from Bouteille and Buguet, 2012). WBC: White blood cell 
count, CTC: Capillary centrifugation technique, CSF: Cerebrospinal fluid, CATT: Card 
Agglutination test for Trypanosomiases, mAECT: mini-anion exchange Chromatography 
technique, T. Neg: Trypanosome Negative  
Treatment failure for these drugs is very rare and pentamidin is even more 
tolerated than Suramin, since it causes very few side effects[79]. Treatment of stage II 
Tbg and Tbr infection currently rely on melarsoprol, which due to severe adverse effects 
is not recommended for the treatment of stage I disease. Between 5–10% of patients 
treated with melarsoprol suffer from encephalopathy and die as a result of side effects 
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such as loss of consciousness, convulsions, edema, coma and subsequent death[80]. 
Alternative stage II treatment of Tbg, but not Tbr infection, are now available and have 
been reported to be more effective, with few relapse cases and side effects. Eflornithin 
and nifurtimox-eflornithine combination therapy (NECT) have recently been 
recommended by the WHO for the treatment of stage II Tbg infection especially in foci 
with high relapse of melarsoprol treatment[81]. Early diagnosis and treatment of 
infection remains the most efficient way to avoid the use of such toxic substances, 
which would not pass the strict safety regulations of today. The search for early, reliable 
and patient-friendly diagnostic biomarkers is thus the first indispensable step towards 
such goals. 
1.2 miRNAs 
miRNAs are a class of highly conserved gene regulatory RNA molecules in 
multicellular organisms playing key roles in the fate of many protein-coding genes. 
miRNAs are among the most abundant regulatory elements in the human genome, 
comprising up to about 5% of known human genes[82]. They are approximately 23 
nucleotide long with anti-sense complementarity to the 3 UTR of their target mRNA. 
Following maturation and integration into the RNA-induced silencing complex (RISC), 
they direct the complex to the target mRNA leading to cleavage or translational 
repression[26, 83]. They are known to control key cellular processes such as regulation 
of neurite outgrowth[84], cell differentiation[85], cell cycle control[86], cellular 
communication and signaling[87], cytokine interaction[88], apoptosis[89], Cholesterol 
biosynthesis[90] and there is mounting evidence for their involvement in some human 
diseases[91], protein homeostasis, glycosphingolipid biosynthesis, purine metabolism, 
axon guidance, and the regulation of actin cytoskeleton[92].  
1.2.1 miRNA Biogenesis 
Clusters of miRNA genes are commonly found in many regions of the genome. 
They frequently found within intergenic regions and introns of protein-coding genes[93, 
94]. Regulation of miRNA transcription units greatly vary depending upon the genomic 
location of the transcription unit; intronic miRNA transcription units that are located 
within a host gene and in the same orientation are transcribed alongside the primary 
transcript of the host gene by the same promoter[94]. Intergenic miRNA transcription 
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units on the other hand are presumably transcribed from their own independent 
promoter[94]. The transcripts of these miRNAs are believed to be polycistronic with 
distinct 5 and 3 boundaries with Cap and polyA tails as in mRNAs[95]. 
In response to diverse endogenous as well as exogenous signals, miRNAs can 
either be transcribed by RNA polymerase II or RNA polymerase III in a process that is 
tightly controlled by transcription factors and other miRNAs or by DNA 
methylation[96-98]. Before miRNAs become biologically functional, they undergo 
a two-step cleavage process performed by two distinct ribonuclease II endonucleases 
(Drosher in the nucleus and Dicer in the cytoplasm). 
The primary miRNA transcript or pri-miRNA is processed in the nucleus by the 
Drosher to yield a pre-miRNA or precursor miRNA which is exported into the 
cytoplasm via Exportin5 and Ran-GTP transporters. It further undergoes cleavage by 
the Dicer to yield a miRNA duplex of the mature miRNA or driver miRNA and 
passenger miRNA. The driver is intergrated into the RNA-induced silencing complex 
(RISC) and a passenger miRNA which can function coordinately with the driver strand 
to enhance repressibility[99, 100]. Once loaded into the RISC, the miRNA leads the 
complex toward the target mRNA, via complementary sequences at the 3 UTR of the 
later leading either to translational repression or degradation. 
1.2.2  Biological Functions of miRNAs 
To date, studies have revealed, that in fine-tuning gene expression as well as the 
expression of other RNA species, miRNA activity can result in a variety of phenotypes. 
As such, miRNAs have been shown to be involved in diverse cellular processes such as 
growth, differentiation, immune responses and in disease states. Physiologically, 
miRNAs have been reported to play key roles in the maintenance of the survival of 
mature neurons and their function[101], in the regulation of apoptosis[102], in cell 
differentiation, and development[103], and in the modulation of immune responses in 
mammals[104]. miRNAs may also mediate angiogenesis in vivo[105] and when 
transported by exosomes, they can actively relay information between cells[106]. There 
is also evidence, that miRNAs may play a role in stabilizing molecular networks, by 
buffering against perturbations. This is as a result of the involvement of miR-7 in 
several interlocking feedback and feed-forward loops. In mammalian reproduction, 
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miRNA play major role in diverse physiological processes such as oocyte maturation, 
luteum development, early embryo development and testis differentiation[107, 108] 
1.2.3  miRNA in Disease 
The implication of miRNAs in both communicable and non-communicable 
diseases has been reported. In viral infections for example, it has been shown, that 
viruses can use host miRNA in their struggle to hijack the host cell metabolism. 
Meanwhile miRNAs are also involved in host innate immune responses and host cells 
do use these molecules in defense against both RNA and DNA viruses. There is 
therefore a mutually exclusive mechanism exerted by both host and parasite in their 
struggle for survival[109, 110]. Several anti-viral miRNAs have been reported to have 
negative effects on the replication and accumulation of some viruses involved in human 
diseases such as hepatitis C virus[111]. miRNAs participate in myocardial diseases 
through their effects on cardiac fibroblast[112] and their involvement in cancer is well 
documented. In gastro-intestinal caners for example, miRNA inhibit the expression of 
oncogenes and anti-oncogenes, thereby influencing tumorigenesis and cancer 
progression. Moreover, in some cancers miRNAs can act as tumor suppressors or 
oncogenes[113, 114]. 
1.2.4  Circulating miRNAs and Biomaker Potentials 
The diagnostic potential of circulating miRNAs has become very eminent since 
they were first describes about half a decade ago[115]. Although more than 50% of all 
circulating miRNAs have been reported to be from blood cells[116], their relatively 
high plasma stability, association with disease conditions and ease of measurement 
makes them promising biomarkers for the diagnosis of several diseases. To date, there 
have been several reports on the biomarker potentials of miRNA in a various cancer 
types and other diseases. About 79 miRNA have been documented as circulating 
biomarkers of solid tumors[117].  
In infectious diseases, mutually exclusive miRNA regulations have been 
reported in viral and bacterial infections. For example, during infection by 
Mycobacterium tuberculosis, the bacterium is said to control the expression of miR-99b 
in murine dendritic cells in its attempt to modulate host immunity[118]. The hepatitis C 
virus has also developed mechanisms to usurp host miRNA to support viral 
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proliferation[119]. During infection by protozoa parasites, miRNA deregulation has 
been reported to be at the basis of important physiological changes that are observed 
post infection. For example, following Leishmania major infection, major changes in 
macrophage function have been reported to be related or caused by differential miRNA 
expression[120]. Meanwhile, following Cryptosporidium parvum infection, there has 
been an NF-kB-dependent transactivation of several miRNA genes[121]. In billary 
epithelial cells (Cholangiocytes), C. pavum is capable of inducing the expression of the 
immune protein B7-H1 by down regulating miRNA-513[33]. There is therefore 
accumulating evidence in support of cross regulation of host miRNA in infectious 
diseases. This has raised the prospects that miRNAs, and especially circulating miRNAs 
could serve as diagnostic biomarkers in some of such diseases.  
Despite this, very few studies have been devoted to the search for miRNA 
biomarkers in most infectious diseases. With no reliable staging biomarker, and the use 
of less reliable and highly invasive diagnostic procedure in HAT, the identification of 
possible circulating biomarkers could go a long way to enhance control measures, 
encourage participation and ease the work of control teams thereby reducing the use of 
highly toxic arsenics that are currently used for treatment. 
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2 Materials and Methods 
2.1 Materials 
Kits 
Product Catalogue  N
o
 Manufacturer 
miScript II RT Kit 218160 Qiagen 
miScript SYBR
®
 Green PCR Kit 218073 Qiagen 
Chemicals 
Product Catalogue  N
o
 Manufacturer 
Biozyme LE Agarose 840004 Biozyme 
Chloroform 288306 Sigma-Aldrich 
Ethanol, absolute 24102 Sigma-Aldrich 
Ethidium bromide M3178.0010 Genaxxon 
Ethylenediaminetetraacetic acid E9884 Sigma-Aldrich 
GeneRuler DNA Marker SM0311 Thermo Scientific 
Guanidine hydrochloride  6069.2 Carl Roth 
Hydrochloric acid (HCl), 37% 85848.290 VWR International 
Isopropanol W292907 Sigma-Aldrich 
Nuclease-free Water AM9939 Life technologies 
Parafilm
® 
M P8505 Labomoderne 
Q5 High-Fidelity DNA polymerase  M0491 New England Biolabs 
RNaseOUT™ Ribonuclease Inhibitor 10777-019 Invitrogen 
Sodium chloride (NaCl) S9888 Sigma-Aldrich 
Sodium phosphate dibasic (Na2HPO4) S9763 Sigma-Aldrich 
Sodium phosphate monobasic (NaH2PO4) S9638 Sigma-Aldrich 
Trizma
®
 Base T1503 Sigma-Aldrich 
Trizma
®
 HCl T3253 Sigma-Aldrich 
TRIzol Reagent 15596-018 Invitrogen 
Labware 
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Product Catalogue  N
o
 Manufacturer 
8 strip PCR tubes (0.2 ml) AM12230 Life technologies 
Adhesive PCR Seal 600208 Biozyme 
Eppendorf safe lock micro centrifuge 
tubes (0.5 ml, 1.5 ml and 2 ml) 
0030121694/ 
0030121597/ 
0030121570 
Eppendorf 
Gloves, Latex Medical Examination BM11228-PF-AV Blossom 
Gloves, Nitril Freeform SE FFS-700 Microflex 
LightCycler
®
 480 Multiwell Plate 384, 
white 
04729749001 Roche 
MultiScreen PCR µ96 Plate LSKM PCR 50 EMD-Millipore 
Thin wall standard 96-well PCR plate 82-0600-A Peqlab 
Equipment 
Name Manufacturer 
Biofuge, pico Hereaus Instruments 
Electronic Balances, Kern 434,440-45 Kern & Sohn GmbH 
Heating Block Grant Instrument 
Ice maker Scotsman 
Microcomputer electrophoresis power supply Renner GmbH 
Microwave oven Bosch 
Nanodrop Spectrophotometer N1000 Peqlab 
Refrigerated centrifuge 2k15 Sigma 
Swing wing Centrifuge R5810 Eppendorf 
Thermocycler MJ Research, LifeEco 
TKA MilliQ watter supply Millipore 
Ultraspec 2000 Spectrophotometer  Pharmacia Biotech 
Vortex Mixer 
Lightcycler®480 System 
Neolab 
Roche 
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2.2 Methods 
2.2.1  Ethical Issues 
Written informed consent forms were obtained from patients and healthy 
individuals whose blood samples were collected and included in the present study. At 
the local level, ethical approval was obtained from the World Health Organization 
(WHO) control program for Trypanosomiases in West Africa (RPC 222/14.06.2007) 
and from the Heidelberg Ethical Commission (S-171/2012). All individuals who 
participated in the present study received an explanation of the scope of the study before 
they signed the consent forms.  
2.2.2  Blood Samples 
During routine field screening by teams of the WHO control program for 
Trypanosomiases in West Africa (Jammoneau and Coworkers), indigenes of in the Bofa 
sleeping sickness focus (Guinea) were screened with the Card Agglutination Test for 
Trypanosomiasis (CATT) for whole blood. Samples with a positive CATT result were 
screened using the CATT plasma dilution test; all individuals who were positive at a 
dilution of ≤¼ were further examined for parasites using the buffy coat concentration 
technique[15], and by examination of lymph node aspirates if available, Stage 
determination was done by white cell count for all newly infected individuals. Five 
hundred microliters of plasma or whole blood was stored for a trypanolysis test[122]. 
All individuals with a positive CATT test, with or without confirmed presence of the 
parasite, and who accepted follow up and treatment were invited to the Bofa local 
Health center for enrollment into the surveillance program. 2.5 ml of blood was 
collected by venopuncture directly into the PAXgene Blood RNA tubes (PreAnalytics-
BD Company) from all consented participants. The tubes were kept in a refrigerator at 
−20°C for 2 days, then at 80°C.  
2.2.3  Total RNA Extraction 
Total RNA was extracted from blood samples using the peqGold RNA extraction 
reagent (PeqLab) following an optimized procedure. Blood samples in Paxgene tubes 
were centrifuged at 5000×g for 10 minutes at 4°C. The supernatant was discarded and 
the pellet completely re-suspended in 10ml of nuclease-free water by vortexing. 
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Samples were again centrifuged at 5000×g for 10 minutes at 4°C and the resulting pellet 
re-suspended in 2 ml of TriFast PeqGold. 400 µl of chloroform was added and the 
samples homogenized for 30 seconds at room temperature before allowed for 3 minutes 
at room temperature. The aqueous phase was separated by centrifuging at 12000×g for 
15 minutes at 4°C and transferred into an RNase-free eppendorf tube containing 500µl 
of Isopropanol. The tubes were kept at –20°C for one hour and centrifuged at 12000×g 
for 10 minutes at 4°C. The resulting RNA pellet was washed two times in 75% ethanol, 
precipitated with 3 M sodium acetate and re-suspended in 50 µl of water. The quality of 
total RNA was checked by gel analysis using the total RNA Nano chip assay on an 
Agilent 2100 Bioanalyzer (Agilent Technologies GmbH, Berlin, Germany). RNA 
concentrations were determined using the NanoDrop spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). 
2.2.4  Molecular Diagnosis 
PCR-based diagnosis was performed on all patient samples using species-
specific primers. DNA was extracted from samples by ethanol precipitation of the 
aqueous phase obtained after RNA extraction using peqGold Trifast following 
manufacturer’s recommendations (Peqlab). The PCR reaction was carried out in a 25 µl 
reaction using the Q5 high-fidelity DNA polymerase (New England Biolabs). The 
primers used allow for specific detection of T. b. gambiense[69]. PCR Product DNA 
was visualized by ethidium bromide staining on a 1.5% agarose gel. 
2.2.5  miRNA Expression Profiling 
Analysis of the differential expression of circulating miRNAs was done using the 
miRNA Microarray System with miRNA Complete Labeling and Hyb Kit (which 
represents 1,205 human and 144 human viral miRNAs) following the manufacturer’s 
instructions (by the DKFZ core facility). Briefly, after total RNA extraction and quality 
control using the Agilent Bioanalyzer, 100 ng of total RNA was dephosphorylated using 
Calf Intestinal Alkaline Phosphatase at 37°C for 30 minutes. The samples were then 
denatured in 100% DMSO at 100°C for 5 minutes and ligated to Cyanine3-pCp at 16°C 
in a circulating water bath for 2 hours and purified on a Micro bio spin column. The 
eluate was vacuum dried in a vacuum concentrator at 55°C. Samples were resuspended 
in 18 µl of Nuclease-free water. 4.5 μl of the 10× GE Blocking Agent and 22.5 μl of 2× 
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Hi-RPM Hybridization Buffer was added to each sample and mixed by vortexing. 
Samples were then heated at 100°C for 5 minutes and kept on ice. Hybridization was 
done in a SureHyb chamber at 55°C for 20 hours in a hybridization oven. Slides were 
washed two times at room temperature and once at 37°C for 5 minutes and scanned 
using an Agilent scanner (SureScan). Data was extracted using Agilent feature 
extraction software and analyzed with Chipster microarray data analysis software. Gene 
functions were annotated using the GeneCard database 
(http://www.genecards.org/)[123].  
2.2.6  qRT-PCR 
qRT-PCR was performed to confirm the profiles observed from miRNA 
expression profiling. To this end, 0.75 µg of total RNA was reverse transcribed into 
cDNA in a total volume of 20 µl using the miScript Reverse transcription kit (Qiagen) 
according to the manufacturers recommendations. Following cDNA synthesis, the 
resulting cDNA was diluted 10 fold before being used for real time PCR. The miScript 
primer assay for Syber green-based real time PCR (Qiagen) was used for qRT-PCR in a 
total volume of 12 µl, containing 1 µl of diluted cDNA in a lightCycler 480 system 
(Roche). The entire reaction was composed of 40 cycles, consisting of an initial 
activation step at 95°C for 15 minutes followed by 40 consecutive cycles of 94°C for 15 
seconds, 55°C for 30 seconds and 70°C for 30 seconds for transcript quantification. 
2.2.7  Gene Expression Profiling 
Gene expression profiling was performed (by the DKFZ Genomic and proteomic 
core facility) using the illumina Human Sentrix-12 BeadChip arrays, which contain 
more than 47,000 probes. Biotin-labeled cDNA samples for hybridization on Illumina 
Human Sentrix-12 BeadChip arrays (Illumina, Inc.) were prepared according to 
Illumina's recommended sample labeling procedure[124]. In brief, 200 ng total RNA 
was used for complementary DNA (cDNA) synthesis, followed by an 
amplification/labeling step (in vitro transcription) to synthesize biotin-labeled cRNA 
according to the Illumina® Total Prep™ RNA Amplification Kit (Life Technologies). 
Biotin-16-UTP was purchased from Roche Applied Science, Penzberg, Germany. The 
cRNA was column purified according to TotalPrep RNA Amplification Kit, and eluted 
in 60 µl of water. Quality of cRNA was controlled using the RNA Nano Chip Assay on 
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an Agilent 2100 Bioanalyzer and spectrophotometrically quantified (NanoDrop). 
Hybridization was performed at 58°C, in GEX-HCB buffer (Illumina Inc.) at a 
concentration of 100 ng cRNA/µl, unsealed in a wet chamber for 20 hours. Spike-in 
controls for low, medium and highly abundant RNAs were added, as well as mismatch 
control and biotinylation control oligonucleotides. Microarrays were washed once in 
High Temp Wash buffer (Illumina Inc.) at 55°C and then twice in E1BC buffer 
(Illumina Inc.) at room temperature for 5 minutes (in between washed with ethanol at 
room temperature). After blocking for 5 min in 4 ml of 1% (wt/vol) Blocker Casein in 
phosphate buffered saline Hammarsten grade (Pierce Biotechnology, Inc., Rockford, 
IL), array signals are developed by a 10-min incubation in 2 ml of 1 µg/ml Cy3-
streptavidin (Amersham Biosciences, Buckinghamshire, UK) solution and 1% blocking 
solution. After a final wash in E1BC, the arrays are dried and scanned. Microarray 
scanning was done using an iScan array scanner. Data extraction was done for all beads 
individually, and outliers were removed when >2.5 MAD (median absolute deviation). 
All remaining data points were used for the calculation of the mean average signal for a 
given probe, and standard deviation for each probe was calculated. 
2.2.8  Target Prediction and Core Analysis 
miRNA target prediction was done using the target prediction software 
incorporated into the Ingenuity Pathway Analysis (IPA) software. To this end, both 
highly predicted and experimentally identified miRNA targets with relevance to 
pathogen induction as well as immune responses were queried. All resulting miRNA 
targets were scored against all regulates genes that were differentially regulated from 
the gene expression profiling experiments. miRNAs and corresponding targets that went 
through this filter were subjected to a core analysis in IPA to find out cross relationships 
and potential downstream effects involving other molecules that could be major players 
in infection. 
2.2.9  Statistical Analysis 
Data analysis was done using Chipster microarray data analysis software. All 
samples were quintile normalized across chips and filtered according to standard 
deviation (0.95) and interquatile range. The empirical Baye’s two group t-tests (p< 0. 
05) was used to test for differential miRNA expression between different sample groups 
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and the Benjamini-Hochberg correction was applied over all p-values of the differential 
expression analysis. For linkage clustering, the pearsons correlation coefficient was 
calculated. Quantitative Real Time (qRT-) PCR was carried out in triplicates for a 
confirmation of microarray data. Resulting data were expressed as mean ± SE and all 
miRNA with a mean difference having a p-value of <0.05 for a two-sided unpaired 
student t-test were considered significantly regulated. 
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3 Results and Discussion 
3.1 Patient Screening 
During a routine screening campaign, a total of 14,445 individuals were screened  
(by the sleeping sickness control program in West Africa ) with the CATT test. Of this 
number, 324 tested positive for the CATT on whole blood while 114 had a positive test 
for the CATT plasma at a fourfold dilution. Trypanosomes could be found in 45 out of 
114 subjects, and the remaining 69 subjects were classified as seropositive. Forty 
samples were chosen for our study (Table 1). They included eight control samples from 
sero-negative, parasite-negative people; five CATT positive, trypanolysis positive but 
parasitologically and PCR-negative individuals, and seven CATT positive, trypanolysis, 
parasitologically and PCR-negative individuals. The remaining 20 subjects were 
parasitologically positive patients: nine in stage I and eleven in stage II. Sixteen of these 
were positive after a single round of PCR, and the remaining two were positive after a 
second PCR round. RNA was prepared from the 40 samples and used for miRNA and 
gene expression analysis. 
Interestingly, a treated patient who was among the seropositives could be 
classified as infected both by miRNA and the trypanolysis test for which it tested 
positive for all three antigens. Besides, some seropositive patients who tested 
trypanolysis negative were classified as being positive. This could be due to co-
infection with other trypanosome strains, or unrelated parasites. Recently, the 
trapanolysis test was miniaturized, and used for the screening of about 480 treated and 
untreated patients, with a close to 100% sensitivity and specificity
[125]
. It is therefore 
possible to speculate, that seropositive subjects classified by both by miRNA and the 
trypanolysis test are patients either at an early stage of infection, or with controlled 
infection. This further explains why they could not be confirmed parasitologically as 
patients.  
The differentially regulated miRNAs were able to distinguish between infected 
and uninfected subjects. Within the group of seropositives, six of them were classified 
as infected by the miRNAs and other as uninfected. Among those classified as infected, 
three of them were positive for at least one of the antigens for the trypanolysis test. 
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Table 1: Sample classification based on multiple diagnostic tests 
Patient CATT Mn-BC 
Parasite 
count 
White 
Cell 
count 
Trypa-
nolysis 
miR-
Class. 
Status Stage 
Bo.488/6  + >100 51 + A HAT II 
Bo 482/6  + >50 32 + A HAT II 
Bo.483/6  + >100 80 + A HAT II 
Bo.477/6  + >20 15 + A HAT II 
Bo.479/6  + 2 13 + A HAT II 
Bo.484/6  + >100 1 + A HAT I 
Bo.470/6  + >100 0 + A HAT I 
Bo.478/6  + >10 228 + A HAT II 
Bo.480/6  + >100 5 + A HAT I 
Bo.473/6  + 6 6 + A HAT II 
Bo.485/6  + >50 6 + A HAT II 
Bo.502/6  +/-  1 + A HAT I 
Bo.486/6  + + 6 + A HAT II 
Bo.487/6  + + 2 + A HAT I 
Bo.481/6  + 6 1 + A HAT I 
Bo.474/6  + 10 212 + A HAT II 
Bo.475/6  + 10 5 + A HAT I 
Bo.476/6  +/- >50 541 + A HAT II 
Bo.472/6  + + 0 + A HAT I 
Bo.471/6  + >50 0 + A HAT I 
Bo.492/6  + Neg  +** A Seropo/AT   
Bo.498/6  + Neg  +** B Seropo   
Bo.499/6  + Neg  - A Seropo   
Bo.491/6  + Neg  - A Seropo   
Bo.490/6  + Neg  +** A Seropo   
Bo500/6  +/- Neg  + B Seropo   
Bo489/6  + Neg  + A Seropo   
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Bo495/6  + Neg  - B Seropo   
Bo.527/6  + Neg  +* B Seropo   
Bo.493/6  + Neg  - B Seropo   
Bo.494/6  + Neg  - A Seropo/AT   
Bo.520/6  + Neg  - B Seropo   
Bo.537/6  - Neg  - B Control  
Bo.538/6  - Neg  - B Control  
Bo.509/6  - Neg  - B Control  
Bo.511/6  - Neg  - B Control  
Bo.514/6  - Neg  - B Control  
Bo.518/6  - Neg  - B Control  
Bo.521/6  - Neg  - B Control  
Bo.529/6  - Neg  - B Control  
for Typanoöysis, +, +* and +** = positive for all, one and two antigens respectively 
A= Classified as Infected, B= Classified as non-infected, AT=treated patient 
3.2 Molecular Diagnosis 
PCR-based diagnosis was carried out on all patients as well as seropositive 
subjects using primers that specifically amplify the Trypanosome brucei gambiense 
glycoprotein (TgsGP). The presence of a 308 bp fragment implies the presence of Tbg 
DNA as previously reported[69]. Of the 20 patients tested, 16 were positive during a 
first PCR (Fig. 4), and the other four were re-amplified in a second PCR. Two 
seropositive subjects tested positive by PCR, meanwhile the others as well as other 
patients gave some non-specific bands slightly above 500 bp. In some cases, multiple 
bands were observed, both for patient and seropositves. However, the said bands could 
not be correlated or interpreted as a positive test, since the size does not correspond to 
that of the expected product.  Sixteen patient samples tested positive for Tbg infection at 
first PCR run, and the others could only be amplified from the products of the first PCR. 
Some confirmed patients gave unspecific amplification of fragments either below or 
above the TgsGP fragment. 
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Figure 4: Gel electroforegram showing molecular diagnosis of T. brucei gambiense by 
TgsGP PCR. (Specific bands at 308bp, nonspecific amplification at 500bp and above) 
This was the case with most of the seropositives as well. This could be as a result 
of a co-infection by other trypanosome species, or parasites that conserved the fragment 
but are not trypanosomes. Such results have recently been observed during the 
molecular diagnosis of Fusobacterium nucleatum, where Gram staining, culture and 
molecular diagnosis were discrepant[126]. Low parasite load can explain in part the fact 
that some patient samples did not amplifiy during the first run. It is also possible, that 
since DNA was extracted from the left over from RNA extraction, the yield and quality 
of DNA might have equally played a role.  
3.3 miRNA Expression Analysis 
We analyzed the expression levels of 1205 miRNAs using circulating miRNA 
extracted from peripheral blood of T. brucei gambiense infected subjects and uninfected 
controls. A total of fourteen miRNAs were found to be differentially expressed between 
all patients, irrespective of disease stage and the control group (Table 2). Of this 
number, 13 were significantly differentially regulated between patients with stage-II 
disease and controls while ten miRNAs were differentially expressed between stage-I 
patients and controls. Combined, ten microRNAs were differentially regulated between 
all patients with respect to the control group. Two miRNA (miR-338-5p miR-146b-5p) 
was up regulated only in patients with stage I disease; meanwhile, four miRNAs (miR-
22*, miR-195, miR-144* and miR-374c) were differentially down regulated in patients 
with stage II disease. Only one miRNA was upregulated in all patients irrespective of 
group. Despite this, none of the stage-regulated miRNA could reliably be considered as 
a stage marker, due to low specificity.  
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Table 2: Summary of miRNA differentially regulated between patient vs control 
 
 
 
 
 
 
 
 
 
 
 
*= Differentially regulated in both Stages FC= Fold Change, Ad = adjusted 
Within the seropositive group, a multiple group analysis comprising patients 
controls and seropositive was performed. Six of the seropositives were classified as 
infected, and the others were classified as uninfected. Four of these samples tested 
trypanolysis positive, meanwhile one trypanolysis positive subject was classified as 
uninfected (Fig. 4). In fact, the seropositive group could be one such heterogenous 
group. Owing to the fact that unspecific reaction of the CATT could classify a subject in 
this group, or just as seen from that molecular diagnosis, co-infected subjects are in this 
group as well. Besides, some of the subjects in this group could be patients or with 
asymptomatic carriers and subjects with controlled infection with low parasite load. 
This could explain the observed classification of these samples as seen in (Figure 5); 
however, it does not explain why a trypanolysis-positive subject was classified as un 
infected.  
Perhaps the general trend for most the differentially regulated miRNAs was, for 
this sample, more toward the uninfected than the infected. This could mean that the 
subject was either having a controlled infection leading to restricted differential 
regulation of the measured miRNA, or the pathways involved in infection control did 
not involve these miRNAs.  
Generally, most of the differentially regulated miRNAs were down regulated in 
patients except for miR-193b (Table 2). In diseases such as cancer, this miRNA has 
been reported to be down regulated and is involved in the regulation of cellular 
proliferation, invasion and migration as well as regulation of cyclin D1 in 
melanoma[127, 128]. In Hepatocellular Cancer (HCC), whose main cause is chronic 
Probe ID Log2FC A. p-Value 
*hsa-miR-199a-3p -6.7 2E‐06 
*hsa-miR-126* -6.4 2E‐06 
*hsa-miR-27b -6.6 2E‐06 
*hsa-miR-98 -6.0 0.0001 
*hsa-miR-4291 -5.6 0.0002 
*hsa-miR-409-3p -5.1 0.001 
hsa-miR-144* -4.2 0.009 
hsa-miR-195 -4.4 0.01 
*hsa-miR-454 -4.0 0.02 
*hsa-miR-193b 4.1 0.02 
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hepatitis C infection, mir-193b has been shown to be 5 fold up regulated[129]. This 
could be an indication that this microRNA is upregulated post-infection. miR-199a-3p 
has been shown to play diverse roles in cancer and other diseases; it is down regulated 
in human Osteosarcoma, where it regulates cell proliferation and migration[130]. 
 
Figure 5: Cluster Dendogram for all Samples showing associations between samples. 
Symbol: 1 = Stage I, 2 = stage II, * = Infected, + =Seropositive, °= Control 
It is equally down regulated in endometrial cancer and regulates cellular 
proliferation by targeting the mammalian targets of ripamycin[131] and in breast cancer 
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it regulates proliferation and survival by targeting caveolin-2[132]. In a recent report, 
this microRNA was found to be significantly upregulated in sera from gastric cancer 
patients and was significantly associated with tumor invasion and with lymph node 
metastasis. It was later proposed was to be a reliable early marker for gastric 
cancer[133].  It was one of the microRNAs with 100% selectivity as reported recently in 
gastric cancer and is also involved in the suppression of hepatitis B viral replication 
without affecting cell proliferation[134]. Although we found this microRNA to be down 
regulated in patients it may however not be a good diagnostic biomarker for HAT, as it 
is also reported to have similar selectivity in other diseases as well[133].  
miRNA-27b just like miR-199a-3p, has been shown to be down regulated post 
infection during cytomegalovirus infection and exert an antiviral activity[135]. During 
Cryptosporadum parvum infection, this microRNA has been reported to be up regulated 
and shown to target KH-type Splicing Regulatory Protein (KSRP) in order to coordinate 
Toll-like Receptor (TLR)- and NF-κB-mediated defense by gastrointestinal epithelial 
cells. 
miR-126* was also down regulated in all patients with respect to controls, and it 
has also been reported to be down regulated in sera from patients with acute myocardial 
infarction[136]. It plays vital roles in lipid metabolism, where for example it has an 
atherosclerosis limiting effect[137]. In cancer, its roles are contrasting where on the one 
hand, it is said to exert anti-cancer effects by impairing tumor proliferation, invasion, 
migration ad survival. On the other hand, it also shows a cancer supportive effect by 
enhancing blood vessel growth and inflammation[138]. 
miR-98 just like most of the other miRNA this miRNA was equally down 
regulated, and like miRNA-27b it is known to be involved in the activation of NF-kB-
mediated defense mechanisms involving the toll-like receptor. In fact, following 
lipopolysaccharide stimulation or during C. parvum infection of gastrointestinal 
epithelial cells (Cholangiocyte), both miRNAs have been shown to enhance the 
expression of Cytokine-Inducible Src Homology 2-Containing protein[139]. This 
miRNA is also thought to inhibit the migration and invasion of human esophageal 
squamous cell carcinoma[140]. 
miRNA 409-3p is known to have several counter cancer activities. In bladder 
cancer, this miRNA is also down regulated and by targeting c-Met, this microRNA can 
impair cell migration and invasion[141]. In gastric cancer, it is also down regulated, 
where it controls cell proliferation and apoptosis by targeting the transcriptional 
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regulator PHF10[142]. Again in gastric cancer, this microRNA suppresses tumor cell 
invasion and metastasis by direct targeting of radixin[143]. 
miRNA-195 as observed has also been reported to be down regulated in Human 
Tongue Squamous Cell Carcinoma, where it inhibits cell cycle progression, promotes 
apoptosis, and reduces Cyclin D1 and Bcl-2 expression[144]. In endometriosis, this 
miRNA promotes apoptosis, meanwhile enhancing proliferation and growth by 
targeting Fractalkine[145]. In normal cells, miR-195 competes with HuR for the control 
of Stim 1 mRNA stability. 
 Some miRNA such as miR-4291, until now have not been reported to be 
involved in any disease or healthy condition. miR-144-3p and miRNA-454 both have 
barely been studied, and no previsions can be made as to the potential role they may 
play in infectious diseases. The former impairs reverse cholesterol transport and 
enhances pro inflammatory cytokine production in atherosclerosis[146]; meanwhile the 
latter is thought to play a role in colon tumorigenesis by regulating TGF-β/Smad 
signaling[147]. 
3.4 Stage-Specific Regulated miRNA 
 Apart from the ten miRNAs that were differentially regulated  in all patients 
irrespective of disease stage, two and four microRNAs were differentially regulated 
only in a stage-specific manner for stage I and stage II disease respectively. Patients 
with stage I disease showed a deregulation of miR-146b-5p and miR-338-5p which 
were down and up regulated respectively (Table 3).  
The level of mi-146b-5p has been reported to be down regulated in monocytes 
during obesity, and has been shown to inhibit NF-kB-mediated inflammatory responses 
by targeting TNF receptor-associated factor-6 (TRAF6)[148]. It has also been shown, 
that its expression is regulated by interferon gamma via the JAK/STAT pathway and 
has a negative effect on the activity of NF-kB by targeting IRAK1[149]. In cancer, this 
microRNA has been reported to impair glioma migration and invasion by targeting 
MMP16[150]. Besides, this microRNA showed a very low selectivity (<60%) when 
used to classify patients and controls, and alone, did not allow for the classification of 
stage I patients (Fig. 6). 
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Table 3: miRNAs differentially regulated between Stage I disease and controls 
*miRNAs differentially regulated only in stage I disease, FC= Fold Change, Ad = adjusted 
miR-338-5p on the other hand has been shown to be involved in the regulation of 
its host gene, the Apoptosis-Associated Tyrosine Kinase (AATK) in rat hippocampal 
neurons during maturation[151]. It has a counter effect on autophagy in colorectal 
cancer, where it is equally up regulated and enhances and promotes the migration of 
colorectal cancer cells by targeting phosphatidylinositol 3-kinase catalytic subunit type 
3 (PIK3C3). 
The down regulation of miR-146b-5p could possibly be related to excessive 
production of interferon gamma, which is  produced by natural killer cells, together 
with CD4 and CD4 cells during the neuropathogenesis if sleeping sickness. These cells 
are activated by the production of the trypanosome lymphocytic triggering factor by 
trypanosomes. They in turn liberate interferon gamma, which activate macrophages to 
produce tumor necrosis factor, interleukin-1 and reactive nitrogen species that are 
thought to be in part responsible for the toxic effects on the brain[36].  
Some microRNAs were differentially regulated only when patients with stage II 
disease and controls were compared (Table 4). Three such microRNA were found 
(miR-22*, miR-374c and miR-144*). When both patient groups were analyzed against 
the control, miR-146b-5p could not be identified among those miRNA that were 
differentially regulated in patients with respect to control (Fig. 7) 
Nonetheless, when individual patient subgroups of patients were considered, it 
was found both in stage I and stage II subjects. All three miRNAs were down regulated 
in patients, and when taken individually, miR-22 family has been reported to play 
 
Probe ID Log2FC Ad. p-Value 
hsa-miR-199a-3p -6.8 0.0002 
hsa-miR-27b -6.7 0.000 
hsa-miR-126* -6.7 0.0003 
hsa-miR-98 -5.9 0.003 
hsa-miR-4291 -5.2 0.007 
hsa-miR-409-3p -5.5 0.007 
*hsa-miR-338 -5p 4.7 0.01 
*hsa-miR-146b-5p -4.4 0.02 
hsa-miR-193b 4.4 0.04 
hsa-miR-454 -4.1 0.04 
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several roles in cancer and other diseases. For example, miR-22 has is known to be 
involved in the selective induction of p53-dependent apoptosis by repressing p21 and 
inhibit the progression of cancer by inducing cellular senescence[152, 153]. In some 
instances, it may function as a proto-oncogene whose aberrations can lead to 
hematopoietic malignancies promoting stemness and metastasis[154]. 
miR-144* is involved in normal physiological processes such as hematopoiesis, 
but its expression post infection leads to a negative regulation of host immune response 
during influenza infection and tends to promote viral replication by suppressing the 
expression of TRAF6. 
 
Figure 6: Cluster dendogram for stage I patients vs controls for ten miRNAs. Seperation of 
patients from controls (1) Group I Patients, (2), Uninfected controls 
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Table 4: miRNAs differentially regulated in Stage II disease and controls 
 
*differentially regulated in stage II subjects with respect to controls FC= Fold Change, Ad = adjusted 
Analysis of single blood cell populations during tuberculosis infection reveals that this 
miRNA is mainly expressed in T-cells, and is up regulated in patients. It inhibits TNF-α 
and IFN-γ production and T cell proliferation and therefore could be involved in the 
modulation of host immune responses by modifying cytokine production[155]. 
Taken together, the data obtained confirms the already existing theory that most 
circulating miRNAs originate from blood cells. Since most of them are equally 
expressed in other diseases and healthy conditions, they may not be suitable for any 
diagnostic purpose, even if three microRNAs could nicely select all patients from 
controls. However, there is strong evidence, that Trypanosoma brucei gambiense 
infection leads to deregulation of several microRNAs, most of which have been 
reported to be involved in host immune responses against communicable diseases. 
Given that not all microRNAs differentially regulated during Tbg infection are 
known to pay any roles host immune response, it is possible, that other infection 
coexisting with trypanosomiasis might have led to the differential expression of such 
microRNAs since patients were not tested for other infectious diseases or even 
 
Probe ID Log2F C A. p-Value 
hsa-miR-199a-3p -6.9 1.40E-05 
hsa-miR-27b -6.7 6.00E-05 
hsa-miR-126* -6.3 0.0002 
hsa-miR-4291 -6.1 0.0006 
hsa-miR-98 -6.3 0.0006 
*hsa-miR-22* -5.1 0.003 
hsa-miR-409-3p -5.1 0.01 
hsa-miR-195 -5.1 0.01 
*hsa-miR-144* -4.7 0.01 
*hsa-miR-146b-5p -4.3 0.02 
*hsa-miR-374c -4.6 0.02 
hsa-miR-454 -4.1 0.04 
hsa-miR-193b 4.1 0.04 
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metabolic diseases. Modulation of cytokine production and function seem to be the 
junction at which the global effects of the action of the individual miRNAs meet. 
 
 
Figure 20: miRNA classification of Stage II patients and controls. 1= controls, 2= 
patients  
It is, however, not clear if the observed differential regulation of some of 
microRNA could be as a result of an exclusive mechanism from the infecting parasites 
in a quest for survival. Even if trypanosomes are not intracellular parasites, this cannot 
be entirely ruled out. The inability of any one of the identified microRNAs to be 
suitable as a diagnostic biomarker or stage maker could be as a result of the 
heterogeneity within the sample groups, and the classification criteria used to attribute 
the disease stage. It could be that the selectivity of some of these microRNAs becomes 
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significant with increased sample size since the actual sample size was very limited (20 
patients; 11 stage II and 9 stage I, 12 seropositives and 8 uninfected controls) and 
therefore potentially underpowered.  
The prospects of identifying a reliable circulating biomarker for HAT may be 
possible if single cell populations are separated and analyzed. This might be helpful, not 
only in finding diagnostic biomarkers, but also correlating miRNA expression profiles 
with gene expression profiles. 
3.5 Biomarker Application of Differentially regulated miRNAs 
 Ingenuity pathway analysis was used to investigate any existing biomarker 
application for any of the differentially regulated miRNA. It turned out that miR-199a-
3p and miR-195 (Table 5) were already reported to be potential diagnostic biomarkers 
in some diseases. MiRNA-199a-3p was one of the three miRNAs that showed 100% 
selectivity in HAT. Its involvement in other diseases however precludes it as a reliable 
diagnostic biomarker for Tbg HAT 
Of the 13 miRNAs, two miRNAs (miR-193b and miR-338-5p) were up 
regulated while others were down regulated (Fig. 8). Three individual miRNAs (miR-
199a-3p, miR-27b and miR-126*) were able to isolate all patients from controls 
(p<0.05) (Fig. 9)  
Table 5: miRNA and biomarker applications from IPA 
 
 
Probe ID Biomarker application A. p-value 
hsa-miR-199a-3p Diagnosis 4.00E-06 
hsa-miR-27b  1.00E-05 
hsa-miR-126*  1.70E-05 
hsa-miR-98 Unspecified Application 7.20E-05 
hsa-miR-4291  0.0003 
hsa-miR-409-3p  0.001 
hsa-miR-193b  0.006 
hsa-miR-195 Diagnosis,Unspecified Application 0.01 
hsa-miR-144*  0.01 
hsa-miR-454 Unspecified Application 0.04 
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Figure 8: Heirachical clustering of Patients and Controls for 10 regulated miRNAs. 
Symbol 1 = Stage II, 2 = stage II, * = Infected, + =Seropositive, °= Control 
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Figure 9: Fold change of individual differentially regulated miRNAs for all sample 
groups. CATT and lysis Negative (Green). CATT positive, lysis Negative (light blue) CATT 
and Lysis Positive (Black) 
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3.6 Validation of expression profiles by qRT-PCR  
To confirm the observed expression profiles, miRNAs expression patterns was 
further analysed by qPCR (Table 9). Three miRNAs (miR-199a-3p, miR-27b, and 
miR126*) were analyzed for their expression patterns in patients and controls. The 
expression profiles for all three miRNAs could be confirmed (p<0.05), with miR-199a-
3p and miR-27b showing and average 2fold change and miR126* showing an 8 fold 
change. Since there was no distinct miRNA(s) that were exclusively differentially 
regulated for the seropositive group, these samples were not considered for further 
validation by qRT-PCR.  
Table 6: qRT-PCR data for selected differentially regulated miRNAs 
 
 
3.7 miRNA target prediction and core analysis 
The targets of the ten miRNAs that were differentially regulated between 
patients and controls were predicted using algorithms incorporated into the Ingenuity 
Pathway Analysis (IPA). More than 3,000 highly predicted or experimentally 
investigated putative targets were found. Since gene expression analysis was performed 
in parallel, the targets were scored against the list of differentially regulated mRNA 
transcripts to see if any of the genes showing differential mRNA levels could also be a 
possible target of the ten miRNAs. This lead to a list of 21 mRNA (Table 7) targeted by 
the ten miRNA, and that are involved either directly or indirectly in infectious diseases.  
TIMP2, a moderately elevated mRNA encoding a metalloprotease inhibitor, is a 
possible target of two of the down-regulated miRNAs (miR-4291 and miR-454). 
Among the down regulated genes, four (GPR146, EIF2S1, PLA2G4D and MAPK10) 
were possible targets of one up regulated miRNA (miRNA-193b). Of the predicted 
targets, pathway analysis indicated that some of the regulated targets were involved in 
NF-kB signaling, some in apoptosis signaling, others in immune deficiency, leukocyte 
extravasations, pathogen recognition and response, oxidative stress response, G-protein  
signal transduction and cell cycle regulation (Index II).  
qRT-PCR ΔCt ΔCt  
Probe Patient Control p-Value 
miR-199a-3p 11,6 ± 0,6 10,69 ± 0,48 0,03 
miR-27b 10,3 ±  1,2 9,1 ±0,8 0,01 
miR-126* 9,4 ± 0,7 6,44 ± 0,04 5,40E-10 
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 It is not possible to draw any conclusions whatsoever, regarding the relationship 
between the expression patterns of the miRNA and their potential mRNA targets. the 
origin of both the miRNAs and the mRNAs are diverse. Even if majority of the miRNA 
might have come from blood cells, this does not directly imply a similar origin for the 
mRNA. There may of course be some cross correlation between the expression patterns 
of some miRNA/´mRNA pairs, but at this point it is practically impossible to draw any 
clear boundaries. 
3.8 Gene Expression Profiling 
Gene expression profiling was carried out in parallel to the miRNA expression 
profiling. A total of about 656 genes were differentially regulated between patients and 
controls. Of this number, 38 of them were differentially regulated between patients and 
controls, meanwhile 21 were found to be targeted by at least one of the differentially 
expressed miRNA and to be involved with pathogen infection. Of the targeted genes, 
only three were up regulated, of which one (TIMP2) was already reported to play a role 
in infection. This gene was found to be targeted by two of the down regulated miRNAs 
(miR-4291 and miR-454). Among the down-regulated genes, four (GPR146, EIF2S1, 
PLA2G4D, and MAPK10) were targeted by one up regulated miRNA (miRNA-193b).  
A core analysis performed on these genes, revealed other related genes whose 
expression are related to parasitic infections. A total of 25 targets and related genes 
were found to be involved in parasitic infections (Table 8), of which 9 (36%) were 
already shown to have either biomarker, diagnostic, drug efficacy, prognostic or disease 
progression evaluation potentials. 
Considering that the samples were from different cell populations mixed 
together, it is difficult to speculate on the basis of the changes in gene expression 
observed. It is possible that some of the observed changes are due to changes in 
lymphocyte behavior, or changes in the proportions of different cell types in the blood 
of patients. Furthermore, the fact that some down regulated gene were identified as 
target of some up regulated miRNAs is not a direct implication of any cause-effect 
relationship, as it is possible, that the miRNA and the gene are from different cell 
populations. This is also true for genes whose targeting miRNAs were not seen to be 
differentially regulated or even reverse trends in miRNA-mRNA expression patterns. 
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 As mentioned earlier, it is difficult to hypothesize on any cause-effect 
relationship whatsoever, since cell populations were used. However, it can clearly be 
seen that key players of innate and adaptive immunity were differentially modulate. 
Table 7: Differentially expressed mRNAs targeted by dysregulated miRNAs 
 
*= Targeted by more than one miRNA 
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Table 8: Dysregulated targets and related genes involved in infectious diseases  
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4 Conclusion 
Analysis of the expression patterns of circulating and blood cell-born miRNA and 
mRNA was performed using Agilent and illumine platforms respectively. A total of 13 
miRNAs were found to be differentially expressed between patients and controls. None 
of the analyzed miRNA was able to show a clear expression profile with seropositive 
subjects. Meanwhile, three miRNAs were able to distinguish between patients and 
controls with a close to 100% selectivity. However, these miRNA were also already 
reported to have similar expression patterns in other infectious and non-infectious 
diseases. They are therefore not suited to be designated as potential disease-specific 
biomarkers at this level.  
Most of the differentially regulated miRNAs have been reported to be involved 
in host defense mechanisms, and pathway analysis of differentially expressed mRNA 
targeted by the differentially regulated miRNA also points to this direction. Gene 
expression analyses led to the identification of 21 transcripts that are potential targets of 
the differentially regulated miRNAs, and are involved in infection. Like some of the 
miRNAs, some of the genes were previously reported to have biomarker applications. 
Considering that a mixture of cell populations was used, and compounded by the fact 
that some of the transcripts might have been from other sources, it is not possible to 
correlate miRNA/mRNA expression patterns. 
The differential expression observed here cannot entirely be attributed to HAT, 
even if it is a major player, as it cannot be excluded that most of the patients might be 
suffering from other diseases and infections. The seropositive group remains a very 
heterogenous group, and differentially expressed miRNA alone cannot be considered 
reliable enough for the classification of individuals in this group. Besides, more scrutiny 
is needed before the initial classification of subjects in this group using established 
serological tests. It is possible that combining the immune trypanolysis test and miRNA 
expression profile could help improve the classification. The root cause of the observed 
differential expression can be assumed to be resulting from host immune responses 
against microbial infection. Limited sample size might have played a considerable role 
in the outcome of this study.Therefore, on the basis of the effect sizes observed in this 
study,future efforts to identify less invasive biomarkers for HAT should make an effort 
to consider sample size in the case where this is possible and, in addition, implement 
cell sorting.  
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Index I: Primers and Oligonucleotides 
 
Gene ID Sense EcoR1  Antisense BamH1 
tb927.10.1510 gccgaattcatgatgttgtatgagca  acggatccccgctagctgggcacgttaac 
tb927.10.1510 gccgaattcatgatggttccgtcggg  acggatccccgctacttcttgccttgagt 
tb927.6.850 gccgaattcatgatgaacaatagcaa  acggatccccgtcagtcccctcccaccac 
tb927.3.1920 gccgaattcatgatgacaaataataa  acggatccccgtcaacgcagctcattctc 
tb927.10.8720 gccgaa ttcatgatgacggatgatgt  acggatccccgtcatgcgcaccatgaaag 
tb927.8.1960 gccgaattcatgatggtggtggagta  acggatccccgttactttagttcatccca 
tb927.6.600 gccgaattcatgatgatgcagtatgg  acggatccccgtcagctatgaccctttac 
tb927.4.410 gccgaattcatgatgcaccaaaccca  acggatccccgtcacgcactggcatcacc 
tb927.10.2100 gccgaattcatgatgggaaaggaaaaggtg  acggatccccgtttcttcgaagccttcac 
tb09.211.0120 gccgaattcatgatgagcgctaacgatg  acggatccccggttgggatccatcgtc 
tb927.11.9700 gccgaattcatgatgccctctattactcaggag  acggatccccgcacttcgctcgctga 
tb927.3.1760 gccgaattcatgatggtggtggtgggg  acggatccccgcctttgggaccgctt 
tb927.8.5380 gccgaattcatgatgtctcaaaatgaagaagc  acggatccccgccacacggtcgcg 
 
Primer List for Gene Amplification 
GeneID forward primer reverse primer 
tb927.10.4430 aaaaagcaggctcagctatgtcgtcggatga agaaagctgggtctatgttcctttcttgct 
tb427_puf11 aaaaagcaggctccaaaatggtatcccctga agaaagctgggtttatttatgcgatgcagg 
tb927.10.12660 aaaaagcaggctcaaacatgtctggttggga agaaagctgggtctacagcgttggcatgca 
tb927.6.820 aaaaagcaggctctacaatggaggccagtgc agaaagctgggttcatcccttcctgccgcg 
tb927.7.4730 aaaaagcaggctcggtaatgcttcgtagggg agaaagctgggttcactcaccgactgcccc 
tb927.10.11760 aaaaagcaggctctaaaatgagttcaaccaa agaaagctgggttcactcggcatcgaagtg 
tb927.1.2600 aaaaagcaggctccattatggaagtacgcga agaaagctgggtctaacattctccgtcatc 
tb927.11.500 aaaaagcaggctcacaaatgtctcaggttcc agaaagctgggttcatttacgggcaggccg 
tb927.11.530 aaaaagcaggctcacaaatggaaccggagtg agaaagctgggtttaattctgctgctgctg 
tb927.11.12100 aaaaagcaggctccagcatgttcaaccagtt agaaagctgggtttaagcagtaatacacgt 
tb927.3.2930 aaaaagcaggctcctgtatgttctaccccaa agaaagctgggttcaaccagcggcaccgcg 
tb927.10.12090 aaaaagcaggctccagtatgccaccgcgggc agaaagctgggttcaccgttgaacacgttg 
tb927.7.320 aaaaagcaggctccaacatgtataccagtgg agaaagctgggtctaaatcacgcgactctc 
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tb927.11.12120 aaaaagcaggctccacaatggcagctgtcac agaaagctgggtttacgacagcgtaggagg 
tb927.8.2780 aaaaagcaggctctaagatgggagactcgat agaaagctgggttcactccattcgaaccgg 
tb927.8.4450 aaaaagcaggctcaatcatggggatcaaggc agaaagctgggtttacgacgggtcgcgctt 
tb927.10.13540 aaaaagcaggctcaggaatgaatttttcacc agaaagctgggtctactcgcccgatccgct 
tb927.6.4530 aaaaagcaggctcgcatatgtcctcttctgc agaaagctgggtctaatacgaatgcaaccg 
tb927.7.1180 aaaaagcaggctcccgaatgcaacgatacaa agaaagctgggttcacctcgcttccaacac 
tb927.8.6440 aaaaagcaggctcaacaatggaagacaatct agaaagctgggttcaacatacaattaaagt 
tb927.3.2000 aaaaagcaggctcccatatggatgagaagcc agaaagctgggttcattggcgagcagcaga 
tb927.5.1080 aaaaagcaggctccaccatgctcgacacgag agaaagctgggtttaatttttttttacttt 
tb927.10.11270 aaaaagcaggctcatatatggtggatccttc agaaagctgggttcagttgtggacttgcac 
tb927.7.880 aaaaagcaggctcaacaatgaacaaacttac agaaagctgggtttacgactcttcatttcc 
tb927.7.3730 aaaaagcaggctcgacaatggaaacgcacca agaaagctgggtttagtttgggctcatgaa 
tb927.10.13570 aaaaagcaggctcagcaatggccgatcgagg agaaagctgggtctaggccacactccggca 
tb927.3.1030 aaaaagcaggctcaaatatgccggcaaaaaa agaaagctgggttcatctccgcagttcctc 
tb927.10.13720 aaaaagcaggctcacggatggcgcatgttgg agaaagctgggttcaacatttattttcaac 
tb927.5.1750 aaaaagcaggctcccttatgtacgcaaaggg agaaagctgggtttagctgcgagacaccgc 
tb927.4.4230 aaaaagcaggctcaaagatgggaaggcggat agaaagctgggtttagcgatccacgccaaa 
tb927.9.4560 aaaaagcaggctccaatatgtatttcccgcg agaaagctgggtttagaacaaccgaatacc 
tb927.8.990 aaaaagcaggctcgaggatgagcacgggtga agaaagctgggtctatgaattgtgacgcat 
tb927.11.3340 aaaaagcaggctcacacatgtccaagttatt agaaagctgggtttactccagcgcagaaat 
tb927.9.12360 aaaaagcaggctcaattatggagggcactgg agaaagctgggtttatgctgactgatgcgg 
tb927.11.16590 aaaaagcaggctcagggatgagcacatcagc agaaagctgggtctacacccacctcctccc 
tb927.11.5850 aaaaagcaggctcagaaatgcctgtgcttcc agaaagctgggttcacaaggggcgaccacg 
tb927.11.15350 aaaaagcaggctcgagcatgtcctccacaca agaaagctgggtctactcaaggtctgccgc 
tb927.6.4440 aaaaagcaggctccgctatgccaacgccaac agaaagctgggttcagctgcgctgcttctg 
tb927.9.13990 aaaaagcaggctccctgatgcaaggaggaaa agaaagctgggttcatgaagtggatttatt 
tb927.9.8740 aaaaagcaggctctcaaatgtacagccaacc agaaagctgggtttaactccactgctgtgt 
tb927.11.14100 aaaaagcaggctccaaaatgcaaacctgtct agaaagctgggttcactcattctgttcgtc 
tb927.6.3480 aaaaagcaggctcgttaatgtggtacagtaa agaaagctgggtttaccagggtccatatac 
tb927.3.3960 aaaaagcaggctcgcacatgatgccgtgcaa agaaagctgggtttaatccactggtgaagg 
tb927.4.400 aaaaagcaggctcgggtatggaaagtatgcc agaaagctgggtttaggcataaagccttgc 
tb927.9.13280 aaaaagcaggctcacgcatgtcgctcaccgc agaaagctgggtctagtgtcccttctccgg 
tb927.11.16020 aaaaagcaggctccgagatggcagcagcgtt agaaagctgggtttagtttgcctcattgtt 
tb927.3.3940 aaaaagcaggctcagtcatggaagttccttt agaaagctgggtttacaaaaacggcacaaa 
tb927.8.6650 aaaaagcaggctcggaaatgacagaccacca agaaagctgggttcaacctacacgcatggt 
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tb927.11.950 aaaaagcaggctcaataatgcaggaaggcca agaaagctgggtttagtaccccttgtcgct 
tb927.8.710 aaaaagcaggctcggaaatgataactccaga agaaagctgggtttaacgaccatcgtccat 
tb927.3.3670 aaaaagcaggctcaagaatgcgaggaagagg agaaagctgggtctaagaagatttcttccc 
tb927.3.720 aaaaagcaggctcagacatgcagggctattt agaaagctgggtttatgccatgggcggaac 
tb927.1.2200 aaaaagcaggctcacctatgcgtttgtatct agaaagctgggtctatttctccgcctcgag 
tb927.3.740 aaaaagcaggctccgcaatgatgcaacggga agaaagctgggttcaatgtaacccagtttg 
tb927.3.790 aaaaagcaggctccaggatggccgagcggcg agaaagctgggtctagcgcttccataaccg 
tb927.3.5250 aaaaagcaggctccgcaatggggcgtggaaa agaaagctgggtctattctgtggttagcag 
tb927.4.1680 aaaaagcaggctctctaatgcctcccaagcg agaaagctgggttcagtaaactggttgcca 
tb927.5.810 aaaaagcaggctcgaaaatgagcactgcaac agaaagctgggttcacaaggaaagaaacat 
tb927.5.1570 aaaaagcaggctctcgaatggcaaagaagaa agaaagctgggtctagaaaacataaaggcc 
tb927.5.1580 aaaaagcaggctctaatatggcgagaaaccg agaaagctgggttcacagagggtacacggg 
tb927.6.4050 aaaaagcaggctcttttatggggttcccttc agaaagctgggtttagtgagaagcaccggg 
tb927.6.4720 aaaaagcaggctcgaccatgcgaccggagca agaaagctgggtctaattcgcacgggttat 
tb927.7.250 aaaaagcaggctcgaagatgcagaaacagcg agaaagctgggtttacacccttgcttccat 
tb927.7.2140 aaaaagcaggctcaaacatgtccttctcaat agaaagctgggttcactgccctaaagaagt 
tb927.7.2580 aaaaagcaggctcaaatatgcgtcacggagc agaaagctgggtctatgcatctatcggcga 
tb927.7.2660 aaaaagcaggctcaattatgcagctcgtagc agaaagctgggtttaattcctgcccctccc 
tb927.7.2670 aaaaagcaggctccattatgagccatccaca agaaagctgggttcaatcgctgattcctcc 
tb927.7.2680 aaaaagcaggctcggatatgttccttcccga agaaagctgggttcaaaagggtacgtgtag 
tb927.7.4980 aaaaagcaggctcattcatgcctggttgcct agaaagctgggttcagtaaaccacgatcag 
tb927.8.4020 aaaaagcaggctctagaatgaccatctcgtc agaaagctgggtctaaggcaacgcagaccc 
tb927.9.3460 aaaaagcaggctccgggatgggaaggaagga agaaagctgggtttacttacgccgcggtgc 
tb927.9.9450 aaaaagcaggctccccaatgtattctagcga agaaagctgggttcacgaacgacccggatg 
tb927.9.9520 aaaaagcaggctctaacatgacacaggtcat agaaagctgggttcaccacaacggcacgga 
tb927.10.1540 aaaaagcaggctctaacatgcctcccgctga agaaagctgggtctacgctttttgccgacg 
tb927.10.5150 aaaaagcaggctcaaaaatgtatcggccaac agaaagctgggtttagatggtttcacgagg 
tb927.10.5250 aaaaagcaggctccatcatgtctggcactaa agaaagctgggttcatctctgtttctgcgt 
tb927.10.11730 aaaaagcaggctcacaaatggatagctcgct agaaagctgggttcacggttccccactcgt 
tb927.10.12330 aaaaagcaggctcgggaatgcaaccatttgg agaaagctgggtttagggggattcggcagc 
tb927.10.12740 aaaaagcaggctcctggatgacgatggatat agaaagctgggtttacctcgcgtatggcca 
tb927.10.12760 aaaaagcaggctcaaatatgtcatcgcagga agaaagctgggtttatgacctgcagagaac 
tb927.10.12780 aaaaagcaggctccataatgccctcaaagaa agaaagctgggtttataacccgtaaggatt 
tb927.10.12800 aaaaagcaggctccaagatgaccacagcaac agaaagctgggtttacagctgctggtaagg 
tb927.10.14930 aaaaagcaggctctaccatgaacgatgccgg agaaagctgggtttaaccaccacctcgagt 
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tb927.10.14950 aaaaagcaggctcgatcatgtacggtaacca agaaagctgggtttaagtacttccctcaga 
tb927.11.1980 aaaaagcaggctccacaatgagcagcgcggt agaaagctgggttcacagggtcttgggctt 
tb927.11.7450 aaaaagcaggctctacgatgagtagggatcg agaaagctgggtctaaaaacgccgcctgcc 
tb927.11.7890 aaaaagcaggctcggatatgtcaatgcacag agaaagctgggttcagctggatctcccgtc 
tb927.11.8470 aaaaagcaggctcaattatgagcgtgggcaa agaaagctgggtttacctttgctgcgcagt 
tb927.11.16550 aaaaagcaggctcgagaatgagtgaagcgaa agaaagctgggtttacacatatgtaagcaa 
tb927.9.10280 aaaaagcaggctctaacatgatcttccccag agaaagctgggttcacttggctacccactc 
tb927.6.3490 aaaaagcaggctcggcaatgcacatttcaac agaaagctgggttcaatcctccaaccttac 
tb927.11.14950 aaaaagcaggctcaggaatggccttcaacca agaaagctgggtctactgctgcagatggtt 
tb927.11.4460 aaaaagcaggctcgcatatgacgacaggaaa agaaagctgggtttacgctgtagccttctc 
tb927.11.4450 aaaaagcaggctcaaagatgtcagaaaaagg agaaagctgggtctactcctttttatcagc 
tb927.4.2040 aaaaagcaggctcgacgatgccttcatatcc agaaagctgggtttactcctcattgccacc 
tb927.4.2030 aaaaagcaggctcgacgatgccttcatatcc agaaagctgggttcagttgccttcacccaa 
tb927.2.3880 aaaaagcaggctccgtcatggaacagtctcc agaaagctgggtttaacagaacatctgtgg 
tb927.5.1960 aaaaagcaggctctaaaatgatcaatgaagc agaaagctgggttcatagttttaatgttct 
tb927.3.1910 aaaaagcaggctctagaatgtccatgactga agaaagctgggtctactgacgctgctggcg 
tb927.10.11990 aaaaagcaggctcgtatatgcgtccgttaac agaaagctgggtctacgtcaagcgtgcctc 
tb927.3.3970 aaaaagcaggctcttcaatggtttccttcac agaaagctgggtttatcccgcctcttcatc 
tb927.10.15870 aaaaagcaggctccctgatgaactacgccga agaaagctgggttcaagatctccttgggac 
tb927.7.7280 aaaaagcaggctcgcccatgccaaacagtga agaaagctgggtctacgttgtttcaatcgt 
tb927.9.12900 aaaaagcaggctcgaaaatgtatcgacacgg agaaagctgggttcactttcgctcatgtag 
tb927.7.5380 aaaaagcaggctcaagaatgagcttattttc agaaagctgggtttacgtaagtgcagcaaa 
tb927.7.6410 aaaaagcaggctctcgcatgtcttcgggggc agaaagctgggttcaagcagtggaagccgc 
tb927.9.6870 aaaaagcaggctcagtgatgtctcgagtgta agaaagctgggttcacggggaacaaggccc 
tb927.7.1390 aaaaagcaggctccgtgatgactgtgaacat agaaagctgggtttagctccaacttgggta 
tb927.3.5460 aaaaagcaggctcctccatggagggccgcaa agaaagctgggttcaggaggaatgcggtag 
tb927.10.3500 aaaaagcaggctctcgcatggggcgtgatag agaaagctgggtttaaccgtcaatacctgc 
tb927.5.760 aaaaagcaggctcggagatgagtggaagcgc agaaagctgggtctaactgctgctgcgctt 
tb927.11.7140 aaaaagcaggctcttttatggccgcaacaat agaaagctgggtctacgaaggtgtttctgg 
tb927.3.1340 aaaaagcaggctcaaaaatgcctcccagacg agaaagctgggtttactccttttcttccac 
tb927.10.15170 aaaaagcaggctcaaacatgtcctccctgac agaaagctgggtctactggttttcctccct 
tb927.8.4540 aaaaagcaggctcgaaaatggaggggtctca agaaagctgggtctatttcccaactcgttt 
tb927.9.9060 aaaaagcaggctctttcatgcctgtctgcaa agaaagctgggttcacttcttggaaagagt 
tb927.6.4770 aaaaagcaggctcaatcatgtacccccgaca agaaagctgggttcaataatatgtttctcg 
tb927.10.7440 aaaaagcaggctcgaatatgcaggatgacat agaaagctgggtctacaggtacagcgacga 
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tb927.10.3990 aaaaagcaggctctacgatggtaaccgatga agaaagctgggtttacgcggtgtacagctc 
tb927.6.2330 aaaaagcaggctcgacgatgcccgcacgtgg agaaagctgggtttagcgtagtgcgtacat 
tb927.11.550 aaaaagcaggctccgtgatggctgcgacacg agaaagctgggtttagttgtagcggccgtt 
tb927.5.3750 aaaaagcaggctcatcaatgccaagttcgtc agaaagctgggtttattggcgcaccctctt 
tb927.7.4900 aaaaagcaggctcagacatgggtgttccaaa agaaagctgggttcatcgtttcctgtctcc 
tb927.8.2810 aaaaagcaggctcagaaatgggtgtcccatt agaaagctgggtttaggtccccagggtggc 
tb927.5.2450 aaaaagcaggctctagaatgggcgtgccaaa agaaagctgggtcaaatttgtaacttcacc 
tb927.10.6220 aaaaagcaggctcagaaatggggattgccgg agaaagctgggttcagcgcccaatgactct 
tb927.11.1550 aaaaagcaggctctgttatgggcaccaaggg agaaagctgggttcattttacacctccatc 
tb927.10.2220 aaaaagcaggctccgacatgatgcggaggac agaaagctgggtttaaaagaaccacagtct 
tb927.8.2370 aaaaagcaggctcaataatggatgaagttgg agaaagctgggttcagcggtttgtgcgaaa 
tb927.10.10850 aaaaagcaggctctaaaatgtctgactggga agaaagctgggtttatagataatgcattgt 
tb927.11.8290 aaaaagcaggctccacgatggatgaaacacc agaaagctgggttcaaacgagacttgtggg 
tb927.8.3220 aaaaagcaggctccactatggggattaaagg agaaagctgggtctaccgtcgcgtataaga 
tb927.5.1200 aaaaagcaggctcgggaatggcagtcatagt agaaagctgggtttagactaaccgaattag 
tb927.9.7070 aaaaagcaggctcacatatgagtgaaacaaa agaaagctgggtttactccttgggaaaata 
tb927.1.2580 aaaaagcaggctccagaatgcagtttggccc agaaagctgggtttacccactactccccgc 
tb927.10.7450 aaaaagcaggctcgtgtatgcctgtgattaa agaaagctgggtttactcgatgttacctaa 
tb927.2.2180 aaaaagcaggctctctcatggcaacaatatc agaaagctgggttcattctagggccatgct 
tb927.6.670 aaaaagcaggctccgccatgcagtaccaacg agaaagctgggttcacgtttctgtttttat 
tb927.11.16600 aaaaagcaggctcttacatgtcacttccacc agaaagctgggtttatccttcctttagggg 
tb927.7.5460 aaaaagcaggctcaaaaatgcaattcgatga agaaagctgggttcaggagttgttagttcc 
tb427tmp.02.5380 aaaaagcaggctcgaagatgtttacgaaaaa agaaagctgggtttactgttgcccctcctc 
tb927.8.5180 aaaaagcaggctcaccgatggatgcgttgac agaaagctgggttcaatcctgaggtacgga 
tb927.9.3530 aaaaagcaggctcagtaatggcttcggtgaa agaaagctgggtctaagaagtggtggaagc 
tb927.5.4030 aaaaagcaggctctgcaatgtcggcacagca agaaagctgggtttactggaatgggttctg 
tb927.3.1780 aaaaagcaggctctcgaatgctttcccaata agaaagctgggtctatccacctttaactga 
tb927.10.1510 aaaaagcaggctcgtccatgttgtatgagca agaaagctgggtctagctgggcacgttaac 
tb927.10.1510 aaaaagcaggctcatctatggttccgtcggg agaaagctgggtctacttcttgccttgagt 
tb927.6.850 aaaaagcaggctctcacatgaacaatagcaa agaaagctgggttcagtcccctcccaccac 
tb927.3.1920 aaaaagcaggctcgataatgacaaataataa agaaagctgggttcaacgcagctcattctc 
tb927.10.8720 aaaaagcaggctcagaaatgacggatgatgt agaaagctgggttcatgcgcaccatgaaag 
tb927.8.1960 aaaaagcaggctcgaatatggtggtggagta agaaagctgggtttactttagttcatccca 
tb927.6.600 aaaaagcaggctcgaaaatgatgcagtatgg agaaagctgggttcagctatgaccctttac 
tb927.4.410 aaaaagcaggctcgaccatgcaccaaaccca agaaagctgggttcacgcactggcatcacc 
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tb927.6.1670 aaaaagcaggctcagaaatgagcgttccgtg agaaagctgggtctttagcaacctcgcgcc 
tb927.11.13970 aaaaagcaggctctgatatggattcaaaggg agaaagctgggtttacaacgttgccgatgt 
tb927.8.2850 aaaaagcaggctcaactatgcaggtgacacg agaaagctgggttcaccttcttagtgcttt 
tb927.10.8360 aaaaagcaggctcggaaatggacgtcgacaa agaaagctgggtctacccactaagacggta 
tb927.9.13510 aaaaagcaggctcaaatatgaagctcattac agaaagctgggtctacttctcagtcaaatg 
tb927.5.2140 aaaaagcaggctcgtttatgttcagtgagca agaaagctgggttcaagactcaccaggcaa 
tb927.10.7080 aaaaagcaggctccggcatgcccgcggagct agaaagctgggttcaaagaggcctaaagtt 
tb927.7.1170 aaaaagcaggctctgttatgattacagaggg agaaagctgggtctactcacgctcccgttt 
tb927.5.1490 aaaaagcaggctcaaacatgaactgctccgc agaaagctgggtttaatttcccccaaggga 
tb927.9.5460 aaaaagcaggctcgaaaatggactcacctga agaaagctgggtctaaacccgcctcacagc 
tb927.8.4500 aaaaagcaggctctacgatggagcaccgcgc agaaagctgggtttatttagatttctcaaa 
tb927.8.4820 aaaaagcaggctcatcaatgcacgtctacac agaaagctgggttcaagtcaaggtcccctt 
tb927.11.10560 aaaaagcaggctcaataatgctgttcaaacc agaaagctgggttcacgcatatataactga 
tb927.9.4680 aaaaagcaggctcaatcatggcccaacaagg agaaagctgggtttactcaccaaggtaggc 
tb927.11.2260 aaaaagcaggctcgtttatgatggctgaatc agaaagctgggtttaggccttgctagcgcc 
tb927.10.16070 aaaaagcaggctccaagatgcagaccttact agaaagctgggttcacaattgatacaaggg 
tb927.11.11770 aaaaagcaggctcttatatgaatccagaagc agaaagctgggtctaaagcgtgaagtcggg 
tb927.6.1870 aaaaagcaggctcgttgatgcaaaatttacg agaaagctgggttcaccaaagccgacgatt 
tb927.11.6160 aaaaagcaggctcggagatgtcaggttgggc agaaagctgggtttaagctttacctgcgtt 
tb927.9.11050 aaaaagcaggctcgacaatgagaactacaat agaaagctgggtctagcggcgctggttggg 
tb927.6.3870 aaaaagcaggctcaagtatggcatcagaccc agaaagctgggttcaatatggcccaccgcg 
tb927.10.1630 aaaaagcaggctctaacatgccacctaaaaa agaaagctgggtctactcgttgctttcatc 
tb927.1.4540  aaaaagcaggctccacgatgtttttgaagga agaaagctgggtctaagatgccgctagtac 
tb927.1.4650  aaaaagcaggctccacgatgtccttggagga agaaagctgggtctacatctcagcgtaatc 
tb927.7.4670 aaaaagcaggctcaatcatgcatcattgtcg agaaagctgggttcaataaattgtacgctt 
tb927.7.930 aaaaagcaggctcagcgatgtctcgtcggcg agaaagctgggttcaccctatttcagcatt 
tb927.6.4960 aaaaagcaggctcagcgatgtcatttacggc agaaagctgggttcacatgtcttccgtgct 
tb927.11.7310 aaaaagcaggctcgccgatgcctagtagggc agaaagctgggtctaatgctcgctgccaga 
tb927.4.1630 aaaaagcaggctcgtatatgtctggctctct agaaagctgggttcacgatttgtttttctt 
tb927.7.7380 aaaaagcaggctcagccatggatcccttcgt agaaagctgggttcagttaacctgatacga 
tb927.3.4210 aaaaagcaggctcaaaaatgatacggccgtg agaaagctgggttcactcaagaagcccaga 
tb927.10.310 aaaaagcaggctctaggatgtggactgtgca agaaagctgggttcagccggagagcggttg 
tb927.11.13960 aaaaagcaggctcaaagatgagtgttaggaa agaaagctgggtttacttcccgcggttacg 
tb927.6.2550 aaaaagcaggctcgaaaatgagcgcaccacc agaaagctgggtttaccgacgcctcttctt 
tb927.4.1310 aaaaagcaggctctgagatgttcggtggtgg agaaagctgggttcaaaactcttttgtcat 
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tb927.3.5150 aaaaagcaggctcacttatggtttcttgcaag agaaagctgggtttactcgcgaaggtgtcg 
tb927.11.11030 aaaaagcaggctctaaaatgggggtgccaac agaaagctgggtctaaaatgcaaactgttc 
tb927.11.2370 aaaaagcaggctctaaaatgcccaacccata agaaagctgggttcactgcgggactgccgc 
tb927.6.4950 aaaaagcaggctcggtgatgcaagcggaaga agaaagctgggtctaccacgccttgatttt 
tb927.1.1470 aaaaagcaggctcaatgggtggtattccttc agaaagctgggttcactgaccccagaagcc 
tb927.1.3070 aaaaagcaggctcgatgtctgcgtgggcctc agaaagctgggttcatggtgcggaagatgt 
tb927.1.4020 aaaaagcaggctcgatgcatttcattatttt agaaagctgggtttaaacttctaaacctga 
tb927.1.4280 aaaaagcaggctctatggagaaggtagcaac agaaagctgggttcacatcactggttcaac 
tb927.1.5000 aaaaagcaggctccatgacaactgaagaggg agaaagctgggtttaccgcagccgaggaac 
tb927.1.670 aaaaagcaggctcgatgatgcaagtcaaact agaaagctgggttcatgcggcagctcgaca 
tb927.10.10020 aaaaagcaggctccatgaattctgctgcgag agaaagctgggtttacgaccgggcgttccg 
tb927.10.11600 aaaaagcaggctcgatggagtattcgtcaga agaaagctgggtctattgataacggtgatg 
tb927.10.11600 aaaaagcaggctcgatggagtattcgtcaga agaaagctgggtctattgataacggtgatg 
tb927.10.11630 aaaaagcaggctcaatgagtgccaagttaca agaaagctgggtttaaactacgatcaaatc 
tb927.10.12020 aaaaagcaggctcaatgtctgtgtgtcctcc agaaagctgggttcagggtaaaaagatgtt 
tb927.10.12210 aaaaagcaggctctatggttcaccgtcaaga agaaagctgggtctaactcgttgtggatcc 
tb927.10.1250 aaaaagcaggctcaatgacaagtgtggaaac agaaagctgggttcagtccaccaactgccc 
tb927.10.12720 aaaaagcaggctccatggagacgcacctcgg agaaagctgggtttagcgccatggtcgagg 
tb927.10.13610 aaaaagcaggctcgatgctgtcgtcccgtag agaaagctgggtctaaaaccgccttcgcgg 
tb927.10.13800 aaaaagcaggctcaatgtctgaggctagcga agaaagctgggtctactgagaacaatcggc 
tb927.10.13980 aaaaagcaggctcaatgtcgatgatcgccat agaaagctgggtctacgatggtccgagact 
tb927.10.14150 aaaaagcaggctcaatgagcaagacagagac agaaagctgggtttacgcaaaatcctcccc 
tb927.10.14660 aaaaagcaggctccatggagggcctgtcgcc agaaagctgggttcatctgtcttcagttct 
tb927.10.14720 aaaaagcaggctcaatgtacggtggttatgg agaaagctgggtctagagttttgtctccct 
tb927.10.14810 aaaaagcaggctcgatggctcgcggtcaaat agaaagctgggttcacttcttcggctgggg 
tb927.10.14900 aaaaagcaggctctatggagtacccagcgga agaaagctgggttcaccccttgcggcgaat 
tb927.10.15310 aaaaagcaggctcaatgtatccaaaaaataa agaaagctgggtttacaaaggggttgtagt 
tb927.10.15760 aaaaagcaggctctatgaaatcagaggggac agaaagctgggtttacgattgctcagcagc 
tb927.10.1860 aaaaagcaggctctatgacagataatcaagg agaaagctgggttcagagatcgatcagctt 
tb927.10.2190 aaaaagcaggctctatgttccacaacagtta agaaagctgggtctaagcgccctctactgg 
tb927.10.2240 aaaaagcaggctcgatgtccattacacaaag agaaagctgggtctagggatagaaccgtgc 
tb927.10.240 aaaaagcaggctctatgtctttgctgctgtc agaaagctgggttcaagctgcctcgccgcc 
tb927.10.3140 aaaaagcaggctccatgtacaccgtggctcc agaaagctgggttcattcaagacacgcgct 
tb927.10.370 aaaaagcaggctcgatggaagttgctgcggt agaaagctgggtttaaaactgcagaacatg 
tb927.10.3950 aaaaagcaggctccatggtacagcagggaaa agaaagctgggtttaaaaagccatgaaaaa 
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tb927.10.5130 aaaaagcaggctcaatgatccttaaggaaga agaaagctgggttcatgttcggtcccgcac 
tb927.10.550 aaaaagcaggctccatgaacgtttacggcaa agaaagctgggtctatctatgcgtcgagtc 
tb927.10.5830 aaaaagcaggctcgatgtatttacattccat agaaagctgggttcaaattttgacgggctt 
tb927.10.5990 aaaaagcaggctccatgtcatcttcccgtgt agaaagctgggtctaccgatgctgggaata 
tb927.10.6450 aaaaagcaggctcaatggatcaccctcccgc agaaagctgggtctaaatgaatgtcgtagc 
tb927.10.7790 aaaaagcaggctccatgtatcctggaaagga agaaagctgggttcagttttttgctgcgtt 
tb927.10.9020 aaaaagcaggctcaatgatgggtgatgctgg agaaagctgggtctacgagtctgaaagatt 
tb927.10.9150 aaaaagcaggctccatggggaaagcaccagt agaaagctgggtctacaaatcagggttcac 
tb927.10.9240 aaaaagcaggctctatggatgacaaacaggc agaaagctgggtctagttaagcagttcatt 
tb927.10.9330 aaaaagcaggctcgatggaacacgaaattca agaaagctgggtttacattcttcccggtac 
tb927.11.10020 aaaaagcaggctccatgcaactcttatcgtg agaaagctgggttcatttctggagagagcg 
tb927.11.11860 aaaaagcaggctcaatgagagaaaaggaagc agaaagctgggttcaaagttccgggctgat 
tb927.11.12070 aaaaagcaggctccatgaacgctaggaagcc agaaagctgggtctacaactgaagactttc 
tb927.11.12640 aaaaagcaggctctatgagctctgcggtttc agaaagctgggttcattcattcaactcctt 
tb927.11.12670 aaaaagcaggctccatgttcgacttgatggc agaaagctgggtctacgcatcggggtgttt 
tb927.11.12730 aaaaagcaggctcaatgagctgccttcatgg agaaagctgggtttaacccggtttgtggca 
tb927.11.1340 aaaaagcaggctcaatgagttctgtgaggct agaaagctgggtttattcatcagtgaagta 
tb927.11.14220 aaaaagcaggctcaatggacagcatcactgc agaaagctgggtctattgttgcggctgctg 
tb927.11.14520 aaaaagcaggctctatgttacggcatttgtt agaaagctgggtttagtggctcaggcgagc 
tb927.11.14750 aaaaagcaggctcaatgttccacgatctgac agaaagctgggtttatttgtacgttggagg 
tb927.11.14800 aaaaagcaggctcaatgccctcagaatcttt agaaagctgggtctatcgctgacgcagatt 
tb927.11.15000 aaaaagcaggctctatggtccggcggaataa agaaagctgggtttactctccacgagcacg 
tb927.11.16130 aaaaagcaggctccatgcccagcgagcggac agaaagctgggtttatgccctttcataaat 
tb927.11.16350 aaaaagcaggctcgatgggtatacttcagca agaaagctgggtttacgagtacttatccac 
tb927.11.16470 aaaaagcaggctcaatgaccgaaactgatgg agaaagctgggttcaagccaattcacgttt 
tb927.11.16610 aaaaagcaggctcaatgagctctcagcaccg agaaagctgggtttacgcatccactacgag 
tb927.11.2030 aaaaagcaggctcgatgtcttcatctttctt agaaagctgggttcaacggttcaagtaata 
tb927.11.220 aaaaagcaggctctatgattgaagcggacgt agaaagctgggttcacatcaacgacctggt 
tb927.11.2250 aaaaagcaggctccatgtacaataacgactc agaaagctgggtttaggaaggcccatctgc 
tb927.11.2300 aaaaagcaggctccatggccgaccacgagtt agaaagctgggtttacataaagtcgtcgtc 
tb927.11.2610 aaaaagcaggctctatggcagccgctgttac agaaagctgggtctacgacgtgcgttcgac 
tb927.11.2900 aaaaagcaggctcaatgacagggatgctccg agaaagctgggttcaggagttaaagtttac 
tb927.11.3100 aaaaagcaggctcgatgaccgcactgtcaaa agaaagctgggtctagcgggaggaaaaccg 
tb927.11.3440 aaaaagcaggctctatggtgtatgagtttgt agaaagctgggtctaagacggatgcatgtc 
tb927.11.360 aaaaagcaggctcgatgaagactattgccct agaaagctgggttcaagtaccttcccgctc 
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tb927.11.3650 aaaaagcaggctccatggccgcggctccaag agaaagctgggtttattgcttgaggtatat 
tb927.11.4320 aaaaagcaggctcgatggagaaaattgttcg agaaagctgggtctaagcatctggtggtgc 
tb927.11.4400 aaaaagcaggctccatgcttggttcatggct agaaagctgggttcaactctgggatttcgt 
tb927.11.4440 aaaaagcaggctcgatgcctcaaagcctgtt agaaagctgggtctatttcccccggcgatg 
tb927.11.4550 aaaaagcaggctcaatgtcgaatgcacttga agaaagctgggttcacgcgtcatcatctct 
tb927.11.5840 aaaaagcaggctcaatgaatgcaaacgacga agaaagctgggttcagttcagcgagtggat 
tb927.11.5960 aaaaagcaggctctatgttctcgaaatccgt agaaagctgggttcaaacggttgcctgctc 
tb927.11.6010 aaaaagcaggctccatgcgcggtgccgatca agaaagctgggtttatacgagctccctttt 
tb927.11.6130 aaaaagcaggctccatggcggaagaggtgtc agaaagctgggtttacgcctcttcgcacca 
tb927.11.6240 aaaaagcaggctccatgcgtccgaggttgta agaaagctgggttcaacagcaccttacttc 
tb927.11.6430 aaaaagcaggctctatggagtccgtgccgcg agaaagctgggttcaaaaagaccactgcgc 
tb927.11.6440 aaaaagcaggctctatgcctccaaaaaacaa agaaagctgggtctaccacctattagggag 
tb927.11.6600 aaaaagcaggctctatggatcccagaaaccc agaaagctgggttcaagcacttatgccaca 
tb927.11.6870 aaaaagcaggctcaatggcgggctttcaaat agaaagctgggttcactccaattcctccat 
tb927.11.7100 aaaaagcaggctctatgcaacaggagaaccg agaaagctgggttcaccgagcgccgatgtg 
tb927.11.7590 aaaaagcaggctccatgtggcactcttttct agaaagctgggtttacacttccacttgggc 
tb927.11.8020 aaaaagcaggctcgatggcacttgaagggtc agaaagctgggtctacacgtgcctcagttc 
tb927.11.830 aaaaagcaggctctatgggccacgctttttg agaaagctgggttcacacactcctgccttc 
tb927.11.860 aaaaagcaggctcaatgcacgctggcactcc agaaagctgggtctaggcccttgttgcacc 
tb927.11.9100 aaaaagcaggctcaatggtcttttcaattcc agaaagctgggttcacaggcgcctaaacac 
tb927.11.9400 aaaaagcaggctcaatgcaacagcaaaaccg agaaagctgggttcaatccctgcttccttc 
tb927.11.9410 aaaaagcaggctctatgcatttacaaataaa agaaagctgggttcattcttctttctgttt 
tb927.11.9440 aaaaagcaggctccatgaacgaattaaagaa agaaagctgggtttacatatttaatctaat 
tb927.11.9530 aaaaagcaggctcaatgacggactgcatcaa agaaagctgggttcagttcacgggttgctc 
tb927.2.3160 aaaaagcaggctcaatgtccagtcggtgctc agaaagctgggttcacctcgcaatccaaga 
tb927.2.3920 aaaaagcaggctctatgttttcttgttgcct agaaagctgggtctacttgcgcctagaata 
tb927.2.4440 aaaaagcaggctccatgtacgatgagaaagt agaaagctgggttcagacttttttttttct 
tb927.2.4710 aaaaagcaggctccatgcaacaatataccct agaaagctgggttcagtcccttacgcggtc 
tb927.2.4930 aaaaagcaggctctatgtctcacattctttt agaaagctgggttcatttcatcaacgtcat 
tb927.2.5000 aaaaagcaggctccatggcaacaagaggtgt agaaagctgggttcacttgtgttgaagcct 
tb927.2.5150 aaaaagcaggctcaatggattacgccgccgc agaaagctgggtctatataaccccaagttg 
tb927.2.5200 aaaaagcaggctcaatggatgagcaaaacag agaaagctgggtctaattgtcggaatcgct 
tb927.3.1300 aaaaagcaggctccatgtggttcacaaacat agaaagctgggtctactttacatttgtcca 
tb927.3.1810 aaaaagcaggctctatgcgaacaaccacgca agaaagctgggttcactgggtgtgctgtgg 
tb927.3.2900 aaaaagcaggctcgatggcagcttacggtat agaaagctgggttcagtccgtgtcttcgcc 
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tb927.3.3060 aaaaagcaggctcgatggattttgattttgt agaaagctgggtctaaaacggatccgctga 
tb927.3.3440 aaaaagcaggctccatgaacaattcacttaa agaaagctgggtctattccactttgcatct 
tb927.3.3490 aaaaagcaggctcgatggcaacagaattgaa agaaagctgggtctacttgggtagtgctgc 
tb927.3.5010 aaaaagcaggctcaatggcggataatgaaga agaaagctgggtttatgaccccctcctcga 
tb927.3.5090 aaaaagcaggctctatgccctccgctgaaac agaaagctgggttcaactccacgactgcca 
tb927.3.5320 aaaaagcaggctctatggcaatgtgtgattg agaaagctgggttcaatggatgtgaagaac 
tb927.3.580 aaaaagcaggctcgatggatttggaaaattg agaaagctgggtctacatatattcatcatc 
tb927.4.1540 aaaaagcaggctccatgcttcgtgtattctc agaaagctgggttcaattctttcccctcct 
tb927.4.1910 aaaaagcaggctccatgtcttcctttaacat agaaagctgggtttacgaagtctgtccctc 
tb927.4.2520 aaaaagcaggctcaatgaggcggcccaatgg agaaagctgggttcatgccgcgggaccctt 
tb927.4.3330 aaaaagcaggctcgatgcctgcttcagcctc agaaagctgggtctaacgatgatttgagag 
tb927.4.3470 aaaaagcaggctcgatgtctcttcgtgacga agaaagctgggtctatgcactcccatgcat 
tb927.4.3970 aaaaagcaggctcaatgtcggcaggttcgga agaaagctgggtttaattgctaaagaactc 
tb927.4.4570 aaaaagcaggctcaatgggtgttgcacccag agaaagctgggtttaggacttcctccagtc 
tb927.4.550 aaaaagcaggctcaatgtacggcaacaaagg agaaagctgggttcactcctcagttttaaa 
tb927.4.640 aaaaagcaggctcgatggacgctgttgtaaa agaaagctgggttcaaaaccttctcttgac 
tb927.4.990 aaaaagcaggctcgatggacaccgctgctga agaaagctgggttcaaacaaacgattttcg 
tb927.5.1600 aaaaagcaggctcaatgagtgaaccattgat agaaagctgggtctattcttcattttcctc 
tb927.5.1990 aaaaagcaggctctatgacgcaatcgcaatc agaaagctgggtttagcgactgaagcgggc 
tb927.5.2120 aaaaagcaggctcgatggagaatcaggcacc agaaagctgggtctacttcatcatggtatt 
tb927.5.2620 aaaaagcaggctcaatgcacgtacttggcag agaaagctgggtttacagctgttcaagaga 
tb927.5.3120 aaaaagcaggctcgatggctgaacaaccgga agaaagctgggtctaaagtgtcatggcttg 
tb927.5.3450 aaaaagcaggctcgatggagtcgaatgtgtc agaaagctgggtctatctccgtttcttctt 
tb927.5.4020 aaaaagcaggctcgatgatgatttcccgcgc agaaagctgggtttagaaagagagggccgt 
tb927.5.4100 aaaaagcaggctctatgacttttctacccgt agaaagctgggtttaaaggctcagtttgaa 
tb927.5.4320 aaaaagcaggctcgatggaagagggcggtga agaaagctgggtttacgtgtcctcagagtg 
tb927.5.4330 aaaaagcaggctcgatgagatcgtttatgta agaaagctgggttcacgccacctcgcccgc 
tb927.5.4450 aaaaagcaggctccatgtcaatgagcaacgg agaaagctgggttcactttacagcagtttt 
tb927.5.4620 aaaaagcaggctcaatgcaccggcttgcaac agaaagctgggtttaagagtacatgaggat 
tb927.5.750 aaaaagcaggctcgatgtctgtagttgttag agaaagctgggtctactctaacatgtactg 
tb927.6.2720 aaaaagcaggctctatgccgcactccatgga agaaagctgggtttacaaaagtttccattg 
tb927.6.3220 aaaaagcaggctcaatgccagttcgacagaa agaaagctgggttcaatcactaagtaactt 
tb927.6.3420 aaaaagcaggctcgatgcggcgaatttttag agaaagctgggttcaaacttgcgtcagcag 
tb927.6.3950 aaaaagcaggctctatggaggatccacggga agaaagctgggtctaacggcgatattcctc 
tb927.6.4270 aaaaagcaggctcaatgaagcggtctttttt agaaagctgggttcaatgaactgcagcact 
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tb927.6.5010 aaaaagcaggctcgatggaacattcgcgtcg agaaagctgggtttaaacactcttccctcc 
tb927.7.1710 aaaaagcaggctcgatgcgcttgttgaaaaa agaaagctgggtttacacaactacacttgc 
tb927.7.1890 aaaaagcaggctcaatgaatgtttctgagtt agaaagctgggtctatgacgtaaacctctt 
tb927.7.2160 aaaaagcaggctcaatgcaagcatctgaatc agaaagctgggttcacgctgcaaccttctg 
tb927.7.2440 aaaaagcaggctcaatgaagatatcatttat agaaagctgggtttaattcaatcccttctc 
tb927.7.2610 aaaaagcaggctctatggatggcgagggatg agaaagctgggtttatctcaaatccatctc 
tb927.7.2780 aaaaagcaggctcaatgtctaaagctccttc agaaagctgggtctatgccgccgctgccgg 
tb927.7.2980 aaaaagcaggctccatgcgccggtctgtata agaaagctgggtttatttaaacaccttaaa 
tb927.7.3220 aaaaagcaggctcaatgcgagctgaaaaggt agaaagctgggttcactcgggaacattttg 
tb927.7.3350 aaaaagcaggctcaatgtgcagctgttgctg agaaagctgggttcaagcaataggttcgtt 
tb927.7.3550 aaaaagcaggctcaatgtctatattcggtga agaaagctgggtttagaaacctcgcccaac 
tb927.7.4120 aaaaagcaggctcgatggatctggattcttt agaaagctgggtttagcttggtggtctaaa 
tb927.7.4430 aaaaagcaggctcaatgcgttccgttattcg agaaagctgggttcaatcattccatggact 
tb927.7.4520 aaaaagcaggctccatgaccgatacaattga agaaagctgggtttaaaatagcgacatttc 
tb927.7.4660 aaaaagcaggctcaatgcgaacacgatttag agaaagctgggtttacttccatggaacacg 
tb927.7.5480 aaaaagcaggctccatgctcagtcttacgcg agaaagctgggtctacaccgccatctccat 
tb927.7.5680 aaaaagcaggctctatgaccgaccttcacat agaaagctgggtttagtatttactgcggga 
tb927.7.7170 aaaaagcaggctctatgaatccacacgcctg agaaagctgggtttatcggtagtccctgta 
tb927.7.7190 aaaaagcaggctcaatgggaaaaaagaaggc agaaagctgggtttacactccgacactgcc 
tb927.7.7220 aaaaagcaggctcaatgagcaccagttcgtc agaaagctgggtctattgttcgtgagaggc 
tb927.8.1460 aaaaagcaggctcgatggcatcccaaaatgc agaaagctgggtctaactggagcgcgaacc 
tb927.8.1680 aaaaagcaggctccatgatggcgagtgcccc agaaagctgggttcaactggggtcaccaat 
tb927.8.1770 aaaaagcaggctcgatggggttgttcatcca agaaagctgggttcaggactgctgtgttgc 
tb927.8.3090 aaaaagcaggctccatgcaagtctctccacg agaaagctgggtctaacttgaaaacggctt 
tb927.8.3780 aaaaagcaggctcaatgccacccaaaaagaa agaaagctgggtctaaccctctttttcatc 
tb927.8.3850 aaaaagcaggctcaatgatagtcagaacgcc agaaagctgggttcaagcggctaccgcgcc 
tb927.8.4190 aaaaagcaggctcaatgagcggccataggca agaaagctgggtttactccccagtaaaaat 
tb927.8.4200 aaaaagcaggctccatgctagatctatttgc agaaagctgggttcaccccttatgttgcgt 
tb927.8.4220 aaaaagcaggctccatgggcaagaaggctga agaaagctgggttcaagaaagatcatacgc 
tb927.8.4370 aaaaagcaggctcaatggctgacagtaacaa agaaagctgggttcactttggtgcactctg 
tb927.8.4390 aaaaagcaggctcgatggggaaacgatcgat agaaagctgggttcagtcctcaggactgta 
tb927.8.4650 aaaaagcaggctcgatgcaaaggtgtgtcca agaaagctgggtttacacagcgggcttgaa 
tb927.8.5370 aaaaagcaggctccatgtccctctcaccaca agaaagctgggttcaggcactcggcgccaa 
tb927.8.6750 aaaaagcaggctcaatgaagatcttcaggga agaaagctgggttcacacgcgttcgccctt 
tb927.8.7760 aaaaagcaggctcaatgggtgctgctccaag agaaagctgggtttatctatctgcgcaata 
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tb927.8.7820 aaaaagcaggctctatgctttttcacacgac agaaagctgggttcatttcccatcaaatcc 
tb927.8.910 aaaaagcaggctcaatgactgaattcaatta agaaagctgggtttaattgaagcgacatcc 
tb927.9.10770 aaaaagcaggctccatggctgcatttgctgc agaaagctgggtctacatgccaatgtgacg 
tb927.9.1120 aaaaagcaggctctatggggattagtttttg agaaagctgggtttatatatcctcttctcc 
tb927.9.12320 aaaaagcaggctcaatgtctaagcagcagca agaaagctgggtctaatggcacatggcatc 
tb927.9.13150 aaaaagcaggctcgatgggatacaggttgtt agaaagctgggtttatgacgtgcaggtggc 
tb927.9.13970 aaaaagcaggctctatgcactgccgcctgct agaaagctgggttcattgtctaggaataag 
tb927.9.14120 aaaaagcaggctcaatggagcattttgcccc agaaagctgggtctaccggttcctatgctt 
tb927.9.15040 aaaaagcaggctcgatgaagcgcgcgcgcaa agaaagctgggttcacgaagttctgtggtt 
tb927.9.17940 aaaaagcaggctccatgacatgtaggagttc agaaagctgggttcattcagatccaaagcc 
tb927.9.3000 aaaaagcaggctcaatgcaatgctcatcatt agaaagctgggttcagaaagttcctggaca 
tb927.9.3580 aaaaagcaggctcgatgcatgtggcctctcc agaaagctgggtctagtcagaatcactgtc 
tb927.9.4080 aaaaagcaggctctatggcatcggaggcagc agaaagctgggtttattcgcccctaactgc 
tb927.9.5260 aaaaagcaggctcgatgctttccctatatgc agaaagctgggtctaggaggcatcaatgga 
tb927.9.5390 aaaaagcaggctctatgtctattgagaggct agaaagctgggtttaatcatcgctaagttc 
tb927.9.6470 aaaaagcaggctccatgacactggagggcgg agaaagctgggtttaggccccttcgccaat 
tb927.9.7110 aaaaagcaggctcgatggagggaagcactgc agaaagctgggtttactgagtgtactgaac 
tb927.9.7480 aaaaagcaggctcaatgaaccaaccgacaac agaaagctgggtctacttggcacgtaggtg 
tb927.9.8060 aaaaagcaggctccatgtacaaggagaccac agaaagctgggtttaccaatcgtcatcatc 
tb927.9.9290 aaaaagcaggctctatgacaatcgctgcaca agaaagctgggtttaagcgcttgaggcgtg 
tb927.9.9550 aaaaagcaggctccatgttggatcacacaat agaaagctgggttcactgttgttgctgttg 
 
Other Oligomers used 
 
THT_fow- gtggcggccgctctagctagcactgaagcttaattc 
THT_rev6- atagggcgaattgggtacacttacaagagatcattatagaagaacat 
THT_rev5- atagggcgaattgggtacacttacgaaacgtcttcaattgtataa 
THT_rev4- atagggcgaattgggtacacttacatacacactaacagcatactg 
THT_rev-atagggcgaattgggtacacttacgatggaaaaacaaaagtatatat 
THT_rev2-atagggcgaattgggtacacttaccaattacctccttcaaac 
THT_rev1-atagggcgaattgggtacacttacaaacaacttcgtcgc    
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Aurora  
Fow_caccatgcatcaccatcatcaccatcatcaccatcacatgaggtcaa ctgaggtc 
Rev_attctctttccctgcagt 
Caf40  
Fow_caccatgcatcaccatcatcaccatcatcaccatcacatgcaccaaa cccaagcg 
Rev_cgcactggcatcaccg 
Fow_SNAPC-atgatgcctcctaaacaattggtgg 
Rev_SNAPC-atagggcgaattgggtacacttacagcagtgtagtactttccttgagg 
Fow_TRF4-atgatggacaatgacttcactggaaac 
Rev_TRF4-atagggcgaattgggtacacttaccctctttgcgtactgtgcaat 
Fow_TFIIA-atgatgtaccgtgagagcctgctgggt 
Rev_TFIIA-atagggcgaattgggtacacttacccgcgagcgcttccgttt 
Fow_U70k-gtggcggccgctctagctatgatgcagacccctggtga 
Fwd_U24k-gtggcggccgctctagctatgatgacgtactgccccattacgc 
Fow_U1c-gtggcggccgctctagctatgatgagtgatagttttgctttgg 
Fow_u70k Topo-caccatgatgcagacccctggtga 
Fow_U1a-gtggcggccgctctagctatgatggaggcgcttcgcgt 
Polo-like kinase 
Fow_caccatgatgcacgcaaccgctgagac  
Rev_aatatcacggttttgtatgagctcgctg 
Tb927.7.3730 
Fow _gtggcggccgctctagctatgatggaaacgcaccaggat 
Rev_ atagggcgaattgggtacacttacgtttgggctcatgaagttgg 
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Tb927.7.2680 
Fow_gtggcggccgctctagctatgatgttccttcccgaacaatc 
Rev_atagggcgaattgggtacacttacaaagggtacgtgtagggga 
Tb927.8.6650 
Fow_gtggcggccgctctagctatg atgacagaccaccaagtcat 
Rev_ atagggcgaattgggtacacttacacctacacgcatggtgg 
Tb927.5.1580 
Fow_gtggcggccgctctagctatgatggcgagaaaccggaa 
Rev_ atagggcgaattgggtacacttaccagagggtacacgggca 
Tb927.7.5380  
Fow_gtggcggccgctctagctatgatgagcttattttcttttac 
Rev_atagggcgaattgggtacacttaccgtaagtgcagcaaatg 
Tb927.5.285b 
Fow_gtggcggccgctctagctatgatgacctcactgctgtcg 
Rev_atagggcgaattgggtacacttacattagcatcattttccgtca 
Tb927.7.3990 
Fow_gtggcggccgctctagctatgatgcgacgtactttcagtcg 
Rev_ atagggcgaattgggtacacttaccctggacaactcccctagtg 
Tb927.11.16520 
Fow_gtggcggccgctctagctatgatgaattattcaaccgggta 
Rev_ atagggcgaattgggtacacttacagtgctactttcccctgtc 
Tb927.11.10500 
Fow_gtggcggccgctctagctatgatgaacgtcgatgatttcc 
Rev_ atagggcgaattgggtacacttaccaggagctgcactcgg 
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Tb927.8.2780 rbp10 
Fow_caccatgatgggagactcgatatcacc 
Rev_ cattcgaaccggaggat 
Trypanothion reductase 
Fow_gtggcggccgctctagcatgtccaaggccttcgatttgg  
Rev_atagggcgaattgggtacacttaccaggttagagtccggaagc 
Z3CH11 
Fow_caccatgatgcaccaccatcaccat 
Rev_acaggagtccaagctcagc  
Tgsgp fow_gctgctgtgttcggagagc  
Tgsgp rev_ gccatcgtgcttgccgctc 
Fow_atg_ggatcctaatacgactcactatagggagaccacaacggtttccctctagaaataatttgttaactttaaggaggggatccgccaccatgcgtggcggccgctctagc 
Rev_myc_ctggaattcgcccttttattacagatcctcttcagagatgagtttctgctcaactttgtacaagaaagctgggtc 
Lib_fow_gaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaagaaggagatatacatatgcatcatcaccaccatcacgaaaaagcaggctc-3’ 
Lib_rev_ 5’-caccgctgagcaataactagctggaattcgcccttttatta gagaaagctgggt-3’ 
RNA probes 
U1snRNA 
aacucaccugcagugcgucaucacgaaagcgccgugcuugcaguaaacuuugagugggaacgaaagcgucccucc 
PUF element 
uaacauuguaccaugcauaacauuguaccaucag 
VSG UTR repeat  
cuugcuacuugacugauauauuuuaac 
ARE Classical 
uauuuauuuauuuauuuauuuau 
ARE Non-classical 
uuauuauuauuauuauuauuauu 
Poly U 
uuuuuuuuuuuuuuuuuuuuuuu 
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Poly C 
CCCCCCCCCCCCCCCCCCCCCCC 
Mutant ARE 
uucuucuucuucuucuucuucuu 
THT1 Oligomer 
cuggugagguauuguuugucucgcucg 
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Index II: Targets involved in immunity and infectious diseases 
miRNA Target Pathways involving Target 
hsa-miR-98 ACSL6 Fatty Acid Activation Fatty Acid Metabolism Fatty Acid β-oxidation I LPS/IL-1 Mediated Inhibition of RXR 
Function Mitochondrial L-carnitine Shuttle Pathway Stearate Biosynthesis I (Animals) Type II Diabetes Mellitus 
Signaling γ-linolenate Biosynthesis II (Animals) 
hsa-miR-98 BCL2L1  Apoptosis Signaling B Cell Receptor Signaling CD27 Signaling in Lymphocytes Chronic Myeloid Leukemia IL-15 
Signaling IL-8 Signaling Induction of Apoptosis by HIV1 JAK/Stat Signaling Lymphotoxin β Receptor Signaling 
hsa-miR-195 PIK3R1  B Cell Receptor Signaling CCR3 Signaling in Eosinophils CD28 Signaling in T Helper Cells CTLA4 Signaling in 
Cytotoxic T Lymphocytes Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes FcγRIIB 
Signaling in B Lymphocytes G-Protein Coupled Receptor Signaling LPS-stimulated MAPK Signaling Leptin 
Signaling in Obesity Leukocyte Extravasation Signaling Myc Mediated Apoptosis Signaling NF-κB Activation by 
Viruses NF-κB Signaling NGF Signaling NRF2-mediated Oxidative Stress Response Natural Killer Cell Signaling 
Neuregulin Signaling Neuropathic PI3K Signaling in B Lymphocytes PKCθ Signaling in T Lymphocytes Role of 
NFAT in Regulation of the Immune Response Role of PI3K/AKT Signaling in the Pathogenesis of Influenza Role 
of Pattern Recognition Receptors in Recognition of Bacteria and VirusesT Cell Receptor Signaling 
hsa-miR-193b EIF2S1  Signaling Role of PKR in Interferon Induction and Antiviral Response Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses VEGF Signaling 
hsa-miR-193b PLA2G4D  Role of MAPK Signaling in the Pathogenesis of Influenza 
hsa-miR-199a-3p CXCL11 IL-17 Signaling IL-17A Signaling in Gastric Cells Pathogenesis of Multiple Sclerosis 
hsa-miR-199a-3p MET  FGF Signaling HGF Signaling  
hsa-miR-27b CXCL11 IL-17 Signaling IL-17A Signaling in Gastric Cells Pathogenesis of Multiple Sclerosis 
hsa-miR-27b FZD7  G-Protein Coupled Receptor Signaling Role of Wnt/GSK-3β Signaling in the Pathogenesis of Influenza 
hsa-miR-27b MAPK10  4-1BB Signaling in T Lymphocytes, B Cell Activating Factor Signaling, CCR5 Signaling in Macrophages CD27 
Signaling in Lymphocytes CD28 Signaling in T Helper Cells Leukocyte Extravasation Signaling Role of MAPK 
Signaling in the Pathogenesis of Influenza Role of Pattern Recognition Receptors in Recognition of Bacteria and 
Viruses 
hsa-miR-27b RFXAP Primary Immunodeficiency Signaling 
hsa-miR-27b UBE2V1  NF-κB Signaling 
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hsa-miR-454 MET  FGF Signaling HGF Signaling 
hsa-miR-454 RFXAP Primary Immunodeficiency Signaling 
hsa-miR-454 TIMP2  Leukocyte Extravasation Signaling 
hsa-miR-4291 UBE2V1  NF-κB Signaling 
 
